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Take home message 
An agnostic association study on lung function using longitudinal population-based cohort data 
shows that differentially methylated genomic sites related to smoking are strongly associated with 





Abstract (248 words) 
Previous reports link differential DNA methylation (DNAme) to environmental exposures which are 
associated with lung function. Direct evidence on lung function DNAme is however limited. We 
undertook an agnostic epigenome-wide association study (EWAS) on pre-bronchodilation lung 
function and its change in adults.  
In a discovery-replication EWAS design, DNAme in blood and spirometry were measured twice, six-
to-15 years apart, in the same participants of three adult population-based discovery cohorts 
(n=2,043). Associated DNAme markers (P<5x10-7) were tested in seven replication cohorts (adult: 
n=3,327; childhood: n=420). Technical-bias adjusted residuals of a regression of the normalized 
absolute beta-values on control-probe-derived principle components were regressed on level and 
change of FEV1, FEV1/FVC and FVC in covariate-adjusted discovery EWAS. Inverse-variance weighted 
meta-analyses were performed on results from discovery and replication samples in all participants 
and never smokers.  
EWAS signals were enriched for smoking-related DNAme. We replicated 57 lung function DNAme in 
adult, but not childhood samples, all previously associated with smoking. Markers not previously 
associated with smoking failed replication. cg05575921 (AHRR) showed the statistically most 
significant association with cross-sectional lung function (FEV1/FVC: Pdiscovery=3.96x10
-21 and 
Pcombined=7.22x10
-50). A score combining ten DNAme markers previously reported to mediate the 
smoking effect on lung function was associated with lung function (FEV1/FVC: P=2.65x10
-20).  
Our results reveal that lung function associated methylation signals in adults are predominantly 
smoking-related and possibly of clinical utility in identifying poor lung function and accelerated 
decline. Larger studies with more repeat time points are needed to identify lung function DNAme in 





Lung function has an estimated heritability between 30 and 70% [1]. The variance in phenotype 
remains incompletely explained by genetic variation, but the impact of environmental exposure on 
respiratory health and lung function over the life course is well recognized. In particular, pro-
inflammatory and oxidative inhalants such as cigarette and environmental tobacco smoke, air 
pollution, and occupational exposures are important contributors to the increased risk of respiratory 
symptoms, accelerated lung function decline in adults and poor lung growth in children. DNA 
methylation (DNAme) has been associated with a large variety of traits and chronic diseases.  
A large body of evidence including results from epigenome-wide association analyses (EWAS) shows 
differentially methylated 5'-cytosine-phosphate-guanine-3' di-nucleotide (CpG) sites throughout the 
genome in response to environmental exposures in particular cigarette smoking [2-4]. In contrast, 
reports of DNAme associated with respiratory diseases and lung function show inconsistent findings 
[5, 6]. Most recently independent reports however pointed to the consistent association of DNAme 
in AHRR gene, cg05575921, with lung function in adults [4, 6, 7]. 
The current study aimed at agnostically identifying lung function-specific DNAme signals. We 
undertook a covariate-adjusted EWAS using questionnaire data, spirometry, and peripheral blood 
samples collected in the same participants (discovery cohorts: ECRHS, NFBC1966, SAPALDIA; see 
online supplement for cohort description) at two time points six-to-15 years apart. EWAS analyses 
were performed on lung function parameters of forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC) and their ratio (FEV1/FVC). The analyses focused on cross-sectional 
associations at different time points and on identifying DNAme markers predicting change in lung 
function. We tested discovery-identified CpGs (P<5x10-7 for at least one lung function parameter) for 
replication in adult samples from five adult cohorts (LBC1936, KORA, LifeLines, NSPHS, FTC) and in 





Study design and participants 
The discovery sample (n=2,043) comprised three population-based cohort studies, part of the Aging 
Lungs in European Cohorts (ALEC) project. ECRHS (n=470, European Community Respiratory Health 
Study) and SAPALDIA (n=962, Swiss Study on Air Pollution Heart and Lung Disease in Adults) are 
adult cohorts designed to investigate respiratory health. NFBC1966 (n=611, Northern Finland Birth 
Cohort 1966) is a birth cohort with follow-up to adult age. The replication sample consisted of five 
adult cohorts, KORA (n= 628, Cooperative Health Research in the Augsburg Region Study), LifeLines 
(n=1,622, LifeLines cohort study), NSPHS (n=535, North Sweden Population Health Study), LBC1936 
(n=449, Lothian Birth Cohort 1936, adult inception birth cohort), FTC (n=93, Finnish Twin Cohort 
study), and two childhood birth cohorts ALSPAC (n=258, Avon longitudinal Study of Parents and 
Children) and IOWBC (n=162, Isle of Wight Birth Cohort). Replication data from two time points was 
available only for KORA, LBC1936 (adult), and ALSPAC, IOWBC (childhood) (for cohort details and 
contribution to analysis see online supplement text and figure S1). All cohorts comply with the 
Declaration of Helsinki and ethical approval was obtained from the respective national and regional 
ethical review committees.  
Procedures 
In the discovery cohorts, DNAme measurement using Illumina® Infinium technology was obtained 
from peripheral blood samples collected at two consecutive follow-up surveys several years apart. 
The 450K BeadChip was used for samples of 984 SAPALDIA participants from both time points and of 
732 NFBC1966 participants collected at time point 1. The EPIC BeadChip was used for samples of 509 
ECRHS participants from both time points and of 716 NFBC1966 participants collected at time point 
2. For cohort-specific EWAS analyses, we used all autosomal markers available for each time point 
and cohort-specific EWAS marker results were meta-analysed without restriction to markers 
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common to both arrays. DNAme data used for replication was restricted to discovery-identified 
(sentinel) CpGs and analyzed on various arrays.  
Epidemiological data, including covariate information at subject level, was collected by interview-
assisted questionnaires and objective measures. Pre-bronchodilation spirometric data was obtained 
by performing ATS/ERS-compliant spirometry (see online supplement).  
Statistical analyses 
Epigenome-wide methylation data was analysed in R (version3.4.3). Differential blood cell count was 
estimated using a reference dataset and the minfi R package [8, 9]. DNAme used as predictors in the 
statistical models for the adult cohorts were obtained by deriving residuals from linear regression of 
the normalized absolute DNA methylation (-values) on the Illumina control probe derived 30 first 
principal components to correct for correlation structures within the data, including technical bias. 
Thus here reported effect sizes of the association are not comparable to elsewhere reported effect 
sizes using normalized -values as predictor. In the childhood data, batch effect was corrected at the 
analysis level by regressing the DNAme values against the technical covariates.  
Epigenome-wide covariate-adjusted linear regression was performed to assess the association of 
single CpG markers with forced expiratory volume in one second (FEV1, (L)), forced vital capacity 
(FVC, (L)), their ratio (FEV1/FVC) and their change during follow-up. This multi-level EWAS design 
tested different models in all and never-smoking participants (figure 1). First, cross-sectional EWAS 
were examined separately at time point 1 (EWAS1) and time point 2 (EWAS2) assessing the 
consistency of the association over follow-up time. Second, the association of DNAme at the first 
time point (DNAme1) with change in lung function during follow-up was assessed (prediction EWAS 
(EWASpredict)). Covariate-adjusted mixed linear regressions with a random intercept on the subject 
were undertaken using data from both time points (repeat cross-sectional analysis (EWASrepeat)).  
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All associations were adjusted for a set of a priori selected covariates known to influence respiratory 
outcomes from previous research conducted by SAPALDIA and ECRHS. The covariate-adjusted model 
Mbase included age, age
2, height, squared deviation of height from the mean, sex and interaction 
terms of sex with four covariates (age, age2, height and squared deviation of height), education, 
body mass index, spirometer type, study center as well as estimated cell composition (CD8-, CD4-, 
natural killer cells, B-cells, monocytes, eosinophils and neutrophils). Analyses in all participants were 
run without (Mbase) and with additional smoking adjustment including smoking status and packyears 
(Msmok). In never smokers Mbase-covariate adjustment was applied. Prediction associations of 
DNAme1 were additionally adjusted for lung function at time point 1. The same covariate 
adjustment was applied in adult replication analyses, whereas childhood covariates did not include 
squared terms.  
Cohort-specific EWAS results were summarized by inverse-variance weighted meta-analyses using 
METAL [10]. Meta-analysis results were not controlled for genomic inflation after confirming its 
negligible influence. Epigenome-wide significance level was set to P-value<1x10-7 (Bonferroni 
correction, 450,000 tests). The selection criteria for replication of sentinel CpGs was less stringent (P-
value<5x10-7). Successful replication was defined as P-value below outcome-specific Bonferroni-
correction threshold.  
Replicated CpGs were characterized by enrichment, pathway, and functional analyses and additional 
post hoc analyses were performed (see details in online supplement). First, a two-sample Mendelian 
randomization analysis based on publicly available data was applied to investigate the causality of 
replicated CpGs associations.  Second, a replication of a recently published mediation analysis [4] 
evidencing ten smoking-related CpGs mediating the smoking effect on lung function was undertaken 
in one discovery cohort (SAPALDIA). Third, to assess the combined effects of smoking-related CpGs 
on lung function in three discovery cohorts, we built two different DNAme smoking indices based 
based on CpGs a) predicting lung function effects of smoking [4] and b) located in GWAS-identified 
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lung function genes [2]. These smoking indices were tested for association with lung function in 
covariate-adjusted linear regression analyses, in all participants and in subgroups stratified by 
smoking status.  
Role of funding sources 
This EWAS was funded by European Union’s H2020 research programme. The funding agency had no 
role in the design, data collection and analysis of the data. Cohort-specific funding details provided 
in the online supplement. 
Data availability statement  
Statistical codes, and full discovery and replication EWAS effect estimates (meta-analysed and 
cohort-specific) are made publically available with no end date on the public repository DRYAD 
(http://datadryad.org/) at the time of publication. Access restrictions apply to the individual 
methylome data underlying the analysis. Contact details for data requests to the contributing 




Differences in the cohorts’ age structure and smoking habits are shown in table 1. Mean age was 
highest for LBC1936 (69.9 years) and youngest (30.4 years) for FTC. Self-report of current smoking 
status was lowest in LBC1936 (5.8%) and highest in LifeLines (43.5% due to over-sampling of current 
smokers for DNAme typed subset).  
Across all discovery EWAS meta-analyses, we identified 111 CpG markers for replication (P<5x10-7; 
74 for FEV1; 47 for FEV1/FVC and 16 for FVC; online supplement tables S1 & S2). We present here the 
results for FEV1/FVC (for FEV1 and FVC see online supplement).  
Cross-sectional associations without smoking adjustment 
In study-specific and meta-analyzed discovery EWAS, the number of lung function associated 
DNAme increased from first to second cross-sectional time point in the same participants, despite 
age-adjustment (figure 2). We therefore meta-analyzed cross-sectional discovery and replication 
results from the older participants’ age time point available. We observed 29 cross-sectional CpG 
associations with FEV1/FVC. 27 of them replicated formally (Bonferroni correction, P<0.0011, 47 
tests on FEV1/FVC; table 2; online supplement table S3). All replicated CpG-lung function associations 
were exclusively DNAme previously associated with smoking [2]. Successful replication was observed 
for cg05575921 (AHRR) showing the strongest signal for FEV1 and FEV1/FVC (FEV1/FVC: P-value 
combining discovery and replication cohorts (Pcombined)=7.22x10
-50) among all identified lung function 
DNAme markers. Methylation at this CpG, previously shown to be hypo-methylated with increased 
smoking, showed positive cross-sectional lung function association. The top ten CpGs associated 
with FEV1/FVC (table 2) were located in six loci: cg03636183 (F2RL3), cg21566642, cg01940273 and 
cg03329539 (vicinity of ALPPL2), cg05575921 and cg21161138 (AHRR), cg23771366 and cg11660018 
(PRSS23), cg21611682 (LRP5), and cg15342087 (IER3). The same CpGs, along with cg19572487 
(RARA) were also among the top 11 markers cross-sectionally associated with FEV1. Formal 
replication of cross-sectional associations with FEV1 was observed for 44 CpGs and with FVC for 
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three CpGs (online supplement tables S4 & S5). Similar results were found for repeat cross-sectional 
analyses (EWASrepeat, online supplement table S6, figure S3). 
Cross-sectional smoking-adjusted associations 
The smoking-adjusted EWAS (Msmok) resulted in fewer genome-wide significant results (figure 2). Yet, 
despite adjustment for self-report of smoking history, the top five CpGs were known smoking-
related CpGs. DNAme at cg05575921 (AHRR) remained the top cross-sectional association signal for 
FEV1/FVC (Pcombined=2.21x10
-11; table S7).  
Predictive associations without smoking adjustment 
The prediction EWAS results (table 3, figure 3) revealed that DNAme at time point 1 (DNAme1) at six 
of nine sentinel CpGs (P<5x10-7) associated with change in FEV1/FVC were replicated (cg05575921 
and cg21161138 (AHRR), cg21566642, cg01940273 and cg03329539 (vicinity of ALPPL2), and 
cg03636183 (F2RL3)). These six replicated CpGs were smoking-related markers. They were also 
associated with cross-sectional FEV1/FVC and four of them also with predicting change in FEV1 (AHRR 
(cg05575921), ALPPL2 (cg05951221, cg01940273), and F2RL3 (cg03636183), online supplement table 
S8). 
Associations in never smokers 
The agnostic discovery EWAS (Mbase) in never smokers, similarly to the entire sample, showed more 
statistically significant associations at time point 2 (older age). Eight CpGs were cross-sectionally 
associated with FEV1/FVC in never smokers (P<5x10
-7), but none replicated (table 4, online 
supplement figure S5). The CpG, cg14366110 (FIBCD1) showed predictive association of DNAme1 
with change in FEV1/FVC (Pdiscovery=4.2x10
-9, Pcombined=3.6x10
-9) in never smokers, but it did not 
replicate in KORA and LBC1936 (Preplication=0.439, replication cohorts with lung function at two time 
points). The direction of effect however was consistent (table 5, online supplement table S9 for 
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cross-sectional associations; table S10 for prediction associations) in discovery and replication 
cohorts.  
Characterization of replicated CpGs 
None of the not-smoking-related discovery-identified sentinel CpGs (n=25) were confirmed by 
replication. In contrast, 78% of the sentinel CpGs (n=86) had previously been identified as smoking-
related and 57 of these (mapping to 43 loci) formally replicated across all models and lung function 
outcomes tested (online supplement table S11). They were used jointly for functional annotation 
and pathway analyses (online supplement tables S12-to-S16). Briefly, these 57 lung function 
associated CpGs displayed enrichment for transcription factors, such as RELA (PFDR=0.002) and EP300 
(PFDR=0.004) and suggestive enrichment (PFDR<0.1) for chromatin state model of flanking active 
transcription start sites, of transcription at gene 5’ and 3’, and of enhancers. Using IPA database, or 
GO term enrichment no significant pathways were revealed. Transcriptional misregulation in cancer, 
pathways in cancer and regulation of actin cytoskeleton were identified (PFDR<0.05) using KEGG 
pathways enrichment. 
Using the weighted Kolmogorov Smirnov test on the entire EWAS discovery results, we noted 
statistically significant enrichment for smoking-related CpGs among the lung function associated 
CpGs. This enrichment was also present in the smoking-adjusted EWAS and even in the EWAS 
restricted to never smokers (online supplement table S17).  
Association of adult lung function CpG markers with childhood lung function 
Using the same scheme of analysis as for the adult replication cohorts, none of the sentinel CpGs 
showed associations with FEV1, FEV1/FVC and FVC in the childhood replication cohorts (ALSPAC, 
IOWBC) (online supplement table S18). The strongest associations observed in children (P<0.01) 
were for five CpGs not known to be smoking-related DNAme markers and one smoking-related CpG, 
cg00310412 (SEMA7A).  
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Comparison with published DNAme – lung function association reports  
Our agnostic results were compared with previously reported lung function- [4, 6, 7, 11] or COPD- 
[12, 13] specific DNAme. We retrieved all CpGs reported being associated with lung function (n=376) 
for a look-up in the cross-sectional FEV1, FEV1/FVC and FVC associations at time point 2. Only 12 out 
of 376 CpGs showed evidence for association (Bonferroni correction for 376 tests: P<1.3x10-4, online 
supplement table S19). Notably, the most recently reported CpG markers [4, 6] – having also been 
related to smoking - showed consistent associations with lung function e.g. cg05575921, 
cg21161138 (AHRR), cg05951221 (near ALPPL2) and cg06126421 (IER3). They were among our top 
replicated lung function association signals. 
Two-sample Mendelian Randomisation investigation 
To assess the causality of replicated DNAme-lung function association, we conducted a post-hoc 
Mendelian randomization (MR) look-up using publicly available databases [14, 15]. Genetic 
instruments were identified for 12 replicated CpGs. For seven CpGs a two sample MR on cross-
sectional lung function could be completed (see online supplement table S20). Results support 
causal effects for cg23771366, cg11660018 (PRSS23); cg21990700 (C1RL); cg00073460 (ZC3H12D) on 
FEV1 and for cg00073460 (ZC3H12D); cg24086068 (SHROOM3) on FVC.  
Integration of DNAme into a smoking index  
A recent smoking EWAS followed-up by a mediation analysis identified ten CpGs as mediators of the 
smoking-lung function association [4]. Eight of these mediating CpGs were among our replicated 
lung-function associated CpGs (see online table S21). In a post hoc mediation analysis in SAPALDIA, 
we showed statistically significant average causal mediation on lung function for nine of these 
mediating CpGs (FEV1/FVC: table 6; FEV1 and FVC: online supplement table S22). 
To assess the combined effect of these smoking-exposure-mediating CpGs on lung function, we 
constructed a mediation-smoking index (Mediation-SI). Its association with lung function by smoking 
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status was tested in covariate-adjusted regression models in the discovery cohorts and following 
EWAS models (SAPALDIA, ECRHS, NFBC1966). Meta-analyzed results of the Mediation-SI showed 
strong association with cross-sectional FEV1/FVC in all participants and ever smokers (table 7, figure 
4; FEV1 and FVC, online supplement table S23). The Mediation-SI association in all participants was 
more pronounced for cross-sectional (coefficient () (standard error (SE))=-1.2 (0.13), P =2.65 x10
-20) 
than for prediction association ((SE)=-0.03% (0.01), P =0.0072). We noted comparable associations 
of the Mediation-SI and of packyears with lung function (figure 5). Both were inversely associated 
with level of FEV1/FVC. Adding the Mediation-SI or self-reported smoking history (smoking status 
and packyears) to the different Mbase-adjusted statistical models showed a comparable increase in 
total adjusted R2. Highest total adjusted R2 was obtained when including both, DNAme score and 
self-reported smoking history. Covariate-adjusted mean Mediation-SI values decreased from never 
to former to current smokers and from more distant to more recent smoking exposure - with 
increase in packyears in current smokers; with fewer years since quitting in former smokers (figure 
6). 
The assessment of a second DNAme-smoking score (lung-function-genes-SI), based on smoking-
related CpGs located in 18 GWAS-identified lung function candidate genes (online supplement table 
S24), showed less prominent associations with lung function (strongest association observed in ever 





The understanding of how environmental exposure and disease are related to site-specific DNAme 
status is growing [16, 17]. Our agnostic EWAS on lung function contributes to this body of evidence. 
Lung function-associated DNAme markers were strongly enriched for smoking-associated loci. More 
than 50 known smoking CpGs were consistently and in several cases causally associated with lung 
function and its change in adults. The current agnostic approach converges with recent results of 
DNAme-lung function studies [4, 6, 7] that were a priori focusing on smoking related loci and 
included pyrosequencing in blood [7] and lung tissue [4] of some of our strongest association signals, 
including AHRR hypomethylation at cg05575921 and cg21161138, cg05951221 and cg21566642 
(ALPPL2) and cg06126421 (IER3). A methylation index integrating ten DNAme that reportedly 
mediates the effect of smoking on lung function [4] was associated with lung function level and its 
change in adults. 
Smoking is an important risk factor for poor lung function and accelerated decline. Several EWAS 
identified a large number of differentially methylated CpG markers to be associated with smoking [2-
4]. In particular, the hypo-methylation of cg05575921, a CpG located in the third intron of the aryl 
hydrocarbon receptor repressor (AHRR) gene, investigated for lung function and respiratory 
symptoms [4], stands out as a robust indicator of smoking status and smoking history [18]. Given the 
consistency of the associations observed for cg05575921 and the smoking index containing it in this 
study, the latter may have potential as a biomarker of clinical utility in predicting smoking-related 
morbidity and mortality [18, 19]. The positive direction of effects observed in identified DNAme-lung 
function association is in accordance with the reported hypo-methylation of smoking-related 
DNAme sites. The identified lung function-associated CpGs in this study have been previously 
reported to be associated with smoking-related molecular phenotypes [20], with increased risk of 
non-communicable disease, including cancer [18, 21], and with epigenetically defined accelerated 
ageing [22].  
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Whether most smoking-related DNAme markers are only markers of exposure or indirectly 
associated with lung function [7] or whether some inform on causal disease pathways cannot be 
answered conclusively by the current study. First, DNAme may just be a more precise measure of 
smoking exposure than self-reporting, as AHRR DNAme was previously shown to correlate with the 
genetic smoking dependency [18]. Second, DNAme identified by previous smoking EWAS [2, 4] may 
not exclusively have picked up methylation effects of smoking, but methylation related to 
phenotypes also affected by smoking. In this case, the observed DNAme-lung function associations 
may result from comorbidity between lung function and other smoking-related phenotypes. 
However some of the results are consistent with a causal disease pathway. First, MR results support 
causal effects from some DNAme. Unfortunately no genetic instrument was available for the top 
ranked AHRR signal. Second, our report confirms nine CpGs, including cg05575921 (AHRR), 
previously shown to mediate the smoking effect of lung function [4]. The observation that many 
smoking DNAme-lung function associations withstood smoking adjustment is consistent with the 
mediating role of DNAme between smoking behaviour (more distant predictor) and lung function. 
Third, smoking was also observed to influence methylation in lung tissue at several lung function 
CpGs including at cg05575921 in AHRR and these methylation levels correlated with AHRR gene 
expression [23] and gene expression of other genes [4]. Hypotheses for a mediating and causal role 
of smoking-related DNAme include altered AHRR DNAme inducing altered phase-2 enzyme activity 
and toxicant metabolism and altered inflammatory pathways in the lung [7]. Other inhalants 
impacting on the same pathways could in part explain the observed enrichment for smoking DNAme 
among never smokers. Methylation of AHRR cg05575921 was previously associated with lung 
function, and chronic bronchitis in never smokers [7]. Maternal smoking, passive smoking, and 
environmental exposures other than cigarette smoking (e.g. air pollution) are known to modify 
DNAme patterns across the genome [24-30]. Maternal smoking during pregnancy has been shown to 
alter offspring’s DNA markers in a number of genes known to contain smoking-related CpGs [25, 26], 
and some of these epigenetic patterns including in AHRR persist to adulthood [27].  
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From our findings in two well-characterized childhood birth cohorts, there was no evidence for 
shared common epigenetic mechanisms underlying lung function in adult- and childhood. The 
comparison was driven by results from the lung function EWAS in adults, given sample size 
limitations in the available birth cohorts. Lung function in childhood versus adulthood is expected to 
be influenced in part by different biological processes. The non-replication of the mostly smoking-
related lung function DNAme signals might reflect the non-smoking status of the children and 
adolescents. Our findings in SAPALDIA point to a dose-response effect of smoking history and 
intensity on the smoking index. Effects of maternal exposure in utero, passive smoking or other 
inhalants on smoking DNAme are likely smaller than the effects of active smoking [28]. Our EWAS 
findings generally showed an age-related increase in number and strength of DNAme-lung function 
associations in adults, despite covariate adjustment for age, as also observed by others [6]. This 
result is consistent with the observed dose-response effect of smoking and possibly other inhalants 
on DNAme. But the inherent interdependency of lung function decline, cumulative smoking 
exposure, and DNAme with aging prohibits attributing associations to single factors. 
A systematic review of peripheral DNAme associated with lung function in population-based cohorts 
pointed to the lack of consistent evidence [5]. Epigenome-wide DNAme profiling studies of lung 
tissue suggested DNAme in genes like NOS1AP, TNFAIP2, and CHRM1 to be associated with COPD 
[12, 13]. An EWAS meta-analysis, adjusted for smoking status and packyears, identified differential 
DNAme related to COPD and lung function in Koreans. Five loci (CTU2, USP36, ZNF516, KLK10 and 
CPT1B) were associated with at least two respiratory traits [11]. Evidence of associations in the 
current EWAS was only observed for 12 of 376 CpGs associated with lung function phenotypes in 
these previous studies. This inconsistency may be due to differences in population ancestry, disease 
status, exposure status, tissue-specific methylation or covariate adjustment. Furthermore limited 
sample size and false discovery findings could contribute to non-replication as could the absence of 
post-bronchodilation lung function in the current EWAS. However, our results confirm the 
associations of two most recently published population-based reports [4, 6] investigating smoking, 
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DNAme and lung function. Both reports and our results reveal the same smoking CpGs as prominent 
signals. 
The strength of this EWAS investigation is the robust and extensive study design with availability of 
repeat measures of DNAme and spirometry data in the same cohort participants, as well as its 
population–based design. The utilization of a multi-level analysis scheme - including cross-sectional 
and longitudinal EWAS analyses at two time points in the same participants, and EWAS with and 
without smoking adjustment in all participants and in never smokers - allowed for a better 
understanding of lung function DNAme being affected by aging and smoking. The lung function 
associated smoking index derived is building on robust evidence that DNAme in blood is correlated 
with DNAme and gene expression in lung tissue [4, 21, 31] and that it is a valid biomarker for 
capturing the effect of smoking on DNA methylation in the lung [7, 18]. 
There are several limitations to this study. Limitations in sample size may explain the inability to find 
association signals in never smokers and therefore signals common to lung function in childhood and 
adulthood. The estimation of decline in lung function from only two spirometry time points is likely 
to misclassify decline. Additionally, not all replication cohorts had data available for more than one 
time point. Pre-bronchodilation lung function is less robust than post-bronchodilator values and may 
increase variability of the findings. The meta-analyzed EWAS results of the cross-sectional analyses 
showed evidence of inflation (>1.1) indicating insufficient genomic control. Yet, adjusting for 
genomic inflation did not alter our main results. The relevance of the smoking index derived from 
CpGs in or close to lung function GWAS genes can be questioned given evidence on the complex 
trans-regulation of gene expression [32].  
In conclusion, our agnostic investigation shows that DNAme at CpGs related to smoking behaviour 
are the predominant signals associated cross-sectionally and prospectively with lung function in 
adults. The findings stimulate further research into the involvement of smoking-related CpGs in lung 
function relevant mechanism and potentially their role as exposure markers beyond active smoking. 
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From our EWAS results it has become clear that larger samples are required to confidently identify 






This work has been conducted within the Aging Lungs in European Cohorts (ALEC) project, funded 
from the European Union’s Horizon 2020 research and innovation programme under grant 
agreement No 633212. For a full list of acknowledgments for each cohort, please see online 
supplement. Also we gratefully acknowledge the contribution of co-author Professor John M. 




table 1: Characteristics of discovery cohorts. 
  
SAPALDIA 2 
time point 1 
SAPALDIA 3 
time point 2 
  
ECRHS 2 
time point 1 
ECRHS 3 




time point 1 
NFBC1966  
age46 
time point 2 










Age (years), mean (SD) 50.5 (11.3) 58.8 (11.3) 
 
43.6 (6.8) 54.5 (6.8) 
 
31.0 (0.3) 46.3(0.4) 
Height (cm), mean (SD) 169.4 (9.2) 168.7 (9.4) 
 
170.0 (9.2) 169.2 (9.3) 
 
171 (8.8) 171 (8.9) 
Weight (kg), mean (SD) 74.2 (14.7) 75.5 (15.4) 
 
72.6 (14.6) 76.2 (15.5) 
 
71.3 (13.6) 78.7 (16.3) 
Body mass index, (kg/m2) mean (SD) 25.8 (4.4) 26.5 (4.6) 
 
25.0 (4.0) 26.5 (4.4) 
 
24.2 (3.7) 26.7(4.8) 
Smoking status, % 
        















Packyears, mean (SD) 20.4 (20.2) 22.6 (22.1) 
 
16.6 (16.9) 20.0 (21.3) 
 
7.7 (5.9) 11.0 (9.6) 
Education†, % 
        















FVC (L), mean (SD) ‡ 4.4 (1.0) 4.1 (1.1) 
 
4.3 (1.0) 3.9 (1.0) 
 
4.8 (1.0) 4.5 (0.9) 
FEV1 (L), mean (SD) ‡ 3.3 (0.8) 3.0 (0.8)  
3.4 (0.7) 3.0 (0.8) 
 
4.0 (0.8) 3.5 (0.7) 
FEV1/FVC, mean (SD) ‡ 0.75 (0.07) 0.73 (0.08)  
0.78 (0.06) 0.75 (0.06) 
 
0.83 (0.06) 0.77 (0.06) 













Respiratory medication,  
% ( % missing values) 






        
Footnote to table 1A: 
* self-reported lifetime non-smoking.† The categorical variable “education”  is defined differently in cohorts. In SAPALDIA low corresponds to primary education; intermediate to secondary, 
middle, or vocational school; and high to technical college or university. In ECRHS and NFBC1966  information of age reached at end of studies is used to define low : ≤16 years; intermediate 
: 17-19 years and high : ≥20 years. 
‡ Values derived from pre-bronchodilation spirometry. Lung function values corrected for spirometer device change in SAPALDIA at time point 2. 





table 1 continued: Characteristics of adult replication cohorts. 
  
KORA 
time point 1 
KORA  
time point 2 
LCB1936  
time point 1 
LCB1936  
time point 2 
Lifelines  
time point 1 
NSPHS  
time point 1 
FTC 
time point 1 
N 628 628 449 449 1622 535 93 
Female, % 53.2 53.2 46.8 46.8 42.8 53.1 47.3 
Age (years), mean (SD) 53.6 (4.5) 60.1 (4.5) 69.6 (0.9) 76.3 (0.7) 46.7 (10.8) 55.1 (16.0) 30.4 (3.8) 
Height (cm), mean (SD) 169.5 (9.3) 168.7 (9.4) 167.2 (8.8) 166.1 (8.81) 176.9 (9.1) 163.8 (9.8) 173.03 (10.5) 
Weight (kg), mean (SD) 79.0 (16.7) 79.9 (17.3) 77.2 (14.6) 76.5 (14.8) 82.1 (14.7) 74.0 (15.2) 82.04 (18.8) 
Body mass index (kg/m2), mean (SD) 27.4 (4.7) 28.0 (5.1) 27.5 (4.3) 27.7 (4.6) 26.2 (3.9) 27.5 (4.7) 27.30 (5.4) 
Smoking status, % 
       
   Never smoker* 38.2 38.2 52.3 52.3 56.6 83.2 53.8 





   Current smoker 18.0 16.2 6.9 5.8 43.5 16.5 19.4 
Packyears, mean (SD) 12.8 (19.3) 13.5 (20.2) 13.9 (24.0) 14.1 (24.6) 21.0 (11.7) 8.1 (21.6) n.a. 
Education† (%) 
       
   Low 47.6 47.6 49.7 49.7 23.1 n.a. 1.1 
   Intermediate 26.43 26.43 32.3 32.3 40.8 n.a. 38.6 
   High  25.96 25.96 18.0 18.0 35.4 n.a. 60.2 
FVC (L), mean (SD) ‡ 4.3(1.0) 3.9 (1.0) 3.2 (0.9) 2.8 (0.9) 4.7 (1.1) 3.4 (1.1) 4.8 (1.1) 
FEV1 (L), mean (SD) ‡ 3.3 (0.8) 3.0 (0.7) 2.5 (0.7) 2.1 (0.7) 3.5 (0.9) 2.8 (0.9) 3.9 (0.9) 
FEV1/FVC, mean (SD) ‡ 0.78 (0.06) 0.75 (0.07) 0.79 (0.09) 0.76 (0.12) 0.73 (0.09) 0.83 (0.09) 0.81 (0.07) 
Airflow obstruction (FEV1/FVC<0.7) ‡, % 8.12 20.06 15.4 26.3 38.4 8.8 5.0 
Airflow obstruction (FEV1/FVC<LLN)‡, % 5.0 9.6 7.6 14.9 27.5 4.3 11.3 
Doctor-diagnosed asthma, % 7.2 8.6 4.5 7.1 9.9 14.2 0 
Respiratory medication, % ( % missing values) 3.3 4.9 6.7 11.8 8.0 7.7 0 
 
Footnote to table 1 continued: 
* self-reported lifetime non-smoking. 
† The categorical variable education is defined differently in cohorts. 
‡ Values derived from pre-bronchodilation spirometry. LLN: lower limit of normal values estimated using GLI2012 reference equations. 
¶ LifeLines:  non-random selection of samples for DNA methylation typing (current smokers versus never smokers. NSPHS: information obtained on current smoking status (yes/no). 




table 2: Combined EWAS meta-analyses of cross-sectional associations* of CpG markers with FEV1/FVC in all participants, base model covariate adjusted EWAS (Mbase†).  Meta-analyses of 
cross-sectional associations obtained using data from the oldest time point available: time point 2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and time point 1 of KORA, LifeLines and NSPHS.  
 
CpG ID chr 
position 
(hg19) 






















direction of effect ‡ 
cg05575921 5 373378 AHRR 0.124 (0.008) 7.22E-50 +++++++ 0.023 yes yes** 6.10E-22 (-) 
cg03636183 19 17000585 F2RL3 0.201 (0.015) 4.50E-43 +++++++ 0.008 yes yes** 5.70E-17 (-) 
cg21566642 2 233284661 ALPPL2 0.151 (0.011) 5.02E-43 +++++++ 0.043 yes yes** 4.50E-21 (-) 
cg01940273 2 233284934 ALPPL2 0.206 (0.015) 4.09E-41 +++++++ 0.031 yes yes** 9.80E-30 (-) 
cg03329539 2 233283329 ALPPL2 0.257 (0.023) 5.58E-30 +++++++ 0.628 yes yes 9.70E-16 (-) 
cg21161138 5 399360 AHRR 0.243 (0.021) 9.72E-30 +++++++ 0.152 yes yes** 7.90E-13 (-) 
cg23771366 11 86510998 PRSS23 0.233 (0.022) 5.38E-27 +++++++ 0.286 yes yes 1.90E-14 (-) 
cg11660018 11 86510915 PRSS23 0.238 (0.023) 3.40E-26 +++++++ 0.318 yes yes 4.40E-21 (-) 
cg21611682 11 68138269 LRP5 0.309 (0.03) 1.26E-25 +++++++ 0.049 yes yes 4.20E-15 (-) 
cg15342087 6 30720209 IER3 0.359 (0.036) 5.44E-24 +++++++ 0.169 yes yes 3.90E-14 (-) 
cg26703534 5 377358 AHRR 0.266 (0.026) 7.34E-24 +++++++ 0.101 yes yes 7.20E-18 (-) 
cg25648203 5 395444 AHRR 0.25 (0.026) 9.84E-22 +++++++ 0.194 yes yes 2.70E-11 (-) 
cg19572487 17 38476024 RARA 0.196 (0.021) 8.87E-21 +++++++ 0.018 yes yes 1.60E-16 (-) 
cg00310412 15 74724918 SEMA7A 0.261 (0.028) 4.01E-20 +++++++ 0.275 yes yes 1.20E-13 (-) 
cg24859433 6 30720203 IER3 0.303 (0.034) 2.05E-19 +++++++ 0.067 yes yes** 2.20E-09 (-) 
cg09935388 1 92947588 GFI1 0.105 (0.012) 7.05E-19 +++++++ 0.034 yes yes** 7.00E-14 (-) 
cg14753356 6 30720108 IER3 0.189 (0.021) 9.08E-19 +++++++ 0.405 yes yes 2.30E-14 (-) 
cg04885881 1 11123118 SRM/EXOSC10 0.168 (0.02) 5.66E-18 +++++++ 0.670 yes yes 2.70E-11 (-) 
cg25949550 7 145814306 CNTNAP2 0.335 (0.039) 6.04E-18 +++++++ 0.013 yes yes 9.30E-21 (-) 
cg19859270 3 98251294 GPR15 0.467 (0.055) 2.80E-17 +++++++ 0.029 yes yes 6.30E-17 (-) 
cg03450842 10 80834947 ZMIZ1 0.265 (0.031) 2.92E-17 +++++++ 0.003 yes yes 2.40E-11 (-) 
cg03707168 19 49379127 PPP1R15A 0.206 (0.025) 1.27E-16 +++++++ 0.668 yes yes 3.50E-07 (-) 
cg17087741 2 233283010 ALPPL2 0.161 (0.02) 4.48E-16 ++++++- <0.001 yes yes 6.10E-07 (-) 
cg21140898 1 51442318 CDKN2C 0.12 (0.017) 4.46E-13 +++++++ 0.103 yes yes 3.70E-08 (-) 
cg01899089 5 369969 AHRR 0.172 (0.027) 1.47E-10 +++++++ 0.005 yes yes 1.80E-12 (-) 
cg08763102 4 3079751 HTT 0.225 (0.039) 1.20E-08 ++++++- 0.001 yes yes 3.80E-15 (-) 
cg21282907 6 74289980 SLC17A5 0.176 (0.031) 1.28E-08 ++++++- 0.003 no yes 1.28E-02 (-) 
cg20853880 2 10184444 KLF11 0.077 (0.014) 6.05E-08 +++++++ 0.052 no yes 3.70E-07 (-) 
22 
 
cg16391678 16 30485597 ITGAL 0.164 (0.031) 1.15E-07 ++++++- 0.003 yes yes 3.00E-11 (-) 
 
Footnote to table 2: 
For complete results for FEV1/FVC associations see Supplementary Material table S3.  See online supplement table S4 and table S5 analogous results for FEV1 or FVC, respectively.  
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 in the combined meta-analysis. Note: DNAme predictors used were technical bias-adjusted, normalized residuals, thus 
effect size of the association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation as predictor. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported direction of effects for association with smoking.[2] 
¶Order of cohorts: ECRHS, NFBC1966, SAPALDIA, KORA, LBC36, LifeLines, NSPHS. FTC was excluded from this meta-analysis, given the smaller sample size and lower mean age (30.4 years) 
compared to the other adult cohorts (ECRHS (mean age: 54.5 years), NFBC1966 (46.3 years), SAPALDIA (58.8 years), LBC1936 (76.3 years) and the single available time point for KORA (60.1 
years), LifeLines (46.7 years) and NSPHS (55.1 years)). 
** Smoking CpG previously reported to mediate the smoking effect on lung function. [4] 





table 3: Combined meta-analyses of the prediction associations* of CpG markers on change in FEV1/FVC (year
-1
), in all participants, base model adjustment (Mbase†).  
 




CpG ID  chr 
position 
(hg19) 


















value  ‡ 
previously reported 
smoking association 
direction of effect ‡ 
cg05575921 5 373378 AHRR 0.006(0.001) 2.77E-13 +++++ 0.005 yes yes** 6.10E-22 (-) 
cg21566642 2 233284661 ALPPL2 0.006(0.001) 3.17E-11 +++++ 0.235 yes yes** 4.50E-21 (-) 
cg01940273 2 233284934 ALPPL2 0.009(0.001) 4.93E-11 +++++ 0.023 yes yes** 9.80E-30 (-) 
cg21161138 5 399360 AHRR 0.011(0.002) 5.81E-09 +++++ 0.103 yes yes** 7.90E-13 (-) 
cg03636183 19 17000585 F2RL3 0.008(0.001) 6.22E-09 +++++ 0.001 yes yes** 5.70E-17 (-) 
cg01377124 2 237172609 ASB18 -0.018(0.003) 7.38E-08 --+-+ 0.005 no no n.a. n.a. 
cg03329539 2 233283329 ALPPL2 0.011(0.002) 7.66E-08 +++++ 0.015 yes yes 9.70E-16 (-) 
cg07222133 5 179499488 RNF130 -0.009(0.002) 2.45E-07 ?-+-+ <0.001 no no n.a. n.a. 
cg14366110 9 133779382 FIBCD1 0.014(0.003) 9.62E-07 +++-- 0.206 no no n.a. n.a. 
 
Footnote to table 3: 
For complete results for FEV1/FVC and analogous results for FEV1 or FVC see Supplementary Material table S8.  
* Predictive associations of DNA methylation at first time point (DNAme 1) with annual change in lung function during follow-up, defined as lung function at second time point – lung 
function at first time point divided by the time of follow-up in years. Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 at discovery or combined meta-analyses level. CpGs 
shown sorted by statistical significance of combined meta-analysis results. Note: DNAme predictors used were technical bias-adjusted, normalized residuals, thus effect size of the 
association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation as predictor. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, FEV1/FVC at time point 1,  squared deviation from the mean of height, sex and interaction terms of age, age 
squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Replication was defined for association if replication P-value<0.0011 (multiple testing correction, 47 tests for FEV1/FVC). 
¶ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported direction of effects for association with smoking.
 
[2] 
** Smoking CpG previously reported to mediate the smoking effect on lung function. [4] 





table 4: Combined meta-analyses* of cross-sectional associations on FEV1/FVC in never smokers only,  obtained using data from time point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and 
from time point T1 of KORA, LifeLines and NSPHS.  
 
    
Combined meta-analysis  
(ECRHS/ NFBC1966/ SAPALDIA/KORA/ LBC1936/ Lifelines/ NSPHS) 
 
CpG ID chr 
position 
(hg19) 




















value  ‡ 
previously reported 
smoking association 
direction of effect ‡ 
cg09884077 15 23086698 NIPA1 -0.308 (0.084) 0.0003 ---+--- 0.001 no no n.a. n.a. 
cg25758394 1 3623859 TP73 0.213 (0.083) 0.0107 ??+--+- <0.001 no no n.a. n.a. 
cg18664508 3 169487465 ARPM1 -0.308 (0.072) 2.02E-05 +------ <0.001 no no n.a. n.a. 
cg19268386 15 23086595 NIPA1 -0.263 (0.14) 0.0615 ??----- <0.001 no no n.a. n.a. 
cg15981995 3 169487311 ARPM1 -0.231 (0.073) 0.0016 ??----+ <0.001 no no n.a. n.a. 
cg05785298 1 204654622 LRRN2 -0.423 (0.111) 1.41E-04 -+-+-+- 0.001 no no n.a. n.a. 
cg20278790 20 57583474 CTSZ 0.319 (0.07) 5.01E-06 -+++--- <0.001 no no n.a. n.a. 
cg13562246 8 33368277 C8orf41 0.349 (0.074) 2.67E-06 +++++-+ 0.206 no no n.a. n.a. 
 
Footnote to table 4: 
For complete results for FEV1/FVC and for FEV1 or FVC in never smokers see online supplement table S8. 
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 at discovery level for cross-sectional association at time point 2, base model adjustment (Mbase†), using data from time 
point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and from time point T1 of KORA, LifeLines and NSPHS. Note: DNAme predictors used were technical bias-adjusted, normalized residuals, 
thus effect size of the association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation as predictor. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported direction of effects for association with smoking.[2] 
¶ Order of cohorts: for discovery: ECRHS, NFBC1966, SAPALDIA; for combined analysis: ECRHS, NFBC1966, SAPALDIA, KORA, LBC1936, LifeLines, NSPHS. 





table 5: Combined meta-analyses of the prediction associations* of CpG markers on change in FEV1/FVC (year
-1
), in never smokers only, base model adjustment (Mbase†).   
 
























value  ‡ 
previously reported 
smoking association 
direction of effect ‡ 
cg14366110 9 133779382 FIBCD1 0.017 (0.003) 3.60E-09 ++-++ 0.315 no no n.a. n.a. 
cg11216682 2 131113867 PTPN18 -0.017 (0.003) 1.10E-07 +-+-- 0.282 no no n.a. n.a. 
 
Footnote to table 5: 
For complete results for FEV1/FVC and for analogous results for FEV1 or FVC see Supplementary Material table S9. 
* Predictive associations of DNA methylation at first time point (DNAme 1) with change in lung function during follow-up, defined as lung function at second time point – lung function at 
first time point divided by the time of follow-up in years. Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 at discovery or replication level. Note: DNAme predictors used 
were technical bias-adjusted, normalized residuals, thus effect size of the association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation 
as predictor. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, FEV1/FVC at time point 1, squared deviation from the mean of height, sex and interaction terms of age, age 
squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported direction of effects for association with smoking.
 
[2] 
¶ Order of cohorts: for discovery: ECRHS, NFBC1966, SAPALDIA; for combined analysis: ECRHS, NFBC1966, SAPALDIA, KORA, LBC1936. 





table 6: Mediation* analysis on the role of previously reported CpGs in the smoking association with FEV1/FVC, the SAPALDIA cohort.   




ACME ADE Total effect Proportion 




cg01940273 ALPPL2 -0.0079 [-0.0119, -0.0041] <0.0001 -0.0026 [-0.0129, 0.0077] 0.604 -0.0106 [-0.0203, -0.0014] 0.026 0.7313 [0.2616, 3.4325] 0.026 
cg03636183 F2RL3 -0.0080 [-0.0122, -0.0040] <0.0001 -0.0029 [-0.0126, 0.0062] 0.556 -0.0108 [-0.0197, -0.0021] 0.018 0.7312 [0.2819, 2.9097] 0.018 
cg05575921 AHRR -0.0102 [-0.0147, -0.0055] <0.0001 -0.0008 [-0.0109, 0.0086] 0.870 -0.0110 [-0.0202, -0.0020] 0.012 0.9213 [0.3818, 4.0453] 0.012 
cg05951221 ALPPL2 -0.0075 [-0.0122, -0.0030] 0.002 -0.0033 [-0.0131, 0.0062] 0.520 -0.0109 [-0.0197, -0.0022] 0.020 0.6836 [0.1942, 2.7656] 0.022 
cg06126421 IER3 -0.0054 [-0.0093, -0.0017] <0.0001 -0.0049 [-0.0148, 0.0049] 0.328 -0.0103 [-0.0194, -0.0012] 0.030 0.5233 [0.1050, 2.5558] 0.030 
cg09935388 GFI1 -0.0033 [-0.0058, -0.0010] 0.002 -0.0073 [-0.0168, 0.0022] 0.122 -0.0105 [-0.0198, -0.0013] 0.034 0.3009 [0.0568, 1.4190] 0.036 
cg21161138 AHRR -0.0056 [-0.0089, -0.0025] <0.0001 -0.0052 [-0.0146, 0.0043] 0.282 -0.0108 [-0.0194, -0.0020] 0.020 0.5127 [0.1647, 2.0961] 0.020 
cg21566642 ALPPL2 -0.0098 [-0.0145, -0.0057] <0.0001 -0.0014 [-0.0116, 0.0089] 0.796 -0.0112 [-0.0209, -0.0011] 0.024 0.8663 [0.3453, 4.6567] 0.024 
cg22994830 PRKAR1B -0.0002 [-0.0009, 0.0003] 0.542 -0.0103 [-0.0201, -0.0010] 0.028 -0.0105 [-0.0202, -0.0013] 0.024 0.0103 [-0.0470, 0.1595] 0.550 
cg24859433 IER3 -0.0024 [-0.0053, 0.0002] 0.068 -0.0082 [-0.0179, 0.0013] 0.112 -0.0107 [-0.0201, -0.0014] 0.022 0.2186 [-0.0438, 1.2776] 0.090 
 
 
Footnote to table 6: 
* performed using R package mediation [33]. 
† previously reported candidate CpG for mediation of smoking effect on lung function [4].  






table 7: Meta-analyses* of discovery cohort specific association of Mediation smoking index (SI) with FEV1/FVC (%), cross-sectionally at time point 2, and longitudinally predicting the annual 
change (%/year) during follow-up, base model adjustment (Mbase†), in all study participant, ever and never smokers. 
 
          























All -0.012 (0.0013) 1.05E-20 --- 0.44 
 
-0.0005 (0.0001) 8.66E-09 --- 0.006 
Ever smokers -0.014 (0.0016) 3.28E-18 --- 0.30 
 
-0.0004 (0.0001) 4.94E-04 --- 0.13 
Never smokers -0.0033 (0.0041) 0.423 --+ 0.62 
 
-0.0007 (0.0002) 1.73E-04 +-+ 0.003 
 
 
Footnotes to table 7: 
*Cohort-specific association results for Mediation-SI were meta-analysed. The 10 CpGs contributing Mediation-SI are shown in online supplement table S21). For analogous results of 
associations of Mediation-SI with FEV1 and FVC see online supplement table S23. Note: DNAme predictors used were technical bias-adjusted, normalized residuals, thus effect size of the 
association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation as predictor. 
† Base model covariate adjustment (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared 
deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. Prediction models were additionally adjusted for 
FEV1/FVC at time point 1. 
‡ P-value of meta-analysis: P<0.008 was considered statistically significant, Bonferroni correction for 6 tests per lung function outcome Order of cohorts for direction of effects: ECRHS, 
NFBC1966, SAPALDIA. 





figure 1: Flow of the multi-level discovery design of the epigenome wide association study (EWAS) on lung function parameters FEV1, FEV1/FVC and FVC.  
* Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center, and cell composition.  ** Smoking model EWAS (Msmok) were 
additionally adjusted for smoking covariates: history of smoking intensity as pack years  smoked up to the time point of data collection for regressions  and  for smoking status (current, 
former and never smoker). EWAS longitudinally predicting the change in lung function (EWASpredict) was additionally adjusted for lung function at time point 1. DNAme1 – DNA methylation at 







figure 2:  
A - Effect of aging on the associations between DNAme and lung function: Increase in numbers of signals with aging. For 
FEV1/FVC, we identified 21 CpGs at time point 2 compared to three CpGs at time point 1 to be statistically significant. Quantile-
Quantile plots of cross-sectional covariate-adjusted EWAS (Mbase*) on FEV1/FVC at first and second time point, all participants. 
Meta-analyses were performed without genomic control (inflation factor  for time point 1 ( = 1.15) and for time point 2 ( = 
1.14)). Analogous figures for cross-sectional association with FEV1 and with FVC, see online supplement figure S2.  
 
B - Effect of smoking adjustment on the associations between DNAme and lung function: Quantile-Quantile plots of the repeat 
cross-sectional covariate-adjusted EWAS (Mbase*,  = 1.13)) and additionally smoking adjusted (Msmok*,  = 1.05), all participants. 






Footnote to figure 2: 
*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, 
sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), 
body mass index, spirometer type, study center, and cell composition. Smoking adjusted model (Msmok): Covariates applied for 





figure 3: Manhattan and Quantile-Quantile plots of covariate-adjusted prediction* EWAS (Mbase†) on FEV1/FVC in all participants. 
Meta-analysis of the prediction association was performed without genomic control ( = 0.95). Analogous figures for association 






Footnote to figure 3: 
* Predictive associations of DNA methylation at first time point (DNAme1) with change in lung function during follow-up  
†Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, FEV1/FVC at time point 1, squared deviation 
from the mean of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, 
education (low, medium, high), body mass index, spirometer type, study center, and cell composition. 
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figure 4: Forest plots of cohort-specific results and meta-analyses of the association of the Mediation Smoking Index with FEV1/FVC and change in FEV1/FVC in ever - and never smokers in 
the discovery cohorts.  Associations run applying base model adjustment (Mbase*).  
 
Footnote to figure 4: 
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*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center, and cell composition. Prediction models were additionally adjusted for 
FEV1/FVC at time point 1.  
 
figure 5: Distribution and association* of Mediation smoking index (SI)† and self-reported smoking history (packyears) with FEV1/FVC, with 95% confidence interval. Dotted lines mark 
boxplot interquartile range borders.   (A) Boxplot of Mediation-SI (median: 0.3 and range: -1.7 to 5.2) in all participants of SAPALDIA. (B) Boxplot of packyears (median: 2.0 and range: 0 to 
145.9) in all participants of SAPALDIA. Analogous figures for association of Mediation-SI with FEV1 and with FVC, see online supplement figure S6 and figure S7.  
 
 
Footnote to figure 5: 
*Associations were adjusted for the base model (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center, and cell composition.  
†The Mediation-SI can be constructed for all participants irrespective of their smoking status. 
The Mbase-adjusted model explained 17.5% of the variance in the outcome. The Mbase-adjusted model additionally adjusted for the Mediation-SI explained 19.6% of the FEV1/FVC variance 
(total adjusted R
2
 = 0.196) of which 2.8% of the variance was specifically explained by the SI variable. This was comparable to the variance explained by the Mbase-adjusted model additionally 
34 
 
adjusted for packyears and smoking status corresponding to the Msmok model (R
2
 = 0.198, and with 1.6% of the variance specifically explained by the packyears variable). Model including 
both smoking adjustments (Msmok and additionally Mediation-SI) explained 20.1% of the FEV1/FVC variance.  
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figure 6: Distribution of adjusted* Mediation smoking index (Mediation-SI) in SAPALDIA at time point 2.  
 
Footnote to figure 6: 
* Mediation-SI were adjusted as follows: A) adjusted for age, sex, and education; never smokers (n=395); former smokers (n=356); current smokers (n=211); B) adjusted for age, sex, 
education, packyears, and cigday; former smokers (n=356); C) adjusted for age, sex, education, and cigday; current smokers n=211); D) adjusted for age, sex, education, and packyears; 
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1. Description of cohorts  
1.1. Discovery cohort: ECRHS - European Community Respiratory Health Survey 
Study description 
The European Community Respiratory Health Survey (ECRHS) is an international multicentre cohort 
study designed to assess the prevalence of asthma and allergic disease and identify their risk 
factors.[1] Young adults of European descent were randomly recruited from community-based 
sampling frames in the ECRHS I (1991-1993) and followed up twice in the 20 years after the first 
assessment (ECRHS II: 1998-2002; ECRHS III: 2008-2013), for full protocols, see 
http://www.ecrhs.org). The study was approved by the local ethics committees in each region: 
Reykjavík, Iceland (The National Bioethics Committee, Reykjavík, Iceland); Umea, Uppsala, 
Gothenburg, Sweden (Regional Ethical Committee in Uppsala, Sweden); Erfurt, Hamburg, Germany 
(Ethic Committee of the Bavarian State Chamber of Physicians, Germany); Norwich, UK (Norwich 
District Ethics Committee); Ipswich, UK (Ipswich–East Suffolk Local Research Ethics Committee); 
Grenoble, France (Ethics committee Paris Bichat-Claude Bernard); Barcelona, Spain (Comité Ético de 
Investigación Clínica del Instituto Municipal de Asistencia Sanitaria, Barcelona, Spain); Albacete, 
Spain (Comité de Ética e Investigación de Complejo Hospitalario de Albacete, Spain); Oviedo, Spain 
(Comité Ético de Investigación Clínica Regional, Hospital Universitario Central de Asturias, Oviedo, 
Spain); Galdakao, Spain (Comité Ético de Investigación del Hospital de Galdakao, Spain); and Basel, 
Switzerland (Swiss Academy of Medical Sciences and the ethics committee of Basel).  




The Northern Finland Birth Cohort 1966 (NFBC 1966) is an unselected, population-based sample of 
all live births in 1966 (n = 12,058) in the provinces of Oulu and Lapland in Finland. Women with 
expected delivery dates in 1966 were recruited through maternity health centers.[2] In 1997, at 
offspring age of 31 years, all cohort participants with known addresses were sent a postal 
questionnaire on health and lifestyle and those living in Northern Finland or Helsinki area were 
invited to a clinical examination which included blood sampling. In total, both questionnaire, clinical 
and biological data were collected for 6,007 participants. DNA was successfully extracted for 5,753 
participants from fasted blood samples[3]. In 2012, all individuals with known address in Finland 
were sent postal questionnaires and an invitation for clinical examination. Both questionnaire, 
clinical and biological data were collected for 5,539 participants. DNA methylation at 31 years was 
extracted for 807 randomly selected subjects of whom questionnaire, clinical and genetic data were 
available at both 31 and 46 years. Of them analyses here included 611 subjects with lung function 
(spirometry both at 31 and 46 years of age), other relevant covariate and methylation data. 
This longitudinal, epidemiological research program is maintained within the Department of Health 
Sciences, Faculty of Medicine, University of Oulu, Finland (http://www.oulu.fi/nfbc/). Informed 
consent for the use of the data including DNA was obtained from all subjects. The study was 
approved by the ethics committees in Oulu (Finland) and Oxford (UK) universities in accordance with 
the Declaration of Helsinki.  
Methylation of genomic DNA was quantified using the Infinium HumanMethylation450 BeadChip 
(Illumina, Inc.) array at age 31 years and The Infinium Methylation EPIC array (Illumina, Inc.) at age 
46 years according to manufacturer’s instructions. Bisulfite conversion of genomic DNA was 
performed using the EZ DNA methylation kit according to manufacturer's instructions (Zymo 
Research, Orange, CA). In NFBC1966 quality control and quantile normalization for DNA methylation data 
was adapted from the CPACOR pipeline.[4] Illumina Background Correction was applied to the intensity values, 
a detection p-value threshold was set at p < 10
-16
, and samples with call rate < 98 % were excluded. Probes 
with call rate < 95 % were excluded from the analyses.  
 
1.3. Discovery cohort: SAPALDIA - Swiss Study on Air Pollution Heart and Lung Disease in Adults 
Study description 
SAPALDIA was initiated in 1991 to specifically study the air pollution impact on respiratory health.[5, 
6] It is a population-based cohort in Switzerland recruiting subjects aged 18 to 60 from population 
registries in eight communities, representing the three largest language groups (German, French, 
Italian) as well as different levels of air pollution and degrees of urbanization. Subjects underwent 
spirometry and answered a detailed questionnaire on respiratory health, allergies, smoking history, 
and lifestyle factors in the baseline (year 1991) and follow-up (year 2002) examination. The study is 
in agreement with the Declaration of Helsinki. Participants provided prior written informed consent 
and ethical approval for the study was given by the Overall Regional Ethics Commission for Clinical 
Medicine (Swiss Academy of Medical Sciences) and by the respective cantonal ethical committee for 




1.4. Replication cohort: ALSPAC - Avon Longitudinal Study of Parents and Children 
Study description 
The Avon Longitudinal Study of Parents and Children (ALSPAC) recruited 14,541 pregnant women 
with expected delivery dates between April 1991 and December 1992.[7, 8] Of these initial 
pregnancies, there were 14,062 live births and 13,988 children who were alive at 1 year of age. 
When the oldest children were approximately 7 years of age, an attempt was made to bolster the 
initial sample with eligible cases who had failed to join the study originally. As a result, when 
considering variables collected from the age of seven onwards (and potentially abstracted from 
obstetric notes) there are data available for more than the 14,541 pregnancies mentioned above. 
The study website contains details of all the data that are available through a fully searchable data 
dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary).  
DNA methylation data and QC and preprocessing 
As part of the ARIES project (http://www.ariesepigenomics.org.uk), a sub-sample of 1,018 ALSPAC 
mother–child pairs had DNA methylation measured using the Infinium HumanMethylation450 
BeadChip (Illumina, Inc.). DNA methylation data was measured in three samples per child, from cord 
blood and venous blood samples at age 7 and again at age 15 or 17 years. All DNA methylation wet-
lab and preprocessing analyses were performed at the University of Bristol as part of the ARIES 
project and has been described in detail previously.[9] 
In detail, peripheral blood was collected according to standard procedures, spun and frozen at -80˚C. 
DNA methylation analysis and data pre-processing were performed at the University of Bristol as 
part of the ARIES project (ariesepigenomics.org.uk). Following extraction, DNA was bisulfite 
converted using the Zymo EZ DNA MethylationTM kit (Zymo, Irvine, CA). Following conversion, the 
genome-wide methylation status of over 485,000 CpG sites was measured using the Illumina 
Infinium® HumanMethylation450k BeadChip assay according to the standard protocol. The arrays 
were scanned using an Illumina iScan and initial quality review was assessed using GenomeStudio 
(version 2011.1). The level of methylation is expressed as a “Beta” value (β-value), ranging from 0 
(no cytosine methylation) to 1 (complete cytosine methylation). Samples from all time-points in 
ARIES were distributed across slides using a semi-random approach (sampling criteria were in place 
to ensure that all time-points were represented on each array) to minimize the possibility of 
confounding by batch effects. Samples failing quality control (average probe detection p-value ≥ 
0.01) were repeated. As an additional quality control step genotype probes on the 
HumanMethylation450k were compared between samples from the same individual and against 
SNP-chip data to identify and remove any sample mismatches. Data were pre-processed in R 
(version 3.0.1) with the WateRmelon package according to the subset quantile normalization 
approach described by Touleimat & Tost in an attempt to reduce the non-biological differences 
between probes. We removed probes that had a detection P-value >0.05 for >5% of samples, probes 
on the X or Y chromosomes and SNPs (rs probes). 
Proportions of cell types were estimated from DNA methylation data using the estimateCellCounts 
function in the minfi R package which is based on the method developed by Houseman et al. .[10, 
11] This estimated the proportion of B cells, CD8 T cells, CD4 T cells, granulocytes, eosinophils, 
neutrophils, NK cells and monocytes at the 7.5 year methylation time-point and at the 16.5 year 
methylation time-point independently. Ten surrogate variables were generated and included in 
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models to adjust for technical batch in cross-sectional and prediction models, using the sva R 
package. In longitudinal models, twenty surrogate variables were used, ten from each of the two 
methylation time points. Asthma status at 7.5 years of age was defined from questionnaires 
completed by the mothers of the study children at approx. 7.5 years of age when they were asked if 
their study child have ever been diagnosed by a doctor with asthma. Mothers were also asked in the 
same questionnaire if their study child had taken any asthma medicine in the past 12 months. The 
mothers of the study children were asked the same questions about asthma doctor diagnosis and 
asthma medications in the past 12 months when study children were 14 years old. 
Lung function and covariates 
Spirometry was done in a research clinic at ages 8.5 and 15 years approximately by using methods 
described previously.[12] Lung function at 15 years was defined as the highest of 3 measures before 
administration of salbutamol (pre-salbutamol measures) and 15 minutes after receiving 400 mg of 
salbutamol (post-salbutamol measures) administered by using metered aerosol and a spacer.  
Maternal education (proxy for social class) was classified for this study as 1”University education”, 
2”A-level” or 3”O-level or lower” based on questionnaires completed by the study mothers. We 
derived smoking status from questionnaires completed by the study children at approximately 16 
years of age. Study participants were asked if they had ever smoked a cigarette. Those responding 
Yes to the smoking question were then asked about their smoking frequency, indicating either 1”I 
have only ever tried smoking cigarettes once or twice” , 2”I used to smoke sometimes but I never 
smoke cigarettes now”, 3”I sometimes smoke cigarettes but I smoke less than one a week”, 4”I 
usually smoke between one and six cigarettes a week”, 5”I usually smoke between one and six 
cigarettes a week but not every day” and 6”I usually smoke one or more cigarettes every day”. 
Height and weight were measured at research clinic attendance at the same ages as lung function 
assessment was carried out. During clinic attendance, height was measured to the last complete mm 
using a Harpenden Stadiometer and weight was measured using a Tanita Body Fat Analyser (Model 
TBF 305; Tanita Europe Ltd, Amsterdam, The Netherlands). 
 
1.5. Replication cohort: FTC - Finnish Twin Cohort 
Study description 
The Finnish Twin Cohort (FTC) study was initiated in 1974 to study genetic and environmental factors 
contributing to complex diseases and behavioral risks.[13] The study participants were recruited 
from the FinnTwin16 cohort,[13] a population-based, longitudinal study of five consecutive birth 
cohorts (1975–1979) of twins, their siblings, and their parents. The FinnTwin16 cohort was 
established in 1991, and the first assessments took place when the twins were 16 years of age, with 
four waves of follow-up when the twins were 17, 18.5, 24,[14] and 34 years,[13] on average. We 
studied young adult twin individuals who were selected by their responses to questions on weight 
and height at the age of 23–36 years to represent a wide range of intra-pair differences in body mass 
index (BMI). 
The spirometric examinations were performed during 2004-2013 by a mass flow sensor (Vmax 
encore, Sensormedics, Palm Springs, CA, USA). The flow device was cleaned before calibration by the 
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device’s automatic cleaning program, after which 0 calibration was performed. Flow calibration was 
then performed with a 3 liter pump between flow values 0.5 l/s and 6 l/s, after which a volume 
calibration was performed. During spirometry, patient was sitting with the nose closed with a clip, 
and at least 3 maximal flow volume curves were measured, the difference of best two FEV1 values 
or FVC values had to be less than 150 ml, and the expiration should last at least 6 seconds. If this was 
not fulfilled, additional measurements were performed. The spirometric results were given 
according to ERS/ATS recommendation from 2005.[15] Forced vital capacity (FVC), forced expiratory 
volume in one second (FEV1) and FEV1/FVC ratio were measured. The 2012 multiethnic reference 
values were used to compare the spirometric results.[16] The study subjects provided written, 
informed consent. The protocol was designed and performed according to the principles of the 
Helsinki Declaration and was approved by the Ethics Committee of the Hospital District of Helsinki 
and Uusimaa. 
DNA methylation data 
DNA extracted from white blood cells of 308 FinnTwin16 twins (112 MZ and 42 DZ pairs) aged 23-36, 
was used to generate DNA methylation data by Infinium HumanMethylation450 BeadChip (Illumina, 
Inc.). All DNA methylation wet-lab analyses were performed at the Norwegian Genomics 
Consortium, Oslo, Norway, and data preprocessing analyses were performed at the University of 
Helsinki, Finland, as part of the ongoing FTC projects, and has been described in detail 
previously.[17] For the current study, 110 MZ twins (55 MZ pairs) with both DNA methylation and 
spirometry data available from the same time point were selected. 
1.6. Replication cohort: IOWBC – Isle Of Wight Birth Cohort 
Study description 
The IOWBC is a single-centre study designed to represent the community population. All children 
born on the Isle of Wight in a defined period (January 1989 to February 1990) were eligible for 
inclusion. The cohort was recruited through the 1509 women who gave birth to 1536 children on the 
IOW during the recruitment period. The children in the IOWBC have been seen on six occasions over 
the course of 26 years, at 1, 2, 4, 10, 18 and 26 years.[18] The focus of the IOWBC is to investigate 
the etiology and natural history of asthma and allergic disease manifestations in an unselected 
population during childhood and early adult life. Spirometry data was performed at follow-ups at 
age 10, 18 and 26. The spirometer used at each follow-up was Koko spirometer and software with a 
portable desktop device (both PDS Instrumentation, Louisville,KY, USA).[19] 
 
DNA methylation data 
Biologic sample collection of peripheral blood was obtained at follow-ups at the age 10 and 18 and 
the samples of a subgroup were used for DNA methylation typing. 817 samples were typed using the 
Illumina Infinium® HumanMethylation450k BeadChip assay according to the standard protocol.[19] 
Methylation data was processed using standard QC-pipelines (CPACOR, quantile normalization and 




1.7. Replication cohort: KORA - Cooperative Health Research in the Augsburg Region Study 
Study description 
The Cooperative Health Research in the Augsburg Region Study, KORA, aims to gain new insights into 
the causes, development and consequences of cardiovascular disease, diabetes as well as lung 
diseases and allergies.[20-22] The KORA S4 survey is an independent population-based sample from 
the general population living in the region of Augsburg, Southern Germany. KORA S4 was conducted 
in 1999/2001 and standardized examinations were applied in the survey (4261 participants). A total 
of 3080 subjects participated in a follow-up examination of S4 in 2006–08 (KORA F4), comprising 
individuals who, at that time, were aged 32–81 years. A subset of 1321 subjects, aged 44-64 years, 
underwent spirometry and were followed up in the KORA FF4 survey 7 years later (2013/2014). Of 
those, a total of 628 subjects had DNA methylation data from blood samples collected at KORA F4 
and data available on spirometry from KORA F4 and KORA FF4.  
DNA methylation data 
DNA methylation was measured in DNA extracted from whole blood of the participants using the 
Infinium HumanMethylation450K BeadChip at the Helmholtz Zentrum München, Research Unit 
Molecular Epidemiology and Genome Analysis Centre. The bisulfite conversion and genome-wide 
methylation assessment were performed as previously described.[23, 24] 
QC and preprocessing 
Normalization of the methylation data was conducted following the CPACOR pipeline,[4] beginning 
with exclusion of 65 single nucleotide polymorphism markers and background correction using the R 
package minfi.[10] Probes were set to NA if the detection p-value ≥0.01 or number of beads ≤3. 
Samples were excluded if the detection rate was ≤0.95. Quantile normalization was then performed 
on the signal intensities. The methylation of a given cytosine was first calculated as a β-value, the 
ratio of the methylated signal intensity to the sum of the methylated and unmethylated signal 
intensities. Following normalization, CpG sites with a detection rate below 95% were excluded. To 
reduce possible impact of non-biological effects, we adjusted the methylation values for technical 
effects prior to analysis. In detail, principal component analysis was performed on the intensities of 
all (non-negative, autosomal) control probes after background correction. We then modeled the 
methylation values of each CpG site across all samples as a function of the first 20 principal 
components. Residuals of these models were used as “technically adjusted” methylation values for 
all analyses.[4] 
 
1.8. Replication cohort: LBC1936 - Lothian Birth Cohort 1936 
Study description 
The Lothian Birth Cohort 1936 (LBC1936) comprises 1,091 community-dwelling individuals who 
agreed to participate in a longitudinal study of cognitive ageing starting at mean age about 70 
years.[25-28] At age 11 years, almost all of them took part in the Scottish Mental Survey of 1947, 
which employed the Moray House Test No. 12, a test of general cognitive ability. At recruitment in 
older age (at age 70 years), between 2004 and 2007, subjects agreed to cognitive testing and other 
medical, physical and psychosocial assessments. Further waves of testing occurred at ages 73 
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(wave2), 76 (wave 3) and 79 years (wave 4). Lung function was measured at each wave using a Micro 
Medical Spirometer. For the purposes of this study spirometry measures at ages 70, 73 and 76 years 
were used. 
DNA methylation data 
Blood samples for methylation were taken from participants at each wave of testing. DNA 
methylation was measured at 485,512 sites using the Infinium HumanMethylation450 BeadChip 
array, at the Edinburgh Clinical Research Facility Genetics Core, Western General Hospital, 
Edinburgh. DNA methylation data, spirometry measures and covariates were available for 449 
individuals at waves 1, 2 and 3.  
 
1.9. Replication cohort: LifeLines Cohort 
Study description and DNA methylation data 
The LifeLines cohort study is a large Dutch population-based cohort study designed to investigate 
chronic diseases and healthy aging.[29, 30] Detailed information about LifeLines can be obtained at 
the official website (http://www.lifelines.net). A subgroup of 1,656 participants of the LifeLines 
cohort was non-random selected based on lung function, smoking status and exposure to 
environmental exposures. Whole blood samples collected for DNA extraction and DNA methylation 
level for each CpG site was measured using the IlluminaInfinium® Human Methylation 450K array 
(Illumina,Inc.) at the UMCG, Groningen, The Netherlands. 
 
1.10. Replication cohort: NSPHS - Northern Sweden Population Health Study 
Study description 
The Northern Sweden Population Health Study (NSPHS) was initiated to provide a health survey of 
the population in a geographically remotes area and to study the medical consequences of lifestyle 
and genetics.[31, 32] According to the Sweden Census, on 31 December 2006, of 826 eligible 
inhabitants (aged 15 years or older) 740 subjects agreed to participate (90%) and 656 subjects 
contributed complete data, resulting in a final sample of 347 (53%) women and 95 (14.5%) 
individuals with a traditional lifestyle. The comprehensive collection of data included genealogy, 
socio-demography, body size, blood samples for clinical chemistry, medical history of participants 
and family members, and lifestyle. Spirometry was performed in a sitting position without nose clips 
using a Spida 5 spirometer (MicroMedical; http://www.medisave.co.uk). Three consecutive lung 
function measurements per participant were performed and the maximum value per measured lung 
function parameter was used for further analysis. Within the scope of this article, Peak Expiratory 
Flow (PEF), Forced Expiratory Volume (FEV), and Forced Vital Capacitiy (FVC) were analyzed. Years of 
spirometry: 2006 and 2009 (same time as blood samples were taken) 
DNA methylation data 
- Number of samples typed: 732 
- Type of biologic sample used to extract DNA: Whole blood 
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- Type of Infinium HumanMethylation BeadChip (Illumina, Inc.) used /Array used: Illumina 
450K 
- Institution in which wet-lab and preprocessing analyses were performed : DNA methylation 
analyses were performed by the SNP & SEQ Technology Platform at Science for Life 
Laboratory (SciLifeLab), Sweden 
 
1.11. Data availability statement 
Statistical codes, and full discovery and replication EWAS effect estimates (meta-analysed and 
cohort-specific) are made publically available with no end date on the public repository DRYAD 
(http://datadryad.org/) at the time of publication. Access restrictions apply to the individual 
methylome data underlying the analysis. The consent given by cohort participants does not cover 
data sharing in public data repositories. Data requests for methodologically sound research proposal 
can be addressed through the cohorts’ websites to the data access committee or directly to the 
principal investigators of the epidemiologic studies.  
 






ALSPAC  A.J.Henderson@bristol.ac.uk 
 
FTC  miina.ollikainen@helsinki.fi 
 
IOWBC  Details on data access are available at: 
http://www.allergyresearch.org.uk/studies/birth-cohort/#cohort-data-use.  
Contact Mr Stephen Potter: stephen.potter@iow.nhs.uk 
 
KORA Application for KORA data can be made via the KORA Project Application Self-Service 
Tool, KORA.PASST, at https://epi.helmholtz-muenchen.de/. 
 
LBC1936 Sarah.Harris@igmm.ed.ac.uk; I.Deary@ed.ac.uk 
 
LifeLines  h.m.boezen@umcg.nl 
 
NSPHS   ulf.gyllensten@igp.uu.se 
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1.12. Childhood replication cohorts: Characteristics of ALSPAC and IOWBC 
Table: Characteristics of childhood replication cohorts. 
 
  ALSPAC Child ALSPAC Teens 
IOWBC 
Time point 1 
IOWBC 
Time point 2 
N 258 258 162 218 
Female, % 43.41 43.41 43.8 52.3 
Age (years), mean (SD) 8.54 (0.14) 15.35 (0.18) 10 (0) 18 (0) 
Height (cm), mean (SD) 132.4 (5.8) 170.5 (8.8) 139.2 (6.4) 171.5 (9.6) 
Weight (kg), mean (SD) 30.0 (5.6) 61.7 (11.3) 35.1 (7.2) 68.5 (13.8) 
Body mass index, (kg/m2) mean (SD) 17.0 (2.3) 21.2 (3.1) 18.0 (2.8) 23.2 (4.1) 
Smoking status, %     
   Never smoker* 100 100 100 100 
Tobacco smoker exposure during childhood or in utero†, % 60.0 60.0 56.2 72.9 
Education‡ 42.3 42.3 12;43;20;24;1 12;41;21;25;1 
FVC (L), mean (SD) 1.9 (0.3) 3.8 (0.9) 2.3 (0.4) 4.7 (0.8) 
FEV1 (L), mean (SD) 1.7 (0.3) 3.4 (0.8) 2.0 (0.3) 4.1 (0.8) 
FEV1/FVC, mean (SD) 0.89 (0.06) 0.91 (0.07) 0.88 (0.06) 0.87 (0.07) 
Airflow obstruction (FEV1/FVC<0.7), % 1.16 1.55 0 1.8 
Doctor-diagnosed asthma, % 20.0 22.7 14.8 16.5 
Respiratory medication, % ( % missing values)
¶
 13.1 (2.3) 12.2 (17.4) 31.5 (0) 12.8 (3.2) 
 
    
Footnote to childhood cohort characteristics table: 
* Analysis restricted to non-smokers. 
† ALSPAC: In utero tobacco smoke exposure is defined as mothers that reported any smoking at either 18wks OR 32 wks of pregnancy. Passive smoke exposure is defined as the child living 
in the same house as a smoker, as reported by the mothers at approximately 65 months of age. IOWBC: Tobacco smoke exposure reported for time point 1: 0 to 10 years of age and for time 
point 2: 0-18 years of age. 
‡Education: Maternal Education used in ALSPAC [O-level or lower]; education at age of 18 used in IoW [very low;low;medium;high;other] 
¶
 
Asthma medication use in the last 12 months. 
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2. Methods: Study design and participants 
2.1. Study population 
The discovery cohorts were three well-characterized longitudinal cohort studies which were part of 
the Aging Lungs in European Cohorts (ALEC) project. Briefly, two discovery cohorts were population-
based studies specifically designed to investigate respiratory health, the European Community 
Respiratory Health Study (ECRHS) (Burney et al. 1994; Janson et al. 2001) and the Swiss Study on Air 
Pollution Heart and Lung Disease in Adults (SAPALDIA) (Ackermann-Liebrich et al. 1997; Martin et al. 
1997) and the third discovery cohort was a birth cohort, the Northern Finland Birth Cohort 1966 
(NFBC1966). As discovery dataset, we used the biological samples and the epidemiological data of 
two consecutive follow-up surveys roughly 10 years apart for ECRHS and SAPALDIA and 15 years 
apart for NFBC1966. The replication cohorts comprised five adult inception cohorts and two 
childhood birth cohorts. The adult replication cohorts included three with population-based design: 
the Cooperative Health Research in the Augsburg Region Study (KORA), the North Sweden 
Population Health Study (NSPHS)) and the LifeLines cohort study with enriched ascertainment of 
smokers (LifeLines); one study of adults with a birth cohort design: the Lothian Birth Cohort 1936 
(LBC1936)), and one with twin cohort design: the Finnish Twin Cohort study (FTC). The childhood 
replication cohorts included two birth cohorts: the Avon longitudinal Study of Parents and Children 
(ALSPAC) and the Isle of Wight Birth Cohort (IOWBC) cohort. All cohorts comply with the Declaration 





2.2. Figure S1: Selection of study participants in discovery cohorts and data availability in replication cohorts 
Figure S1: Discovery cohorts: Flow chart of the selection of study participants. Replication cohorts: Contribution of each replication cohort to the meta-analyses based 








* Study participants with complete data on outcome, covariates, in particular 
smoking status and packyears information, genome wide genetic information 
and with peripheral blood samples available for DNA methylation typing. In the 
discovery cohorts a random sample of study participants aged 30 years or older 
at the first time point, with complete data on outcome and covariates, as well as 
blood samples available for DNA extraction at two consecutive follow-up surveys 
was selected. [1) Selection of study participants to be typed with Infinium® 
HumanMethylation 450K or 850K Bead Chip (Illumina) based on a random 
selection procedure. 2) Selection of study participants: DNA methylation data 
processing related sample quality control criteria (exclusion of samples if call 
rate <95% or sex mismatch based on XY probes; for SAPALDIA and NFBC1966 
detection P-value > 10-16 and for ECRHS detection P-value > 0.05).] 
 
†FTC did not contribute to the combined meta-analyses of cross-sectional 
associations (using data from the oldest time point available: time point 2 of 
ECRHS, NFBC1966, SAPALDIA, LBC1936 and time point 1 of KORA, LifeLines and 
NSPHS). The exclusion of FTC was due to the lower mean age (30.4 years) 
compared to the other adult cohorts’ mean age (ECRHS (54.5 years), NFBC1966 
(46.3 years), SAPALDIA (58.8 years), LBC1936 (76.3 years) and the single 





2.3. Discovery and replication data availability 
For the current analysis purposes the data availability across eight adult inception cohorts (three discovery and five 
replication cohorts) was maximal for a one time-point cross-sectional association analysis. Among the replication 
cohorts, only one adult birth cohort (LBC1936, n=449) and both childhood birth cohorts (ALSPAC, n=258 and IOWBC, 
n=162) had methylation information and epidemiological data available from two time points. The sample size for 
the replication of repeat cross-sectional associations in adults was limited to the LBC1936 data. The replication 
sample size for the prediction EWAS on change in lung function over follow-up time was limited to two cohorts 
(KORA, n= 628, and LBC1936, n=449). The data available on spirometry was obtained from two follow-ups was 7 
years apart for KORA and 6 years apart for LBC1936 and DNA methylation data was obtained from blood samples 
collected at the time of first spirometry. The remaining replication cohorts had DNA methylation, spirometry and 
epidemiological data available from only one time point (LifeLines (n=1622), NSPHS (n=535) and FTC (n=93)).  
2.4. Whole blood sample collection and DNA methylation typing in discovery cohorts  
For discovery cohorts, biological samples of peripheral blood were collected using standard operating procedures at 
two time points on two consecutive follow-up surveys from which DNA was extracted. Genome-wide DNA 
methylation typing including DNA bisulphite conversion was performed at the Wellcome Trust Center for Human 
Genetics (Oxford, UK) for the samples of both time points of SAPALDIA and ECRHS, and for the second time point of 
NFBC1966. Quantification of DNA methylation across the genome using the Illumina® Infinium Human Methylation 
technology was obtained successfully using the 850K BeadChip for ECRHS on samples of 509 participants from both 
time points (1,018 samples) and for NFBC1966 samples collected at the second time point from 766 participant, as 
well as using the 450K BeadChip for SAPALDIA on samples of 984 participants from both time points (1,968 samples). 
For ECRHS and SAPALDIA, paired samples of the same participant from both time points were randomized across the 
methylation arrays to be typed in parallel in order to minimize batch effects. For NFBC, the samples collected at the 
first time point from 816 participants had been previously typed using the 450K BeadChip. The quality control (QC) 
and normalization procedures applied in the discovery cohorts are described in table at 2.6 of this Appendix. In total 
4,568 samples of 2,259 participants were typed in the discovery cohorts. The methylation data was QC-processed, 
normalized and correction for technical batch effects were performed separately in each cohort. Cohort specific QC-
steps were performed. A call rate of 95% was applied as selection criteria on marker and sample level; we had 2,043 
samples for both time points (ECRHS: n=470, NFBC1966: n=611 and SAPALDIA: n= 962). For cohort-specific EWAS 
analyses, we used all autosomal markers available for each time point. Given the use of two different DNAme typing 
arrays (850K BeadChip and 450K BeadChip), all cohort-specific EWAS marker results were meta-analysed without 
restricting to a set of common markers. 
2.5. QC- processing of DNA methylation data 
We performed the methylation data processing within each cohort separately using R packages minfi,[10] 
RnBeads,[33] and CPACOR.[4] After standard QC cleaning steps regarding duplicates, sex inconsistency, low sample 
16 
 
quality (sample call rate >95%) for all three cohorts, ECRHS additionally excluded outlier samples beyond 1.5 
interquartile range (IQR) and NFBC1966 excluded samples with their 1st PC score of the DNA methylation values 
outside the interval given by the mean +/- 4SD (see table at 2.6 of this Appendix). Call rate detection P-value was set 
to P>10-16 for NFBC1966 and SAPALDIA, and P>0.05 for ECRHS. Dye-bias correction and absolute methylation level (-
values) were computed using the minfi R-package. Low marker quality exclusion for probes with call rate below 95% 
was applied, leading to the probe exclusion of 9.5% (n=80’264) and 10.0% (n=85’152) for ECHRS using the 850K 
BeadChip at first and second time point, respectively; 3.1% (n=14’486, using 450K BeadChip) and 1.72% (n=14’586, 
using 850K BeadChip) for NFBC1966 at first and second time point, respectively; 0.4% (n=1’894) and 0.37& (n=1’785) 
for SAPALDIA using the 450K BeadChip at first and second time point, respectively. Beta mixture quantile 
normalization (BMIQ)[34] of -values was applied for SAPALDIA methylation data and quantile normalization[35] for 
ECRHS and NFBC1966. For technical bias correction the first 30 principal components derived from the control 
probes were used for ECRHS and SAPALDIA methylation data. We excluded methylation markers on sex 
chromosome and used all remaining markers for cohort-specific EWAS analyses (number of markers for time point 1: 
n=766’891 (ECRHS2), n=459’378 (NFBC1966 (1997)), n=471’970 (SAPALDIA2); number of markers for time point 1: 
n=762’003 (ECRHS2), n=832’569 (NFBC1966 (2012)), n=472’079 (SAPALDIA3)). For cohort-specific EWAS analyses, we 
used all autosomal markers available for each time point and cohort-specific EWAS marker results were meta-
analysed without restriction to common markers. 
 








samples successfully typed 509 509 816 766 984 987 
duplicates excluded 0 0 9 8 0 0 
95% sample call rate 14 2 67 40 0 0 
sex mismatch 7 11 7 1 1 4 
outliers* 1 3 1 1 na na 
remaining QC-ed samples  487 493 732 716 983 983 
* outlier definition was cohort specific, either >1.5 IQR for ECRHS and SAPALDIA and 1st PC score of the DNA methylation values outside mean 
+/- 4SD for NFBC1966. 
 
2.7. Spirometry and epidemiological data collection 
Detailed description of data collection and study design has been previously published for the discovery cohorts: 
ECRHS,[36, 37] SAPALDIA,[38-40] and NFBC1966,[41] and for the replication cohorts: KORA,[42] LBC1936,[25, 27, 28] 





2.8. Table: Use of spirometers in discovery cohorts. 
The cohorts used spirometers of different brands and models and change in spirometers between surveys did occur. 
Spirometric comparability across time points was addressed within cohorts.[38]  
Spirometer 
brand and model 
SAPALDIA 2 
time point 1 
SAPALDIA 3 
time point 2 
ECRHS 2 
time point 1 
ECRHS 3 
time point 2 
NFBC1966 
age31 
time point 1 
NFBC1966 
age46 
time point 2 
SensorMedics 2200 100% -- 
-- -- -- -- 
EasyOne ndd -- 100% 












-- -- -- 
NDD EasyOne 
-- -- -- 
100% 
-- -- 
Vitalograph P Model 




-- -- -- -- 
-- 100% 
 
3. Methods: Statistical analysis  
In the discovery cohorts, two types of smoking score were generated to test their combined effect. Briefly, an ALEC 
custom SI specific for each lung function outcome (FEV1, FEV1/FVC or FVC) was generated from a subset of CpGs 
selecting known smoking-related markers from the ALEC discovery repeat cross-sectional EWAS 100 top association 
signals; second a lung-function-gene-SI including smoking associated CpGs located in 18 GWAS-identified lung 
function candidate genes. 
3.1. Statistical models  
Residuals model  




Linear model formulas of 12 statistical models for cross-sectional associations (three outcomes (FEV1/FVC, FEV1, 
FVC), two time points (T1 and T2) and two covariate adjustments (Mbase, Msmok)): 
Linear regression model, mathematical formula 








Model for cross-sectional associations, Mbase adjustment: 
𝐿𝐹 =  𝛽0 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝐷𝑁𝐴𝑚 + 𝛽2𝑎𝑔𝑒 + 𝛽3𝑎𝑔𝑒
2 + 𝛽4ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽5(ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
       + 𝛽6𝑠𝑒𝑥
+ 𝛽70𝑎𝑟𝑒𝑎1 +⋯+ 𝛽7𝑘𝑎𝑟𝑒𝑎𝑘 + 𝛽8𝑏𝑚𝑖 + 𝛽91𝑒𝑑𝑢𝑐1 + 𝛽92𝑒𝑑𝑢𝑐2 + 𝛽10 𝐵𝑐𝑒𝑙𝑙 + 𝛽11𝐶𝐷4𝑇
+ 𝛽12𝐶𝐷8𝑇 + 𝛽13𝐸𝑜𝑠 + 𝛽14𝑀𝑜𝑛𝑜 + 𝛽15𝑁𝑒𝑢 + 𝛽16𝑁𝐾 + 𝛽17𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒 + 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2 + 𝛽19𝑠𝑒𝑥
∗ ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽20𝑠𝑒𝑥 ∗ (ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
+ 𝑒𝑖                              
All variables are participant’s characteristics of the same time point. At T1 all covariates and LF parameter are from 
T1. At T2, all covariates and LF parameters are from T2. 
Model for cross-sectional associations, Msmok adjusted:  
𝐿𝐹 =  𝛽0 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝐷𝑁𝐴𝑚 + 𝛽2𝑎𝑔𝑒 + 𝛽3𝑎𝑔𝑒
2 + 𝛽4ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽5(ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
       + 𝛽6𝑠𝑒𝑥
+ 𝛽70𝑎𝑟𝑒𝑎1 +⋯+ 𝛽7𝑘𝑎𝑟𝑒𝑎𝑘 + 𝛽8𝑏𝑚𝑖 + 𝛽91𝑒𝑑𝑢𝑐1 + 𝛽92𝑒𝑑𝑢𝑐2 + 𝛽10 𝐵𝑐𝑒𝑙𝑙 + 𝛽11𝐶𝐷4𝑇
+ 𝛽12𝐶𝐷8𝑇 + 𝛽13𝐸𝑜𝑠 + 𝛽14𝑀𝑜𝑛𝑜 + 𝛽15𝑁𝑒𝑢 + 𝛽16𝑁𝐾 + 𝛽17𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒 + 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2 + 𝛽19𝑠𝑒𝑥
∗ ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽20𝑠𝑒𝑥 ∗ (ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
+ 𝛽211𝑆𝑚𝑜𝑘_𝑠𝑡𝑎𝑡𝑢𝑠1
+ 𝛽212𝑆𝑚𝑜𝑘_𝑠𝑡𝑎𝑡𝑢𝑠2 + 𝛽22𝑝𝑎𝑐𝑘𝑦𝑟𝑠 + 𝑒𝑖 
 
Linear model formulas of 6 statistical models for prediction associations (three outcomes (FEV1/FVC, FEV1, FVC) and 
two covariate adjustments (Mbase, Msmok)): 
Linear model for prediction association:  








“𝑎𝑛𝑛𝑢𝑎𝑙 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝐿𝐹” =
(𝐿𝐹2−𝐿𝐹1)
(𝑇2−𝑇1)𝑖𝑛 𝑦𝑒𝑎𝑟
 𝑤ℎ𝑒𝑟𝑒 𝐿𝐹1𝑎𝑛𝑑 𝐿𝐹2𝑎𝑟𝑒 𝑡ℎ𝑒 𝐿𝑢𝑛𝑔 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑎𝑛𝑑 𝑓𝑜𝑙𝑙𝑜𝑤 −
𝑢𝑝 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑇1 𝑎𝑛𝑑 𝑇2, 𝑟𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒𝑙𝑦.  
 
Linear model for prediction associations, Mbase adjusted: 
(𝐿𝐹2 − 𝐿𝐹1)
(𝑇2 − 𝑇1)𝑖𝑛 𝑦𝑒𝑎𝑟
= 𝛽0 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝐷𝑁𝐴𝑚 + 𝛽2𝐿𝐹1 + 𝛽3𝑎𝑔𝑒 + 𝛽4𝑎𝑔𝑒
2 + 𝛽5ℎ𝑒𝑖𝑔ℎ𝑡
+ 𝛽6(ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
       + 𝛽7𝑠𝑒𝑥 + 𝛽80𝑎𝑟𝑒𝑎1 +⋯+ 𝛽8𝑘𝑎𝑟𝑒𝑎𝑘 + 𝛽9𝑏𝑚𝑖 + 𝛽101𝑒𝑑𝑢𝑐1
+ 𝛽102𝑒𝑑𝑢𝑐2 + 𝛽11 𝐵𝑐𝑒𝑙𝑙 + 𝛽12𝐶𝐷4𝑇 + 𝛽13𝐶𝐷8𝑇 + 𝛽14𝐸𝑜𝑠 + 𝛽15𝑀𝑜𝑛𝑜 + 𝛽16𝑁𝑒𝑢 + 𝛽17𝑁𝐾
+ 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒 + 𝛽19𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2 + 𝛽20𝑠𝑒𝑥 ∗ ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽21𝑠𝑒𝑥
∗ (ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2




Model for cross-sectional associations, Msmok adjusted:  
 
(𝐿𝐹2 − 𝐿𝐹1)
(𝑇2 − 𝑇1)𝑖𝑛 𝑦𝑒𝑎𝑟
= 𝛽0 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝐷𝑁𝐴𝑚 + 𝛽2𝐿𝐹1 + 𝛽3𝑎𝑔𝑒 + 𝛽4𝑎𝑔𝑒
2 + 𝛽5ℎ𝑒𝑖𝑔ℎ𝑡
+ 𝛽6(ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
       + 𝛽7𝑠𝑒𝑥 + 𝛽80𝑎𝑟𝑒𝑎1 +⋯+ 𝛽8𝑘𝑎𝑟𝑒𝑎𝑘 + 𝛽9𝑏𝑚𝑖 + 𝛽101𝑒𝑑𝑢𝑐1
+ 𝛽102𝑒𝑑𝑢𝑐2 + 𝛽11 𝐵𝑐𝑒𝑙𝑙 + 𝛽12𝐶𝐷4𝑇 + 𝛽13𝐶𝐷8𝑇 + 𝛽14𝐸𝑜𝑠 + 𝛽15𝑀𝑜𝑛𝑜 + 𝛽16𝑁𝑒𝑢 + 𝛽17𝑁𝐾
+ 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒 + 𝛽19𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2 + 𝛽20𝑠𝑒𝑥 ∗ ℎ𝑒𝑖𝑔ℎ𝑡 + 𝛽21𝑠𝑒𝑥 ∗ (ℎ𝑒𝑖𝑔ℎ𝑡 − 𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡))
2
+ 𝛽211𝑆𝑚𝑜𝑘_𝑠𝑡𝑎𝑡𝑢𝑠1 + 𝛽212𝑆𝑚𝑜𝑘_𝑠𝑡𝑎𝑡𝑢𝑠2 + 𝛽22𝑝𝑎𝑐𝑘𝑦𝑟𝑠 + 𝑒𝑖       
 
Linear mixed regression model, mathematical formula 








 𝑦𝑖𝑗 = 𝛽0  +∑𝛽𝑘𝑥𝑘𝑖𝑗
𝑝
𝑘=1
+ 𝛾0𝑖 + 𝑒𝑖𝑗  





(𝛾0𝑖 , … , 𝛾0𝑛)𝑖𝑛𝑑𝑑(𝛾0𝑖 , … , 𝛾0𝑛)
 
 
Model for repeat cross-sectional associations, Mbase adjusted:  
𝐿𝐹𝑗 =  𝛽0 + 𝛾0𝑗 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝑗𝐷𝑁𝐴𝑚 + 𝛽2𝑎𝑔𝑒𝑗  + 𝛽3𝑎𝑔𝑒
2
𝑗 + 𝛽4ℎ𝑒𝑖𝑔ℎ𝑡𝑗 + 𝛽5(ℎ𝑒𝑖𝑔ℎ𝑡𝑗 −𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡)𝑗)
2
       
+ 𝛽6𝑠𝑒𝑥 + 𝛽70𝑎𝑟𝑒𝑎1𝑗 +⋯+ 𝛽7𝑘𝑎𝑟𝑒𝑎𝑘𝑗 + 𝛽8𝑏𝑚𝑖𝑗 + 𝛽91𝑒𝑑𝑢𝑐1𝑗 + 𝛽92𝑒𝑑𝑢𝑐2𝑗 + 𝛽10 𝐵𝑐𝑒𝑙𝑙𝑗
+ 𝛽11𝐶𝐷4𝑇𝑗 + 𝛽12𝐶𝐷8𝑇𝑗 + 𝛽13𝐸𝑜𝑠𝑗 + 𝛽14𝑀𝑜𝑛𝑜𝑗 + 𝛽15𝑁𝑒𝑢𝑗 + 𝛽16𝑁𝐾𝑗 + 𝛽17𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒𝑗
+ 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2
𝑗 + 𝛽19𝑠𝑒𝑥 ∗ ℎ𝑒𝑖𝑔ℎ𝑡𝑗 + 𝛽20𝑠𝑒𝑥 ∗ (ℎ𝑒𝑖𝑔ℎ𝑡𝑗 −𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡)𝑗)
2
+ 𝑒𝑖𝑗                𝑗
= 1,2 
 
Model for repeat cross-sectional associations, Msmok adjusted:  
𝐿𝐹𝑗 =  𝛽0 + 𝛾0𝑗 + 𝛽1𝑟𝑒𝑠𝑖𝑑𝑢𝑗𝐷𝑁𝐴𝑚 + 𝛽2𝑎𝑔𝑒𝑗  + 𝛽3𝑎𝑔𝑒
2
𝑗 + 𝛽4ℎ𝑒𝑖𝑔ℎ𝑡𝑗 + 𝛽5(ℎ𝑒𝑖𝑔ℎ𝑡𝑗 −𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡)𝑗)
2
       
+ 𝛽6𝑠𝑒𝑥 + 𝛽70𝑎𝑟𝑒𝑎1𝑗 +⋯+ 𝛽7𝑘𝑎𝑟𝑒𝑎𝑘𝑗 + 𝛽8𝑏𝑚𝑖𝑗 + 𝛽91𝑒𝑑𝑢𝑐1𝑗 + 𝛽92𝑒𝑑𝑢𝑐2𝑗 + 𝛽10 𝐵𝑐𝑒𝑙𝑙𝑗
+ 𝛽11𝐶𝐷4𝑇𝑗 + 𝛽12𝐶𝐷8𝑇𝑗 + 𝛽13𝐸𝑜𝑠𝑗 + 𝛽14𝑀𝑜𝑛𝑜𝑗 + 𝛽15𝑁𝑒𝑢𝑗 + 𝛽16𝑁𝐾𝑗 + 𝛽17𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒𝑗
+ 𝛽18𝑠𝑒𝑥 ∗ 𝑎𝑔𝑒
2
𝑗 + 𝛽19𝑠𝑒𝑥 ∗ ℎ𝑒𝑖𝑔ℎ𝑡𝑗 + 𝛽20𝑠𝑒𝑥 ∗ (ℎ𝑒𝑖𝑔ℎ𝑡𝑗 −𝑚𝑒𝑎𝑛(ℎ𝑒𝑖𝑔ℎ𝑡)𝑗)
2




3.2. Generation of smoking scores  
For the discovery cohorts, two types of smoking indices (SI) were constructed according to an algorithm based on 
the deviation from the reference group mean of the measured DNAme across a subset of CpGs in a given 
participant.[44]  To build smoking indices specific to each lung function outcome in the discovery cohorts, we used 
the technical bias-adjusted residuals of the measured DNAme. Never smokers were defined as the reference group 
to derive the mean and standard deviation (µc and σc) used in the index equation. For each CpG of the selected 
subset, the mean DNAme, μc, and its standard deviation, σc, across the group of never smokers (reference group) 
was computed. In detail, the smoking index was defined across a subset of a number of CpGs (N) in a given 
participant (SI(s)) using the DNAme measured in the biological sample (s) by summing the difference in DNAme level 
at a given CpG (βcs) from the mean reference DNA methylation (µc) divided by the standard deviation in the 
reference group (σc) and by taking the direction hyper- or hypomethylation the smoking-associated CpG into 
account (wc, hypermethylation =+1 and hypomethylation=-1). The direction of the effect of smoking on DNAme was 
derived from Joehanes et al[45]. 
 
Using this algorithm, an SI can be constructed for all participants irrespective of their smoking status.  Two different 
subsets of CpGs were selected to test their combined effect in a SI score, the Mediation-SI (i) and the lung-function-
gene-SI (ii) 
i) Mediation- SI: In a recent report 10 CpGs had been identified to be associated with smoking applying an 
independent  EWAS in the LifeLines cohort study and confirmed by mediation analysis to be mediators of 
smoking on lung function [46]. We used these 10 CpGs for constructing a mediation SI. The mediator 
CpGs were marked in the single CpG association result tables  
ii) Lung-function-gene-SI: A smoking index based on the previously identified Bonferroni-corrected smoking 
associated (p<0.05) CpGs located in 18 GWAS-identified lung function candidate genes, namely 
ADAM19, ARMC2, C10orf11, CDC123, CFDP1, FLJ20184, HDAC4, HTR4, LRP1, MECOM, MFAP2, PPT2, 
RARB, RHOBTB3, TGFB2, TLE3, TNS1, ZNF323/ZKSCAN3 [45]. One CpG per locus was selected, choosing 
the CpG most consistently associated with smoking as reported previously [45] to contribute to the 
candidate smoking index score (see table S24).  
3.3. Annotation of genomic loci of replicated CpGs 
Annotation to genomic location was achieved by permutations testing. To determine whether enrichment occurred 
more often than expected by chance we drew 10000 random sets with matched SD structure as the lung funciton 
associated loci from the Illumina 450K arrays probes. For each set, we recorded the overlap to the genomic feature 
under test, creating a distribution that reflected the overlap of a random permuted set of 450K probes with the 
same standard squared deviation (SD) structure to the genomic feature. We obtained enrichment p-values 
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empirically from distribution of overlaps generated by the permuted sets and the observed overlap in the lung 
function associated loci, and performed a Fisher exact test by cross tabulation of the mean overlaps from the 
permuted sets versus the observed overlap in lung function associated loci. The SD structure of the 450k probes was 
recorded in NFBC1966. Subsequently, the 450K probes were divided into 10 SD bins. The 10000 permuted sets were 
created containing the same number of probes per SD bin as the credible set of loci.  
We assessed the overlap of our lung function specific marker to histone modification H3K4, H3K27me3 and the 
chromatin state model reported by Roadmap.[47] DNAse hypersensitivity sites as well as transcription factor binding 
sites data were retrieved from ENCODE project.[48] Chromosomal contact points and domains (HiC) were 
downloaded from GEO and concordant experiments were undertaken as previously described.[49] To assess the 
overlap to SNP signatures we used the NHGRI-EBI GWAS catalogue (downloaded June 2016). SNPs per trait were 
pruned across studies using a 1MB window. We restricted this analysis to traits with 50 or more independent 
variants. To define enrichment in regions relative to the transcription start site of a gene and CpG island we used 
Illumnina’s 450K manifest file.  
3.4. Pathway analyses of replicated CpGs 
Genes from the 57 confirmed sentinel CpGs, replicated in independent cohorts, were selected for further analysis. 
The annotation has been used provided by Illumina and any missing genes were populated using Snipper v1.2 
(https://csg.sph.umich.edu/boehnke/snipper/). The gene list was then used for enrichment in KEGG (Kyoto 
Encyclopedia of Genes and Genomes)[50] and GO (Gene Ontology) databases[51] using topGO and topKEGG 
function in the missMethyl package.[52] Additionally, the Ingenuity Pathway Analysis system - IPA® (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) was used to identify global canonical 
pathways.[53] 
3.5. Smoking enrichment analysis 
We performed an enrichment analysis to test if CpGs previously identified as being associated with smoking were 
statistically overrepresented among the top lung function associated CpG markers of the discovery meta-analyses 
EWAS. We defined a CpG marker to be a smoking CpG if it was part of a previously reported set of CpG markers (n = 
18,760) associated with smoking behavior at a FDR-corrected P-value<0.05.[45] The test statistics (t-values) were 
retrieved from each EWAS result and tested for the enrichment of the smoking-related CpG sites. The Weighted 
Kolmogorov Smirnov (WKS) test was used to assess if the test statistics on a certain set of loci differed from those in 
random loci of the same size.[54] The WKS is a better alternative to the commonly used gene set enrichment 
analysis[55] for examining an enrichment of custom curated CpG marker sets, as this method may be less biased 
towards identifying enrichment of large genes with increased number of probes represented on the arrays. 
3.6. Replication of mediation analysis in SAPALDIA 
We conducted mediation analysis for each of the 10 CpGs used to compute the Mediation-SI, using R package 
“mediation”. SAPALDIA samples at time point 2 were analyzed (n = 962). Mediation model was fitted by linear 
regression of technical variable adjusted residuals of the methylation level on smoking status (ever vs never-smoker) 
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after adjustment for age, sex, body mass index, education, study center, and cell composition. Outcome model was 
fitted by linear regression of lung function on the technical variable adjusted residuals of the methylation level after 
adjustment for the same covariates of base model. The total effect of smoking, the effect of changing smoking status 
from never to ever-smoker, would be then decomposed into two causal mediation effect and direct effect. The 
causal mediation effect denotes the effect of changing technical variable adjusted residuals by one unit, conditional 
on the smoking status. The population average of the causal mediation effect and the direct effect, adjusted for the 
base model covariates, was estimated by quasi-Bayesian Monte Carlo simulations. 
3.7. Two-sample Mendelian randomization study of the replicated CpGs 
Using the publicly available database, Accessible Resource for integrative Epigenomic Studies (ARIES), we identified 
methylation quantitative trait loci (mQTL) in peripheral blood of participants of the ALSPAC study, at four different 
life stages (birth, childhood, adolescence, middle age) for 13 of the 57 replicated CpGs.[56] To look-up in a two-
sample Mendelian randomization (MR) approach whether the identified mQTL-associated single nucleotide 
polymorphisms (SNPs) were associated with FEV1 or FVC, we used the publicly available curated genome-wide 
association study database (MR-Base).[57] The alleles were harmonized to ensure that SNP-exposure effect 
correspond to the same allele for SNP-outcome effect at the adult time point (termed middle age in the ARIES data). 
MR effect estimates were calculated using Wald ratio and the resulting effect estimate represents the change in 
outcome per unit increase in the exposure. The SNP-outcome effect sizes were selected based on outcome FEV1 and 
FVC. All analyses were done in R/3.4.4 environment using “Two Sample MR” package. 
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4. Results: Sentinel CpG marker selection for replication 
4.1. Table S1: List of sentinel CpGs for replication, all participants 
Table S1: Selection of sentinel CpGs for replication for FEV1, FEV1/FVC or FVC in all participants of the discovery cohorts, EWAS meta-analyses, basic covariate-adjusted 
(Mbase) and additionally smoking adjusted (Msmok) associations are presented in brackets. CpG markers with P-value <5x10-7 were selected. 
  FEV1 FEV1/FVC FVC 











   




















































































































cg04885881 1 11123118   +++ 14 x           3.51E-07 6.42E-09 8.51E-09           
cg21393163 1 12217629 
 TNFRSF
1B +++ 16 x         3.01E-07                 
cg27537125 1 25349681  RUNX3 +++ 7 x         2.04E-08                 
cg21140898 1 51442318   +++ 17 x             3.04E-08             
cg09935388 1 92947588 GFI1 +++ 19 x               3.60E-07           
cg19266329 1 145456128   +++ 
1 
(1) x x   
5.44E-11 
(1.83E-07)               
1.03E-08 
(2.29E-07)     
cg11231349 1 162050656 NOS1AP ??+ 47 x     1.92E-07       2.99E-07             
cg03547355 1 227003060   +++ 40 x     1.22E-07                     
cg20853880 2 10184444 KLF11 +++ 20 x             1.23E-07             
cg22475025 2 43864340 PLEKHH2 ++- 2   x       3.47E-07                 
cg22040631 2 129153820   ??+ 30 x     4.85E-08                     
cg18826637 2 145116633   +++ 11 x     8.92E-10                     
cg05135521 2 161188335 RBMS1 +++ 37 x     8.53E-08                     
cg02514318 2 197201183 HECW2 +++ 63 x     4.78E-07                     
cg27241845 2 233250370  ALPPL2 +++ 20 x     7.77E-09   2.85E-08                 
cg17087741 2 233283010  ALPPL2 +++ 6 x             5.13E-12             
cg03329539 2 233283329  ALPPL2 +++ 9 x     2.36E-07       1.77E-10 7.41E-08           
cg05951221 2 233284402  ALPPL2 ?++ 11 x         5.81E-08                 
cg21566642 2 233284661  ALPPL2 +++ 3 x     1.77E-11   3.67E-13 2.77E-07 3.47E-17 1.39E-11 2.93E-08         
cg01940273 2 233284934  ALPPL2 +++ 2 x     5.77E-11   1.27E-12   8.11E-18 3.10E-11 1.05E-07         
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cg01377124 2 237172609 ASB18 --+ 
1 
(1) x x               
1.01E-09 
(2.70E-09)         
cg11610350 3 64253705   +++ 1   x             1.63E-07           
cg16990174 3 72496875 RYBP +++ 16 x               3.09E-07           
cg19859270 3 98251294 GPR15 +++ 29 x     3.68E-08       8.07E-08             
cg22870429 3 114027859 TIGIT +++ 23 x     1.52E-08                     
cg13457961 3 186501085 SNORD2 --- 3   x       4.71E-07                 
cg01598596 3 187464648 BCL6 +++ 58 x     3.48E-07                     
cg14855367 3 191048308 UTS2D +++ 28 x             3.12E-07             
cg00741986 4 2748332 TNIP2 +++ 60 x     4.06E-07                     
cg08763102 4 3079751 HTT +++ 11 x               1.19E-07           
cg24086068 4 77356008 
SHROO
M3 +-+ 3 x     7.80E-09               1.59E-07     
cg01899089 5 369969 AHRR -++ 15 x               3.08E-07           
cg05575921 5 373378 AHRR +++ 1 x     9.33E-14 1.25E-07 2.01E-15 5.12E-10 3.96E-21 3.59E-16 1.59E-08       3.97E-07 
cg26703534 5 377358 AHRR +++ 15 x         5.87E-08   1.33E-08             
cg25648203 5 395444 AHRR +++ 8 x     3.64E-08   7.15E-09   5.02E-11             
cg21161138 5 399360 AHRR +++ 5 x       2.01E-08 1.43E-08 2.73E-07 6.36E-14 1.62E-10           
cg05673882 5 74862702 POLK +++ 10 x     3.31E-10                     
cg23205886 5 138611766 SNHG4 +++ 4 x     2.07E-09               2.55E-07     
cg05487895 5 139080952   --- 2   x                   2.79E-07     
cg07222133 5 179499488 RNF130 ?-+ 
6  
(3) x x               
2.00E-07 
(3.95E-07)         
cg01882991 6 6677756   +++ 22 x     1.22E-08                     
cg15930777 6 12343201   +++ 13 x   4.88E-07                       
cg14753356 6 30720108   +++ 4 x           8.01E-08 2.04E-07             
cg24859433 6 30720203   +++ 12 x           3.80E-07               
cg15342087 6 30720209 FLOT1  +++ 8 x     6.23E-11   2.04E-07   4.18E-09 1.62E-07         7.53E-08 
cg05593667 6 35490744   +?+ 51 x     2.26E-07                     
cg03149958 6 36326677  ETV7 +++ 
1  
(3) x x   
5.44E-12 
(9.31E-09)   1.39E-07           
5.19E-08 
(3.78E-07)   
2.77E-10 
(1.92E-08) 
cg03957124 6 37016869   +++ 33 x     6.01E-08                     
cg21282907 6 74289980   +++ 10 x     4.60E-09       1.65E-09             
cg12761472 6 119031922   +++ 32 x     5.28E-08                     
cg00073460 6 149806502 
ZC3H12
D +++ 27 x     3.60E-08                     
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cg06762457 6 149806635 
ZC3H12
D +++ 25 x     2.59E-08   3.58E-07                 




(1) x x           
1.52E-07 
(3.89E-07)             
cg08549335 7 30387954 ZNRF2 +++ 16 x             3.16E-09       4.74E-07     
cg26521259 7 43435880 HECW1 ?++ 7(1) x x         
2.10E-07 
(1.17E-07)               
cg10691866 7 65817282 TPST1 +++ 59 x     3.89E-07                     
cg25949550 7 145814306 CNTNAP2 +++ 24 x             1.95E-07             
cg01651915 8 55795551 XKR4  +++ 4 x     1.56E-07   
 
              3.86E-07 
cg13353574 8 61326925   +++ 18 x               3.51E-07           
cg20090859 8 80590435   ?-- 
2 
(2) x x                 
2.08E-07 
(2.07E-07)       
ch.8.917481
19F 8 91678943   +++ 
10 
(1)   x       
3.47E-08 
(4.29E-08)                 
cg07292140 8 94210841   ??+ 27 x             3.06E-07             
cg19589396 8 103937374   +++ 62 x     4.51E-07                     
cg13064897 8 135747178   +++ 
6 
(2) x x         
2.00E-07 
(3.57E-07)               
cg12075928 8 141801307 PTK2 +++ 46 x     1.82E-07                     
cg05329578 9 2241688   +++ 17 x               3.39E-07           
cg02716826 9 33447032 
SUGT1P
1 +++ 55 x     2.53E-07                     
cg13891189 9 116164001 ALAD +++ 8 x                   2.45E-07       
cg13657200 9 117266029 DFNB31 +++ 49 x     2.07E-07                     
cg14366110 9 133779382 FIBCD1 +++ 5(2) x x               
1.24E-07 
(1.66E-07)         
cg04813697 10 22920025 PIP4K2A +++ 43 x     1.70E-07                     
cg25953130 10 63753550 ARID5B +++ 5 x     2.74E-09               2.79E-07     
cg00210249 10 71135679 HK1 --- 18 x         3.68E-07                 
cg03450842 10 80834947 ZMIZ1 +++ 23 x             1.80E-07             
cg18879828 11 46942432   +++ 64 x     4.99E-07                     
cg21611682 11 68138269 LRP5 +++ 16 x             1.63E-08 1.78E-07           
cg11660018 11 86510915 PRSS23 +++ 6 x     3.21E-08     1.29E-08 5.14E-09 7.12E-11           
cg23771366 11 86510998 PRSS23 +++ 3 x       2.07E-07     2.69E-09 1.37E-11           
cg21990700 12 7260776 C1RL +++ 12 x     1.18E-09                     
cg07986378 12 11898284 ETV6 +++ 8 x         2.11E-08                 
cg06826457 12 12867669   +++ 53 x     2.46E-07                     
26 
 
cg26165146 12 27484656 ARNTL2 +++ 5 x           1.93E-07               
cg20059012 12 53613154 RARG +++ 45 x     1.77E-07                     
cg02583484 12 54677008 
HNRNPA
1 +++ 34 x     6.76E-08                     
cg00666749 13 21637118 LATS2 +++ 41 x     1.50E-07                     
cg16708465 13 95933097 ABCC4 +++ 38 x     9.83E-08                     
cg12033216 14 59130157   +++ 57 x     3.24E-07                     
cg13976502 14 74227875 C14orf43 +++ 35 x     7.06E-08                     
cg16288101 14 88621538   +++ 19 x     5.80E-09                     
cg25292882 15 39431467   +++ 31 x     5.07E-08                     
cg22952142 15 68549178   +++ 20 x               4.03E-07           
cg00310412 15 74724918 SEMA7A +++ 14 x     2.08E-09       3.10E-08 1.27E-07           
cg06505619 16 698072 WDR90 +++ 54 x     2.49E-07                     
cg05557932 16 3929351 CREBBP +++ 36 x     7.10E-08                     
cg16391678 16 30485597 ITGAL +++ 21 x             3.31E-07             
cg01243823 16 50732212 NOD2 +++ 48 x     2.05E-07                     
cg27367615 16 86229910   +++ 2   x             3.31E-07           
cg01747591 16 89703612 DPEP1 +++ 6 x                     4.20E-07     
cg09395195 17 29645782 EVI2A +++ 50 x     2.24E-07                     
cg19572487 17 38476024 RARA +++ 7 x     6.04E-11         2.49E-09     4.89E-11     
cg20458044 17 57904327 TMEM49 +++ 61 x     4.38E-07                     
cg18181703 17 76354621 SOCS3 +++ 39 x     1.04E-07                     
cg03636183 19 17000585 F2RL3 +++ 4 x     5.38E-13 1.75E-07 5.64E-11 7.09E-08 1.47E-15 5.25E-13           
cg07709627 19 30156658 PLEKHF1 --- 
1  
(1) x x                     
2.23E-08 
(2.38E-08)   
cg26768816 19 30302793 CCNE1 --+ 
1  
(1) x x                 
3.46E-08 
(3.84E-08)       
cg07626482 19 47289503 SLC1A5 +++ 18 x     5.39E-09                     
cg03707168 19 49379127 
PPP1R15
A +++ 29 x             4.38E-07             
cg16201146 20 19191526   +++ 21 x               4.97E-07           
cg12303084 20 45985741 ZMYND8 +++ 14 x     2.72E-07   1.66E-07                 
cg23110422 21 40182073 ETS2 +++ 44 x     1.74E-07                     




4.2. Table S2: List of sentinel CpGs for replication, never smokers 
Table S2: Selection of sentinel CpGs for replication for FEV1, FEV1/FVC or FVC in never smokers of the discovery cohorts.  
CpG markers with P-value <5x10-7 were selected. 
      
FEV1 FEV1/FVC FVC 




































































cg25758394 1 3623859 TP73 ??+ 1 
 
1.727E-09 
   
2.687E-08 
   
1.435E-07 
  cg22508172 1 24069723 TCEB3 --- 2 
          
1.166E-07 
 cg12752420 1 43751363 C1orf210 +++ 4 
         
1.961E-07 
  cg10212705 1 154297848 ATP8B2 --- 3 
          
1.961E-07 
 cg18938392 1 157248950 
 
+++ 2 
      
2.874E-08 
     cg05785298 1 204654622 LRRN2 -+- 6 
     
9.099E-08 
      cg11216682 2 131113867 PTPN18 +-+ 2 
       
9.054E-08 
    cg15981995 3 169487311 ARPM1 ??- 5 
     
5.042E-08 4.286E-07 
     cg18664508 3 169487465 ARPM1 --- 2 
 
1.917E-08 
   
2.929E-08 
      cg04030659 6 22570704 HDGFL1 --- 4 
          
3.66E-07 
 cg27235034 6 29976917 HLA-J -++ 3 
    
3.535E-07 
       cg12647932 6 70576740 COL19A1 --- 1 
    
3.669E-08 
       cg17838734 6 83073924 TPBG --- 1 
  
7.973E-09 
         cg20098854 8 898407 
 
--- 1 
           
1.316E-07 
cg25633955 8 1616622 DLGAP2 --- 3 
         
3.865E-07 
  cg19931644 8 12623485 
 
+++ 3 
   
2.757E-07 
        cg13562246 8 33368277 C8orf41 +++ 8 
     
1.928E-07 
      
cg04460372 9 130661175 
ST6GALNA
C6 
+++ 2 3.544E-07 
           
cg14366110 9 133779382 FIBCD1 --- 1 
      
1.718E-10 4.237E-09 
    cg05831672 10 103543172 NPM3 --- 1 
          
3.929E-08 
 cg04774364 10 106100810 
 
+++ 2 
           
1.618E-07 
cg00911551 12 8234647 NECAP1 --- 1 2.431E-07 
           cg25668058 12 115183175 
 
--- 2 
        
2.097E-07 
   cg07922154 14 68087339 ARG2 +++ 2 
  
9.626E-08 
         cg04975143 14 106438118 ADAM6 --- 1 
        
1.784E-07 
   cg05622686 16 58501611 NDRG4 +++ 2 
         
2.977E-07 
  cg08447479 16 75589467 TMEM231 +++ 1 
   
3.28E-07 









5. Results: Cross-sectional associations with each lung function measure, without smoking adjustment 
 
Cross-sectional association with each lung function measure at time point 1 and at time point 2, separately: 
discovery, replication and combined EWAS meta-analyses in all participants are presented in table S3 for FEV1/FVC; 
table S4 for FEV1 and table S5 for FVC. 
The top association signals observed in the repeat cross-sectional associations with each lung function measure is 
presented in table S6.  
 
5.1. Table S3 (FEV1/FVC), Table S4 (FEV1) and Table S5 (FVC) 
Table S3: Discovery and replication meta-analyses of cross-sectional association with FEV1/FVC in all participants*, 
base model covariate adjusted EWAS (Mbase†) separately at two time points. Combined meta-analyses of cross-
sectional associations obtained using data from time point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and from 
time point T1 of KORA, LifeLines and NSPHS (excluding FTC replication cohort due to the younger mean age).See 
table in See table in EXCEL file: Additional_Tables_Imbodenetal.xlsx 
Table S4: Discovery and replication meta-analyses of cross-sectional association with FEV1 in all participants*, base 
model covariate adjusted EWAS (Mbase†) separately at two time points. Combined meta-analyses of cross-sectional 
associations obtained using data from time point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and from time point 
T1 of KORA, LifeLines and NSPHS (excluding FTC replication cohort due to the younger mean age).See table in EXCEL 
file: See table in EXCEL file: Additional_Tables_Imbodenetal.xlsx 
Table S5: Discovery and replication meta-analyses of cross-sectional association with FVC in all participants*, base 
model covariate adjusted EWAS (Mbase†) separately at two time points. Combined meta-analyses of cross-sectional 
associations obtained using data from time point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and from time point 
T1 of KORA, LifeLines and NSPHS (excluding FTC replication cohort due to the younger mean age). 
See table in EXCEL file: Additional_Tables_Imbodenetal.xlsx 
Footnote to table S3, table S4 and table S5: 
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 at combined meta-analysis. CpGs consistent in direction of the cross-
sectional associations at both time points were for FEV1/FVC: cg05575921, cg21161138, cg26703534 and cg25648203 (AHRR), cg03636183 
(F2RL3), cg21566642, cg01940273 and cg03329539 (in vicinity of ALPPL2), cg23771366 and cg11660018 (PRSS23), cg15342087 (IER3), 
cg19572487 (RARA), cg24859433, and cg14753356, cg15342087 (FLOTL1) and cg04885881 (SRM); for FEV1: cg03636183 (F2RL3), cg11660018 
(PRSS23), cg19572487 (RARA), cg23771366 (PRSS23), cg03149958 (ETV7), cg18181703 (SOCS3), cg05673882 (POLK), cg01127300, cg04813697 
(PIP4K2A), cg21990700 (C1RL), cg06826457, cg25953130 (ARID5B), cg01882991 (intergenic), cg16288101 (intergenic), cg12761472 
(intergenic), cg11231349 (NOS1AP); and none for FVC. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and 
interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, 
spirometer type, study center as well as cell composition. 
‡ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and direction of effects.[45] 
¶ For combined meta-analysis: FTC was excluded from this meta-analysis, given the smaller sample size and lower mean age (30.4 yrs) 
compared to the other adult cohorts (ECRHS (mean age: 54.5 yrs), NFBC1966 (46.3 yrs), SAPALDIA (58.8 yrs), LBC1936 (76.3 yrs) and the single 





5.2. Figure S2: Quantile-Quantile plot of cross-sectional EWAS on FEV1 and FVC 
Figure S2: Quantile-Quantile plots of cross-sectional covariate-adjusted EWAS (Mbase*) on FEV1 and on FVC at first 
and second time point, all participants. Increase in numbers of signals with aging. Meta-analyses were performed 
without genomic control. For FEV1, we identified 34 CpGs at time point 2 compared to none at time point 1 to be 
statistically significant (inflation factor  for time point 1 ( = 1.14) and for time point 2 ( = 1.14)). For FVC, we 
identified three CpGs at time point 2 compared to none at time point 1 to be statistically significant (inflation factor 






Footnote to Figure S2: 
*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and 
interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, 
spirometer type, study center as well as cell composition. 
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6. Results: EWASrepeat - Repeat cross-sectional EWAS in the same study participants – combining the 
data from both time points 
The discovery EWASrepeat was undertaken using mixed linear regression with a random intercept on the study 
participant to assess the data from both time points in the same model. The EWASrepeat results are presented only in 
the online supplement (Figure Box1 and Table S6, this Appendix). For FEV1, we found seven CpGs associated either in 
discovery EWAS meta-analysis or in the combined meta-analysis of four cohort studies to be associated with a 
P<5x10-7. Three CpGs did formally replicate in the LCB36 replication cohort (P<0.0071, Bonferroni correction for 7 
tests). All three replicated differentially methylated markers had previously been identified as smoking-related CpGs: 
cg05575921, in the AHRR gene replicating at Preplication= 0.0033 (Pcombined=1.86x10
-9), cg21566642 in the ALPPL2 gene 
(2q37.1) at Preplication= 0.0033 (Pcombined=1.86x10
-9) and cg04813697 in the PIP4K2A gene at Preplication= 0.0006 
(Pcombined=4.61x10
-7). Results (not shown) see Box3 Figure “Manhattan and Q-Q plots of EWASrepeat”). For FEV1/FVC, 
there were 23 CpG markers found to be associated at P-value < 5x 10-7 and six replicated formally at a P<0.0021 
(Bonferroni correction for 23 tests). Again all replicated CpGs were known smoking-related CpGs. In addition to the 
five prominent differentially methylated markers (cg21566642 and cg01940273 in the ALPPL2 gene (2q37.1), 
cg05951221 in the AHRR gene, and cg03636183 in the gene F2RL3), we identified cg09935388 in gene GFI1 
replicating at Preplication=0.0001 (Pcombined=2.54x10
-9).  
For FVC, only one CpG marker (cg07709627 in gene PLEKHF1) reached the genome-wide selection threshold for 
replication in the repeated cross-sectional analyses, but it did not replicate. This method performed poorer as fewer 
statistically significant CpGs were identified compared to the cross-sectional EWAS using data from the second time 
point. Comparing the results of the repeated cross-sectional EWAS with the results of two cross-sectional EWAS, we 
noted for some CpGs consistent associations for both approaches. For other CpGs it seemed that fixed effect linear 
approach at two time points revealed more easily consistent and statistically significant associations compared to 
the mixed linear models likely due to increased sample size of the replication cohort for the cross-sectional analyses. 
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Box1 Figure: EWASrepeat Manhattan and QQ plots, in all participants  
Figure: Manhattan and Quantile-Quantile plots of repeat cross-sectional EWAS (Mbase*) combining data from both time points, 
all participants A) on FEV1 (=1.23); B) FEV1/FVC (=1.13); and C) FVC (=1.13).
 
Footnote: 
*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, 
sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), 




6.1. Table S6: Repeat cross-sectional associations with lung function in all participants (EWASrepeat, Mbase)  
Table S6: Discovery, replication and combined EWAS meta-analyses of repeat cross-sectional association with lung function in all participants*, base model covariate 
adjusted EWAS (Mbase†). Covariate-adjusted mixed linear regressions with a random intercept on the subject were undertaken using data from both time points (repeat 
cross-sectional analysis (EWASrepeat)). 
 
     
Discovery (ECRHS/NFBC/SAPALDIA) Replication (LCB1936) 
  
Combined meta-analysis (ECRHS/NFBC/SAPALDIA/LBC1936) 
CpG ID chr position Locus 
smoking 













of effect  
Repli-
cated 









                
cg21566642 2 233284661 ALPPL2 yes 0.391(0.081) 1.41E-06 +++ 0.220 0.497(0.165) 0.0027 + no 0.411(0.073) 1.59E-08 ++++ 0.339 
cg05575921 5 373378 AHRR yes 0.362(0.068) 1.25E-07 +++ 0.408 0.478(0.163) 0.0033 + no 0.379(0.063) 1.86E-09 ++++ 0.527 
cg04813697 10 22920025 PIP4K2A yes 0.459(0.124) 0.0002 +++ 0.460 0.502(0.146) 0.0006 + yes 0.477(0.095) 4.61E-07 ++++ 0.659 
cg23771366 11 86510998 PRSS23 yes 0.743(0.143) 2.07E-07 +++ 0.362 0.33(0.223) 0.1402 + no 0.623(0.121) 2.36E-07 ++++ 0.216 
cg16288101 14 88621538 
 
yes 0.53(0.108) 1.01E-06 +++ 0.101 0.329(0.173) 0.0575 + no 0.473(0.092) 2.56E-07 ++++ 0.136 
cg19572487 17 38476024 RARA yes 0.525(0.116) 5.50E-06 +++ 0.281 0.457(0.174) 0.0084 + no 0.504(0.096) 1.58E-07 ++++ 0.450 
cg03636183 19 17000585 F2RL3 yes 0.543(0.104) 1.75E-07 +++ 0.987 0.484(0.192) 0.0117 + no 0.53(0.091) 6.88E-09 ++++ 0.992 
                 
FEV1/FVC 














of effect  
Repli-
cated 







cg04885881 1 11123118 
 
yes 0.116(0.02) 8.51E-09 +++ 0.408 0.072(0.054) 0.1792 + no 0.111(0.019) 4.55E-09 ++++ 0.497 
cg09935388 1 92947588 GFI1 yes 0.063(0.012) 3.60E-07 +++ 0.463 0.165(0.043) 0.0001 + yes 0.07(0.012) 2.54E-09 ++++ 0.077 
cg11231349 1 162050656 NOS1AP yes 0.128(0.027) 2.56E-06 ??+ 1.000 0.085(0.042) 0.0447 + no 0.116(0.023) 4.58E-07 ??++ 0.396 
cg03329539 2 233283329 ALPPL2 yes 0.095(0.018) 7.41E-08 +++ 0.182 0.116(0.067) 0.0816 + no 0.096(0.017) 1.63E-08 ++++ 0.320 
cg21566642 2 233284661 ALPPL2 yes 0.082(0.012) 1.39E-11 +++ 0.275 0.162(0.04) 5.58E-05 + yes 0.088(0.012) 2.29E-14 ++++ 0.101 
cg01940273 2 233284934 ALPPL2 yes 0.105(0.016) 3.10E-11 +++ 0.791 0.215(0.055) 7.95E-05 + yes 0.113(0.015) 7.72E-14 ++++ 0.233 
cg11610350 3 64253705 
  
0.135(0.027) 5.06E-07 +++ 0.481 0.101(0.074) 0.1718 + no 0.131(0.025) 2.12E-07 ++++ 0.648 
cg16990174 3 72496875 RYBP 
 
0.106(0.021) 3.09E-07 +++ 0.978 -0.003(0.052) 0.9491 - no 0.091(0.019) 2.26E-06 +++- 0.275 
cg08763102 4 3079751 HTT yes 0.151(0.028) 1.19E-07 +++ 0.284 -0.048(0.069) 0.4879 - no 0.122(0.026) 3.73E-06 +++- 0.022 
cg01899089 5 369969 AHRR yes 0.125(0.024) 3.08E-07 -++ 0.006 0.033(0.051) 0.5185 + no 0.108(0.022) 9.63E-07 -+++ 0.005 
cg05575921 5 373378 AHRR yes 0.083(0.01) 3.59E-16 +++ 0.520 0.201(0.038) 1.48E-07 + yes 0.091(0.01) 2.65E-20 ++++ 0.017 
cg21161138 5 399360 AHRR yes 0.13(0.02) 1.62E-10 +++ 0.891 0.117(0.053) 0.0286 + no 0.128(0.019) 1.44E-11 ++++ 0.963 
cg24859433 6 30720203 
 
yes 0.142(0.031) 3.58E-06 +++ 0.514 0.173(0.079) 0.0283 + no 0.146(0.029) 3.15E-07 ++++ 0.691 
cg15342087 6 30720209 FLOT1 yes 0.181(0.035) 1.62E-07 +++ 0.719 0.221(0.075) 0.0034 + no 0.188(0.031) 2.22E-09 ++++ 0.827 
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cg13353574 8 61326925 
 
yes 0.134(0.026) 3.51E-07 +++ 0.210 -0.026(0.06) 0.6673 - no 0.109(0.024) 6.94E-06 +++- 0.029 
cg05329578 9 2241688 
 
yes 0.074(0.015) 3.39E-07 +++ 0.937 0.026(0.043) 0.5457 + no 0.069(0.014) 4.95E-07 ++++ 0.747 
cg21611682 11 68138269 LRP5 yes 0.136(0.026) 1.78E-07 +++ 0.943 0.055(0.074) 0.4517 + no 0.127(0.025) 2.29E-07 ++++ 0.761 
cg11660018 11 86510915 PRSS23 yes 0.143(0.022) 7.12E-11 +++ 0.927 0.207(0.061) 0.0008 + yes 0.151(0.021) 3.55E-13 ++++ 0.778 
cg23771366 11 86510998 PRSS23 yes 0.15(0.022) 1.37E-11 +++ 0.391 0.159(0.058) 0.0058 + no 0.151(0.021) 2.89E-13 ++++ 0.594 
cg22952142 15 68549178 
  
0.071(0.014) 4.03E-07 +++ 0.813 0.002(0.035) 0.9627 + no 0.062(0.013) 2.32E-06 ++++ 0.286 
cg00310412 15 74724918 SEMA7A yes 0.145(0.028) 1.27E-07 +++ 0.348 0.123(0.074) 0.0970 + no 0.142(0.026) 3.19E-08 ++++ 0.534 
cg19572487 17 38476024 RARA yes 0.11(0.018) 2.49E-09 +++ 0.980 0.11(0.051) 0.0324 + no 0.11(0.017) 2.38E-10 ++++ 0.998 
cg03636183 19 17000585 F2RL3 yes 0.113(0.016) 5.25E-13 +++ 0.752 0.254(0.049) 2.75E-07 + yes 0.126(0.015) 3.40E-17 ++++ 0.046 
cg16201146 20 19191526 
 
yes 0.133(0.027) 4.97E-07 +++ 0.786 -0.057(0.06) 0.3436 - no 0.102(0.024) 2.44E-05 +++- 0.032 
                 
FVC 














of effect  
Repli-
cated 







cg07709627 19 30156658 PLEKHF1 -4.071 (0.729) 2.38E-08 --- 0.170 1.559 (1.01) 0.1224 + no -2.14 (0.591) 0.0003 ---+ 2.53E-05 
 
Footnote table S6: 
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 in the combined meta-analysis.  
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared deviation of 
height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Replication was defined for association with FEV1 if replication P-value<0.00067 (multiple testing correction for 74 tests), with FEV1/FVC if replication P-value<0.0011 (multiple testing correction for47 tests) 
and with FVC if replication P-value<0.0031 (multiple testing correction for 16 tests). 




7. Results: Effect of smoking adjustment on the cross-sectional EWAS (Msmok): 
After applying smoking adjustment, we identified generally fewer genome-wide significant associations. 
Interestingly, the top five CpGs were still smoking related methylation markers, but the strength of their association 
with lung function was greatly diminished e.g. cg23771366 (PRSS23) had P=4.61x10-8 (Msmok) versus P=5.38x10
-27 
(Mbase), cg05575921 (AHRR) had P=2.69x10
-11 (Msmok) versus P=7.22
-50 (Mbase), cg03636183 (F2RL3) had P=1.02x10
-8 
(Msmok) versus P=4.5x10
-43 (Mbase). In contrast, the CpG not modified by smoking behavior, cg13064897 on chr8 at 
135Mb, did not show an important alteration of the association with FEV1/FVC after smoking adjustment. The 
increase in signal strength of the associations observed at time point 2 remained notable even after smoking 




7.1. Figure S3: Quantile-Quantile plots of smoking adjusted EWAS, in all participants. 
Figure S3: Quantile-Quantile plots of cross-sectional covariate-adjusted EWAS (Msmok*) at first and second time 
point, in all participants on A) FEV1 (inflation factor  for time point 1 ( = 1.02) and for time point 2 ( = 1.04)); B) 
FEV1/FVC (inflation factor  for time point 1 ( = 1.07) and for time point 2 ( = 0.98)); and C) FVC (inflation factor  
for both time points ( = 1.00)). 
 
Footnote to Figure S3: 
*Smoking adjusted model (Msmok): EWAS were adjusted for smoking covariates (history of smoking intensity as pack years smoked up to the 
time point of data collection for regressions and for smoking status (current, former and never smoker)) in addition to the base model 
covariate adjustments (age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, 





7.2. cg16288101: Smoking adjusted meta-analyses of cross-sectional associations (Msmok), in all participants.  
Table S7: Meta-analyses of cross-sectional association with FEV1, FEV1/FVC, and FVC in all participants*, smoking adjusted EWAS (Msmok†). Meta-analyses of cross-sectional 
associations obtained using data from time point T2 of ECRHS, NFBC1966, SAPALDIA, LBC1936 and from time point T1 of KORA, LifeLines and NSPHS. 
 
     
Discovery meta-analysis at time point 2  
(ECRHS,NFBC1966, SAPALDIA) 
Replication meta-analysis  
(KORA,LBC1936, LifeLines, NSPHS, FTC) 
Combined meta-analysis 
(ECRHS,NFBC1966, SAPALDIA, KORA,LBC1936, LifeLines, NSPHS) 
CpG ID chr positions Locus 
known 
smoking 





























    
  
   
  
   
  
   
cg07626482 19 47289503 SLC1A5 yes 1.826 (0.41) 8.23E-06 +++ 0.690 1.086 (0.331) 0.0010 +-++- 0.259 1.612 (0.258) 4.32E-10 +++++++ 0.919 
cg03149958 6 36326677 ETV7 yes 1.319 (0.23) 9.31E-09 +++ 0.339 0.337 (0.237) 0.1554 +-++- 0.303 0.896 (0.164) 4.32E-08 +++++++ 0.069 
cg05575921 5 373378 AHRR yes 0.496 (0.146) 0.0007 +++ 0.791 0.468 (0.123) 0.0001 ++++- 0.356 0.496 (0.094) 1.27E-07 +++++++ 0.758 
cg18181703 17 76354621 SOCS3 yes 1.038 (0.248) 2.93E-05 +++ 0.939 0.558 (0.2) 0.0052 ++++- 0.512 0.819 (0.158) 2.14E-07 +++++++ 0.894 
                 
FEV1/FVC 
    
  
   
  
   
  
   
cg05575921 5 373378 AHRR yes 0.094 (0.021) 9.32E-06 +++ 0.167 0.091 (0.018) 6.63E-07 +++++ 0.993 0.094 (0.014) 2.21E-11 +++++++ 0.726 
cg03636183 19 17000585 F2RL3 yes 0.092 (0.03) 0.0022 +++ 0.223 0.127 (0.026) 1.27E-06 ++++- 0.570 0.117 (0.02) 1.02E-08 +++++++ 0.343 
cg21566642 2 233284661 ALPPL2 yes 0.084 (0.023) 0.0002 +++ 0.862 0.091 (0.021) 1.57E-05 ++++- 0.487 0.09 (0.016) 1.42E-08 +++++++ 0.863 
cg01940273 2 233284934 ALPPL2 yes 0.126 (0.031) 3.88E-05 +++ 0.353 0.104 (0.029) 0.0003 +++++ 0.630 0.12 (0.022) 2.75E-08 +++++++ 0.620 
cg23771366 11 86510998 PRSS23 yes 0.104 (0.035) 0.0034 +++ 0.189 0.156 (0.03) 2.78E-07 +++++ 0.993 0.13 (0.024) 4.61E-08 +++++++ 0.598 
cg03329539 2 233283329 ALPPL2 yes 0.107 (0.041) 0.0092 +++ 0.737 0.143 (0.033) 1.30E-05 ++++- 0.660 0.134 (0.026) 3.92E-07 +++++++ 0.903 
                 
FVC 
    
  
   
  
   
  
   
cg03149958 6 36326677 ETV7 yes 1.315 (0.259) 3.78E-07 +++ 0.484 0.654 (0.276) 0.0179 +-++- 0.161 1.08 (0.189) 1.07E-08 +++++++ 0.401 
cg08549335 7 30387954 ZNRF2 yes 0.953 (0.205) 3.24E-06 +++ 0.441 0.359 (0.132) 0.0067 +++++ 0.932 0.64 (0.121) 1.12E-07 +++++++ 0.434 
 
Footnote to table S7: 
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 in the combined meta-analysis.  
† Smoking model (Msmok) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared deviation of 
height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition and additionally for adjusted for smoking covariates: history of smoking intensity as 





8. Results: Prediction of DNAme1 association with lung function (EWASpredict) 
8.1. Table S8: Prediction EWAS (Mbase) for change in FEV1 and for FVC, in all participants. 
Table S8: Prediction EWAS meta-analyses* on annual change in lung function on FEV1 and FVC, in all participants, base model adjustment (Mbase†). Replicated‡ 
associations indicated show replication P-value in bold. 































change in FEV1 
       
P-value  
replication <0.00067‡ 
   cg05575921 5 373378 AHRR yes 6.1e-22 (-----------+----) 2.01E-15 +++ 0.535 4.89E-07 ++ yes 0.334 1.96E-20 +++++ 0.318 
cg01940273 2 233284934 ALPPL2 yes 9.8e-30 (----------------) 1.27E-12 +++ 0.139 6.32E-05 ++ yes 0.488 5.63E-16 +++++ 0.263 
cg21566642 2 233284661 ALPPL2 yes 4.5e-21 (----------------) 3.67E-13 +++ 0.107 0.0004 ++ yes 0.596 7.16E-16 +++++ 0.307 
cg03636183 19 17000585 F2RL3 yes 5.7e-17 (----------------) 5.64E-11 +++ 0.511 1.70E-05 ++ yes 0.139 1.08E-14 +++++ 0.265 
cg05951221 2 233284402 ALPPL2 yes 6.8e-23 (----------------) 5.81E-08 ?++ 0.377 0.0002 ++ yes 0.447 8.54E-11 ?++++ 0.520 
cg25648203 5 395444 AHRR yes 2.7e-11 (----------------) 7.15E-09 +++ 0.716 0.0040 ++ 
 
0.018 1.16E-10 +++++ 0.165 
cg27241845 2 233250370 ALPPL2 yes 2.7e-10 (-----------+----) 2.85E-08 +++ 0.077 0.0044 ++ 
 
0.011 4.44E-10 +++++ 0.021 
cg26703534 5 377358 AHRR yes 7.2e-18 (-----------+----) 5.87E-08 +++ 0.477 0.0106 ++ 
 
0.158 2.15E-09 +++++ 0.466 
cg21161138 5 399360 AHRR yes 7.9e-13 (----------------) 1.43E-08 +++ 0.742 0.0520 +- 
 
0.010 2.72E-09 ++++- 0.101 
cg27537125 1 25349681 RUNX3 yes 5.5e-16 (-----------+----) 2.04E-08 +++ 0.001 0.0554 ++ 
 
0.187 5.25E-09 +++++ 0.002 
cg03329539 2 233283329 ALPPL2 yes 9.7e-16 (-----------+----) 3.59E-06 +++ 0.169 0.0015 ++ 
 
0.172 2.49E-08 +++++ 0.206 
cg12303084 20 45985741 ZMYND8 yes 4.2e-15 (---+------------) 1.66E-07 +++ 0.454 0.0595 ++ 
 
0.281 4.05E-08 +++++ 0.469 
cg21393163 1 12217629 TNFRSF1B yes 3.8e-12 (----------------) 3.01E-07 +++ 0.949 0.0484 ++ 
 
0.767 5.06E-08 +++++ 0.959 
cg15342087 6 30720209 FLOT1 yes 3.9e-14 (-----------+----) 2.04E-07 +++ 0.851 0.0816 ++ 
 
0.045 5.66E-08 +++++ 0.299 
ch.8.91748119F 8 91678943 
   
4.29E-08 +++ 0.089 0.2817 ++ 
 
0.060 9.18E-08 +++++ 0.026 
cg07986378 12 11898284 ETV6 yes 3.3e-07 (-----------+-+--) 2.11E-08 +++ 0.364 0.4656 ++ 
 
0.808 2.03E-07 +++++ 0.136 
cg00210249 10 71135679 HK1 yes 5.4e-06 (++++++++++++++++) 3.68E-07 --- 0.738 0.5329 -- 
 
0.757 1.08E-06 ----- 0.532 
cg03149958 6 36326677 ETV7 yes 1.6e-08 (----------------) 1.39E-07 +++ 0.228 0.9343 +- 
 
0.657 1.54E-06 ++++- 0.099 
cg06762457 6 149806635 ZC3H12D yes 1.1e-06 (-----------+----) 3.58E-07 +++ 0.259 0.8538 +- 
 
0.002 2.26E-05 ++++- 4.44E-04 
change in FVC 
        
P-value  
replication <0.0031‡ 
   cg03149958 6 36326677 ETV7 yes 1.6e-08 (----------------) 2.77E-10 +++ 0.325 0.7705 ++ 
 
0.937 3.37E-09 +++++ 0.125 
cg05575921 5 373378 AHRR yes 6.1e-22 (-----------+----) 3.97E-07 +++ 0.025 0.3186 ++ 
 
0.315 3.68E-07 +++++ 0.055 
cg03636183 19 17000585 F2RL3 yes 5.7e-17 (----------------) 2.90E-07 +++ 0.080 0.4964 -+ 
 
0.146 5.72E-07 +++-+ 0.062 
cg15342087 6 30720209 FLOT1 yes 3.9e-14 (-----------+----) 7.53E-08 +++ 0.026 0.9616 -+ 
 
0.698 8.98E-07 +++-+ 0.016 
cg01651915 8 55795551 XKR4 yes 2.1e-07 (----?------+-+--) 3.86E-07 +++ 0.757 0.6393 +- 
 




Footnote to table S8: 
* Prediction association of DNA methylation at first time point (DNAme1) with annual change in lung function during follow-up, defined as lung function at second time point – lung function at first time point 
divided by the time of follow-up in years. Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 at discovery or replication level. CpGs shown sorted by statistical significance of combined meta-
analysis results. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, lung function at time point 1 (FEV1 or FVC respectively), squared deviation from the mean of height, sex and interaction terms of 
age, age squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Replication was defined for association with FEV1 if replication P-value<0.00067 (multiple testing correction for 74 tests), and with FVC if replication P-value<0.0031 (multiple testing correction for 16 tests). 





8.2. Figure S4: Plots of prediction EWAS on FEV1 and FVC 
Figure S4: Manhattan and Quantile-Quantile plots of covariate-adjusted prediction* EWAS (Mbase†) in all participants 
A) on FEV1 ( = 1.26); and B) on FVC ( = 1.23).  
 
Footnote to Figure S4: 
* Prediction association of DNA methylation at first time point (DNAme 1) with annual change in lung function during 
follow-up  
†Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, lung function at time point 1 (FEV1 
or FVC respectively),  squared deviation from the mean of height, sex and interaction terms of age, age squared, 
height and squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, 




9. Results: EWAS meta-analyses in never smokers 
9.1. Figure S5: Quantile-Quantile plots for cross-sectional associations, in never smokers.  
Figure S5: Quantile-Quantile plots of cross-sectional covariate-adjusted EWAS (Mbase*) at first and second time point, 
in never smokers A) on FEV1 (inflation factor  for time point 1 ( = 1.09) and for time point 2 ( = 1.05));B) FEV1/FVC 
(inflation factor  for time point 1 ( = 1.11) and for time point 2 ( = 0.96)); and C) FVC (inflation factor  for time 
point 1 ( = 1.08) and for time point 2 ( = 1.03)). 
 
Footnote to Figure S5: 
*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and 
interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, 





9.2. Table S9: Cross-sectional associations, in never smokers.  
 
Table S9: Detailed results in never smokers: cross-sectional associations with lung function at time point 1 and at 
time point 2, separately: discovery, replication and combined EWAS meta-analyses, base model covariate adjusted 
EWAS (Mbase†). Meta-analyses of cross-sectional associations obtained using data from time point T2 of ECRHS, 
NFBC1966, SAPALDIA, LBC1936 and from time point T1 of KORA, LifeLines and NSPHS.  
See table in EXCEL file: Addtional_Tables_Imbodenetal.xlsx 
Footnote to table S9: 
* Presentation of CpG markers showing meta-analysis P-value < 5x10-7 in the combined meta-analysis.  
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean 
of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, education 
(low, medium, high), body mass index, spirometer type, study center as well as cell composition. 
‡ Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status 




9.3. Table: EWASrepeat in never smokers:  
 
In the repeat cross-sectional EWAS cg14366110 was the top hit (Pdiscovery=1.72 x10
-10) for association with FEV1/FVC, yet this association did not replicate in the LBC1936 
sample (Preplication= 0.454) though the direction of the effect was consistent and the Pcombined = 4.63 x10
-10 remained statistically epigenome-wide significant.  
 
Table: EWASrepeat in never smokers: Discovery, replication and combined EWAS meta-analyses of repeat cross-sectional association with lung function in never smokers*, 
base model covariate adjusted EWAS (Mbase†).  
 






Combined meta-analysis  
(ECRHS/NFBC/SAPALDIA/LBC1936) 
CpG ID chr position Locus 
known 
smoking 




























    
  
   
  
   
  
   cg17838734 6 83073924 TPBG no -2.507 (0.435) 7.97E-09 --- 0.685 0.408 (0.502) 0.4169 + na -1.259 (0.329) 0.0001 ---+ 1.68E-04 
cg19931644 8 12623485 
 
no 0.917 (0.178) 2.76E-07 +++ 0.695 0.121 (0.218) 0.5803 + na 0.598 (0.138) 1.50E-05 ++++ 0.033 
cg07922154 14 68087339 ARG2 no 1.098 (0.206) 9.63E-08 +++ 0.299 0.193 (0.292) 0.5077 + na 0.798 (0.168) 2.13E-06 ++++ 0.032 
FEV1/FVC 
    
  
   
  
   
  
   cg18938392 1 157248950 
 
no 0.08 (0.014) 2.87E-08 +++ 0.825 -0.009 (0.035) 0.7893 - na 0.067 (0.013) 4.59E-07 +++- 0.121 
cg15981995 3 169487311 ARPM1 no -0.952 (0.188) 4.29E-07 ??- 1.000 0.39 (0.309) 0.2063 + na -0.588 (0.161) 0.0003 ??-+ 2.06E-04 
cg14366110 9 133779382 FIBCD1 no -0.255 (0.04) 1.72E-10 --- 0.904 -0.078 (0.104) 0.4539 - na -0.232 (0.037) 4.63E-10 ---- 0.440 
FVC 
    
  
   
  
   
  
   cg05831672 10 103543172 NPM3 no -4.404 (0.802) 3.93E-08 --- 0.871 -0.759 (1.345) 0.5727 - na -3.449 (0.689) 5.491E-07 ---- 0.127 
cg22508172 1 24069723 TCEB3 no -4.431 (0.836) 1.17E-07 --- 0.582 -0.634 (1.22) 0.6033 - na -3.218 (0.69) 3.09E-06 ---- 0.053 
cg10212705 1 154297848 ATP8B2 no -5.875 (1.129) 1.96E-07 --- 0.277 0.784 (3.445) 0.8200 + na -5.229 (1.073) 1.10E-06 ---+ 0.114 
cg04030659 6 22570704 HDGFL1 no -2.095 (0.412) 3.66E-07 --- 0.442 0.419 (0.531) 0.4299 + na -1.15 (0.326) 0.0004 ---+ 0.001 
                 
                  
Footnote table EWASrepeat in never smokers: 
* Presentation of CpG markers showing meta-analysis P-value < 5x10
-7
 in the combined meta-analysis.  
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. 




9.4. Table S10: Prediction EWAS, in never smokers.  






Combined meta-analysis  
(ECRHS/NFBC/SAPALDIA/ KORA/LCB1936) 
  


































        
  
   
  
   
  
cg21393163 1 12217629 TNFRSF1B yes 0.08 (0.025) 0.0013 +++ 0.347 0.122 (0.054) 0.0242 ++ 0.443 0.087 (0.022) 0.0001 +++++ 0.523   
cg08447479 16 75589467 TMEM231 no 0.40 (0.078) 3.28E-07 +++ 0.727 -0.135 (0.114) 0.2357 -- 0.950 0.229 (0.065) 0.0004 +++-- 0.004   
         
  
   
  
   
  
FEV1/FVC 
        
  
   
  
   
  
cg14366110 9 133779382 FIBCD1 no 0.018 (0.003) 4.24E-09 ++- 0.152 0.01 (0.013) 0.4390 ++ 0.414 0.017 (0.003) 3.639E-09 ++-++ 0.315   
cg11216682 2 131113867 PTPN18 no -0.018 (0.003) 9.05E-08 +-+ 0.114 -0.006 (0.016) 0.6795 -- 0.666 -0.017 (0.003) 1.086E-07 +-+-- 0.282   
         
  
   
  
   
  
FVC 
        
  
   
  
   
  
cg20098854 8 898407 
 
no -0.085 (0.016) 1.32E-07 --- 0.108 0.059 (0.061) 0.3394 -+ 0.291 -0.076 (0.016) 1.16E-06 ----+ 0.030   
cg04774364 10 106100810 
 
no 0.188 (0.036) 1.62E-07 +++ 0.566 0.003 (0.071) 0.9635 +- 0.557 0.151 (0.032) 2.59E-06 ++++- 0.145   
cg20278790 20 57583474 CTSZ no 0.24 (0.047) 2.72E-07 +++ 0.004 -0.011 (0.094) 0.9071 +- 0.775 0.19 (0.042) 5.36E-06 ++++- 0.002   
                  
 
Footnote to table S10: 
* Prediction association of DNA methylation at first time point (DNAme 1) with annual change in lung function during follow-up, defined as lung function at second time 
point – lung function at first time point divided by the time of follow-up in years. Presentation of CpG markers showing meta-analysis P-value < 5x10-7 at discovery or 
replication level. 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, lung function at time point 1 (FEV1, FVC or FEV1/FVC respectively), squared deviation from 
the mean of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, 






10. Results: Functional characterization of replicated CpGs 
10.1.  Table S11: 43 differentially methylated loci associated with lung function  
Table S11: 43 Loci associated with lung function differentially methylated loci associated with lung function based on 
57 replicated CpGs. 






cg04885881 1 11123118 SRM -3027 F used 
cg21393163 1 12217629 TNFRSF1B 9429 R used 
cg27537125 1 25349681 RUNX3 -92911 F used 
cg21140898 1 51442318 CDKN2C -2009 F used 
cg09935388 1 92947588 GFI1 0 F used 
cg18826637 2 145116633 ZEB2 25307 F used 
cg27241845 2 233250370 ALPPL2 
 
R pruned 
cg17087741 2 233283010 ALPPL2 
 
F pruned 
cg03329539 2 233283329 ALPPL2 
 
F pruned 
cg05951221 2 233284402 ALPPL2 
 
F pruned 
cg21566642 2 233284661 ALPPL2 -9237 R used 
cg01940273 2 233284934 ALPPL2 
 
R pruned 
cg19859270 3 98251294 GPR15 0 R used 
cg00741986 4 2748332 TNIP2 0 R used 
cg08763102 4 3079751 HTT 
 
F pruned 
cg24086068 4 77356008 SHROOM3 243 R used 
cg01899089 5 369969 AHRR 
 
F pruned 
cg05575921 5 373378 AHRR 0 F used 
cg26703534 5 377358 AHRR 
 
F pruned 
cg25648203 5 395444 AHRR 
 
R pruned 
cg21161138 5 399360 AHRR 
 
R pruned 
cg05673882 5 74862702 POLK 0 F used 
cg14753356 6 30720108 intergenic 
 
R pruned 
cg24859433 6 30720203 intergenic 
 
R pruned 
cg15342087 6 30720209 FLOT1 -7882 R used 
cg05593667 6 35490744 TULP1 -10097 F used 
cg03149958 6 36326677 ETV7 7292 R used 
cg00073460 6 149806502 ZC3H12D 
 
F pruned 
cg06762457 6 149806635 ZC3H12D -487 F used 
cg08549335 7 30387954 ZNRF2 0 R used 
cg25949550 7 145814306 CNTNAP2 0 F used 
cg19589396 8 103937374 AZIN1 -60977 F used 
cg12075928 8 141801307 PTK2 0 F used 
cg02716826 9 33447032 AQP3 0 R used 
cg04813697 10 22920025 PIP4K2A 0 R used 
cg25953130 10 63753550 ARID5B 0 F used 
cg00210249 10 71135679 HK1 0 R used 
cg03450842 10 80834947 ZMIZ1 0 F used 
cg21611682 11 68138269 LRP5 0 F used 
cg11660018 11 86510915 PRSS23 
 
F pruned 
cg23771366 11 86510998 PRSS23 491 R used 
cg21990700 12 7260776 C1RL 0 R used 
cg07986378 12 11898284 ETV6 0 R used 
45 
 
cg06826457 12 12867669 P27_CRE 2528 R used 
cg02583484 12 54677008 HNRNPA1 0 F used 
cg13976502 14 74227875 ELMSAN1 0 F used 
cg00310412 15 74724918 SEMA7A 0 R used 
cg16391678 16 30485597 ITGAL 0 F used 
cg01243823 16 50732212 NOD2 0 R used 
cg19572487 17 38476024 RARA 0 R used 
cg18181703 17 76354621 SOCS3 0 R used 
cg03636183 19 17000585 F2RL3 0 R used 
cg07626482 19 47289503 SLC1A5 0 F used 
cg03707168 19 49379127 PPP1R15A 0 F used 
cg12303084 20 45985741 ZMYND8 -267 F used 
cg23110422 21 40182073 ETS2 0 F used 
cg01127300 22 38614796 TMEM184B 500 F used 
 
10.2. Table S12: Functional annotation: Transcription binding sites  







observed p-value FDR p-value 
RELA 2.5863 15 <1.00E-04 0.002 
EP300 4.3584 18 <1.00E-04 0.004 
POLR2A 12.787 29 <1.00E-04 0.012 
EBF1 1.5989 10 <1.00E-04 0.012 
IKZF1 0.3509 7 <1.00E-04 0.015 
FOXM1 1.4265 9 <1.00E-04 0.021 
POU2F2 1.6033 9 <1.00E-04 0.021 
STAT3 1.8665 9 <1.00E-04 0.021 
TBL1XR1 1.5904 9 <1.00E-04 0.021 
RUNX3 2.4005 10 1.00E-04 0.039 
PAX5 1.76 8 <1.00E-04 0.039 
 
10.3. Table S13: Functional annotation: Chromatin State Models  
Table S13: Enrichement for chromatin state model reported by Roadmap. 




observed p-value FDR p-value 
E128 [NHLF Lung Fibroblast Primary Cells] 3 [Transcr. at gene 5′ and 3′] 0.4589 5 1.00E-04 0.06249932 
E096 [Lung] 7 [Enhancers] 5.5423 14 7.00E-04 0.06356541 
E017 [IMR90 fetal lung fibroblasts Cell Line] 7 [Enhancers] 2.989 9 0.0026 0.06542811 
E034 [Primary T cells from peripheral blood] 2 [Flanking active TSS] 4.2305 12 2.00E-04 0.07681021 
E128 [NHLF Lung Fibroblast Primary Cells] 7 [Enhancers] 2.9174 8 0.0083 0.10937309 
E001 [ES-I3 Cells] 7 [Enhancers] 4.7668 11 0.0052 0.11846625 
E088 [Fetal Lung] 6 [Genic enhancers] 0.3166 4 2.00E-04 0.12499918 




10.4. Table S14: Functional annotation: Canonical Pathways  
Table S14: Canonical pathways (p-value < 0.05) from Ingenuity Pathway Analysis system. 
Ingenuity Canonical Pathways P-vaule FDR Ratio Focused Genes 
Aryl Hydrocarbon Receptor Signaling 0.004 0.16 0.022 AHRR,RARA,CDKN1B 
Spermidine Biosynthesis I 0.005 0.16 0.500 SRM 
Th2 Pathway 0.005 0.16 0.021 RUNX3,SOCS3,GFI1 
Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency 0.005 0.16 0.044 ETS2,RARA 
Semaphorin Signaling in Neurons 0.006 0.16 0.039 PTK2,SEMA7A 
Regulation of Cellular Mechanics by Calpain Protease 0.007 0.16 0.036 PTK2,CDKN1B 
Th1 and Th2 Activation Pathway 0.008 0.16 0.017 RUNX3,SOCS3,GFI1 
Cell Cycle: G1/S Checkpoint Regulation 0.010 0.16 0.030 CDKN2C,CDKN1B 
Agrin Interactions at Neuromuscular Junction 0.010 0.16 0.030 PTK2,ITGAL 
Trehalose Degradation II (Trehalase) 0.011 0.16 0.200 HK1 
Molecular Mechanisms of Cancer 0.012 0.16 0.010 PTK2,LRP5,CDKN2C,CDKN1B 
VDR/RXR Activation 0.013 0.17 0.026 LRP5,CDKN1B 
Cyclins and Cell Cycle Regulation 0.014 0.17 0.025 CDKN2C,CDKN1B 
Small Cell Lung Cancer Signaling 0.016 0.17 0.024 PTK2,CDKN1B 
IL-7 Signaling Pathway 0.017 0.17 0.023 PTK2,CDKN1B 
Crosstalk between Dendritic Cells and Natural Killer Cells 0.018 0.17 0.023 TNFRSF1B,ITGAL 
GDP-glucose Biosynthesis 0.020 0.18 0.111 HK1 
Glucose and Glucose-1-phosphate Degradation 0.023 0.18 0.100 HK1 
IGF-1 Signaling 0.025 0.18 0.019 PTK2,SOCS3 
UDP-N-acetyl-D-galactosamine Biosynthesis II 0.025 0.18 0.091 HK1 
Type I Diabetes Mellitus Signaling 0.025 0.18 0.019 SOCS3,TNFRSF1B 
Paxillin Signaling 0.026 0.18 0.018 PTK2,ITGAL 
HGF Signaling 0.028 0.18 0.018 PTK2,ETS2 
Rac Signaling 0.029 0.18 0.017 PTK2,PIP4K2A 
PTEN Signaling 0.030 0.18 0.017 PTK2,CDKN1B 
RhoA Signaling 0.032 0.18 0.016 PTK2,PIP4K2A 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 0.032 0.18 0.010 SOCS3,LRP5,TNFRSF1B 
Telomere Extension by Telomerase 0.034 0.18 0.067 HNRNPA1 
IL-6 Signaling 0.035 0.18 0.016 SOCS3,TNFRSF1B 
Th1 Pathway 0.035 0.18 0.015 RUNX3,SOCS3 
G_12/13 Signaling 0.038 0.19 0.015 PTK2,F2RL3 
Inflammasome pathway 0.045 0.20 0.050 NOD2 
Type II Diabetes Mellitus Signaling 0.048 0.20 0.013 SOCS3,TNFRSF1B 
Polyamine Regulation in Colon Cancer 0.049 0.20 0.046 AZIN1 
D-myo-inositol-5-phosphate Metabolism 0.049 0.20 0.013 SOCS3,PIP4K2A 
 
10.5. Table S15: Functional annotation: Pathway analysis using KEGG   
Table S15: Pathway analysis by topKEGG showing top 10 pathways.  
Here, Pathway corresponds to the KEGG pathway being tested; N corresponds to number of genes in KEGG term; DE 
corresponds to the number of genes differentially methylated; P.DE corresponds to the p-values for 
overrepresentation of the KEGG terms; FDR corresponds to the false discovery rate corrected p-value. 
Pathway N DE P.DE FDR 
Transcriptional misregulation in cancer 180 4 1.02E-05 0.003 
Pathways in cancer 515 5 2.91E-05 0.005 
Regulation of actin cytoskeleton 207 3 0.0005 0.05 
Type II diabetes mellitus 46 2 0.0009 0.07 
Central carbon metabolism in cancer 65 2 0.002 0.09 
TNF signaling pathway 108 2 0.002 0.09 
Leukocyte transendothelial migration 110 2 0.002 0.09 
Small cell lung cancer 93 2 0.002 0.09 
Insulin signaling pathway 137 2 0.004 0.15 




10.6. Table S16: Functional annotation: GO term enrichment analysis 
Table S16: GO enrichment analysis by topGO. Here, Term = the gene ontology term being tested; Ont = Ontology 
(here, BP = biological process) N = number of genes in GO term; DE = number of genes differentially methylated; 
P.DE = p-values for overrepresentation of the KEGG terms; FDR = False discovery rate 
Term Ontology N DE P.DE PFDR 
regulation of immune response BP 800 9 6.28E-06 0.133 
immune system process BP 2268 14 1.82E-05 0.192 
regulation of immune system process BP 1238 10 5.23E-05 0.264 
vitellogenesis BP 4 2 6.86E-05 0.264 
regulation of transcription from RNA polymerase II promoter BP 1770 13 7.28E-05 0.264 
positive regulation of immune response BP 593 7 7.49E-05 0.264 
positive regulation of immune system process BP 853 8 0.0001 0.373 
transcription from RNA polymerase II promoter BP 1957 13 0.0002 0.435 
cytoplasm organization BP 10 2 0.0002 0.522 
negative regulation of cellular macromolecule biosynthetic process BP 1262 10 0.0003 0.540 
 
11. Results: Enrichment analysis of smoking-related CpGs in discovery EWAS. 
11.1. Table S17: Overrepresentation of smoking-related CpGs among the lung function associated CpG markers.  
Table S17: Enrichment analysis results testing for overrepresentation of smoking-related CpGs among the lung 
function or prediction of change in lung function* associated CpG markers. P-values from Weighted Kolmogorov 
Smirnov Test (WKS).[54] P-values < 0.05 are considered statistically significant and shown in bold. Prior to WKS 
testing we excluded cross-reactive probes.[58]  
 
  FEV1 FVC FEV1/FVC 
Cross-sectional 
time point 1 
All, Mbase† 0.00036 0.99 0.00036 
All, Msmok‡ 0.00053 0.81 0.00036 
Never smokers, Mbase† 0.00036 0.088 0.00036 
Cross-sectional 
Time point 2 
All, Mbase† 0.00036 0.00036 0.00036 
All, Msmok‡ 0.00036 0.00082 0.0011 
Never smokers, Mbase† 0.00036 0.0048 0.23 
Prediction 
Association*  
All, Mbase† 0.00036 0.00036 0.00036 
All, Msmok‡ 0.71 0.078 0.25 
Never smokers, Mbase† 0.65 0.0026 0.049 
 
Footnote to table S17: 
*Prediction association of DNA methylation at first time point (DNAme1) with annual change in lung function during 
follow-up, defined as lung function at second time point – lung function at first time point divided by the time of 
follow-up in years. Prediction models were additional adjusted for lung function at time point 1 (FEV1, FVC or 
FEV1/FVC respectively). 
† Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean 
of height, sex and interaction terms of age, age squared, height and squared deviation of height with sex, education 
(low, medium, high), body mass index, spirometer type, study center as well as cell composition.  
‡ Smoking model EWAS (Msmok) were additionally adjusted for smoking covariates: history of smoking intensity as 
pack years smoked up to the time point of data collection for regressions and for smoking status (current, former 




12. Results: Associations of sentinel CpGs with lung function in childhood cohorts (ALSPAC, IOWBC) 
12.1. Table S18: Associations of sentinel CpGs with FEV1, FEV1/FVC, and FVC in childhood birth cohorts, ALSPAC and IOWBC 
Table S18: Adjusted* associations of sentinel replication CpG markers† with FEV1, FEV1/FVC, and FVC in childhood birth cohorts, IOWBC and ALSPAC. The list of CpGs represent markers with 
suggestive evidence‡ for association in children (P≤0.05) with cross-sectional¶ lung function, FEV1 (L), FEV1/FVC and FVC (L), and prediction of annual change, FEV1 (L/year), FEV1/FVC(year
-1
) 
and FVC (L/year). Boxed coefficients beta(SE) indicate consistency with meta-analyses results observed in adults for direction of effect (outcome and model specific comparison of childhood 
results with adult meta-analyses combining discovery and replication cohort results). Underlined CpGs showed successfully replication in adults. Dark grey-boxed CpGs showed associations 
observed in adult never smokers. 
     
  cross-sectional time point 1 cross-sectional time point 2 repeat cross-sectional prediction in annual  change 








































    
    
   
  
   
  
   
  
   cg27537125 1 25349681 RUNX3 yes 5.28E-13 1.399 (0.695) 0.044 -+ 0.16 1.532 (1.564) 0.327 ++ 0.54 1.384 (0.873) 0.113 ++ 0.83 -0.073 (0.177) 0.680 -- 0.45 
cg03547355 1 227003060 
 
yes 1.54E-10 -0.353 (0.217) 0.104 -- 0.34 -0.709 (0.456) 0.120 -- 0.44 -0.551 (0.235) 0.019 -- 0.79 0.044 (0.079) 0.578 ++ 0.72 
cg27241845 2 233250370 ALPPL2 yes 1.63E-21 -0.115 (0.098) 0.241 -- 0.41 -0.291 (0.269) 0.278 -- 0.91 -0.309 (0.15) 0.040 -- 0.45 0.059 (0.041) 0.147 ++ 0.71 
cg01940273 2 233284934 ALPPL2 yes 3.30E-34 -0.131 (0.243) 0.591 -- 0.91 -1.161 (0.513) 0.024 -- 0.23 -0.656 (0.292) 0.025 -- 0.47 -0.003 (0.083) 0.967 +- 0.01 
cg00741986 4 2748332 TNIP2 yes 6.52E-10 0.054 (0.198) 0.785 +- 0.46 -1.187 (0.54) 0.028 -- 0.67 -0.454 (0.228) 0.046 -- 0.81 -0.112 (0.066) 0.091 -- 0.09 
cg25648203 5 395444 AHRR yes 2.87E-17 -0.609 (0.257) 0.018 -- 0.47 0.139 (0.683) 0.839 +- 0.78 -0.212 (0.327) 0.517 -- 0.67 0.045 (0.096) 0.637 -+ 0.27 
cg23205886 5 138611766 SNHG4 yes 5.63E-11 0.483 (0.229) 0.035 ++ 0.50 0.108 (0.661) 0.870 ++ 0.85 -0.117 (0.303) 0.700 -+ 0.48 0.077 (0.084) 0.355 ++ 0.59 
cg19931644 8 12623485 
  
2.75E-07 -0.299 (0.144) 0.037 -+ 0.10 0.017 (0.334) 0.960 -+ 0.61 -0.054 (0.22) 0.807 -+ 0.11 -0.011 (0.049) 0.826 -+ 0.51 
cg21990700 12 7260776 C1RL yes 1.06E-11 0.222 (0.29) 0.445 +- 0.25 1.463 (0.619) 0.018 ++ 0.16 0.547 (0.405) 0.178 -+ 0.05 0.083 (0.092) 0.368 ++ 0.76 
cg16708465 13 95933097 ABCC4 yes 1.15E-08 0.036 (0.269) 0.893 -+ 0.53 1.066 (0.629) 0.090 ++ 0.30 0.700 (0.344) 0.042 ++ 0.44 -0.06 (0.102) 0.553 -- 0.80 
cg07922154 14 68087339 ARG2 
 
9.63E-08 0.193 (0.203) 0.341 ++ 0.87 1.187 (0.586) 0.043 ++ 0.69 0.17 (0.294) 0.563 ++ 0.63 0.078 (0.078) 0.314 ++ 0.44 
cg13976502 14 74227875 C14orf43 yes 7.86E-12 -0.518 (0.234) 0.027 -- 0.47 -0.254 (0.574) 0.658 -- 0.88 -0.183 (0.314) 0.561 -+ 0.10 0.003 (0.081) 0.968 +- 0.83 
cg00310412 15 74724918 SEMA7A yes 4.15E-15 -0.177 (0.266) 0.506 -- 0.59 -0.905 (0.688) 0.188 -- 0.45 -0.872 (0.327) 7.69E-03 -- 0.42 0.063 (0.098) 0.524 +- 0.32 
cg05557932 16 3929351 CREBBP yes 2.99E-08 -0.733 (0.371) 0.048 -- 0.95 0.547 (0.657) 0.406 ++ 0.84 0.359 (0.427) 0.400 +- 0.37 -0.032 (0.103) 0.754 -+ 0.02 
cg20278790 20 57583474 CTSZ 
 
1.62E-07 0.361 (0.262) 0.167 ++ 0.02 -1.442 (0.708) 0.042 -- 0.43 -0.566 (0.384) 0.141 -+ 0.04 0.202 (0.101) 0.045 +- 0.02 
cg01127300 22 38614796 
 
yes 1.19E-12 -0.354 (0.181) 0.050 -- 1.00 -0.244 (0.387) 0.527 -- 0.54 -0.164 (0.218) 0.452 -- 0.69 -0.021 (0.066) 0.751 -+ 0.24 
FEV1/FVC 
    
    
   
  
   
  
   
  
   cg18664508 3 169487465 ARPM1 
 
1.92E-08 -0.213 (0.249) 0.394 -- 0.98 -0.38 (0.317) 0.230 +- 0.25 -0.449 (0.195) 0.022 -- 0.89 0 (0.035) 1.000 +- 0.94 
cg15930777 6 12343201 
  
4.88E-07 0.078 (0.061) 0.201 ++ 0.87 0.14 (0.058) 0.015 ++ 0.52 0.114 (0.04) 4.05E-03 ++ 0.51 -0.017 (0.01) 0.093 -- 0.49 
cg15342087 6 30720209 FLOT1 yes 5.44E-24 -0.036 (0.119) 0.765 -+ 0.22 0.292 (0.135) 0.030 ++ 0.53 0.099 (0.068) 0.144 ++ 0.22 -0.01 (0.02) 0.624 +- 0.34 
cg14366110 9 133779382 FIBCD1 
 
1.72E-10 0.295 (0.121) 0.014 ++ 0.95 -0.113 (0.117) 0.335 -- 0.77 0.053 (0.068) 0.443 ++ 0.57 -0.036 (0.019) 0.061 -- 0.93 
cg09884077 15 23086698 NIPA1 
 
1.38E-08 -0.504 (0.296) 0.088 -- 0.24 -0.748 (0.287) 9.03E-03 -- 0.90 -0.471 (0.203) 0.021 -- 0.17 -0.019 (0.042) 0.658 +- 0.18 
cg22952142 15 68549178 
  
4.03E-07 0.125 (0.056) 0.025 +- 0.05 0.109 (0.061) 0.074 ++ 0.34 0.141 (0.043) 1.08E-03 ++ 0.33 -0.009 (0.009) 0.302 -+ 0.06 
cg27367615 16 86229910 
  
3.31E-07 -0.05 (0.052) 0.336 -- 0.65 -0.084 (0.058) 0.144 -- 0.86 -0.079 (0.035) 0.023 -- 0.89 0.003 (0.008) 0.746 -+ 0.47 
FVC 
    
    
   
  
   
  
   
  
   cg23205886 5 138611766 SNHG4 yes 5.63E-11 0.547 (0.276) 0.048 ++ 0.28 -0.439 (0.729) 0.547 +- 0.14 -0.2 (0.332) 0.547 -- 0.57 0.072 (0.095) 0.445 +- 0.56 
cg25633955 8 1616622 DLGAP2 
 
3.87E-07 0.143 (0.192) 0.457 ++ 0.30 -1.416 (0.686) 0.039 -- 0.66 -0.134 (0.289) 0.642 -- 0.44 0.082 (0.073) 0.261 ++ 0.16 
cg25953130 10 63753550 ARID5B yes 1.55E-07 0.032 (0.163) 0.845 +- 0.76 0.071 (0.373) 0.849 ++ 0.94 -0.084 (0.225) 0.710 +- 0.17 0.126 (0.056) 0.025 ++ 0.72 
cg05831672 10 103543172 NPM3 
 
3.93E-08 1.23 (1.294) 0.342 ++ 0.57 3.154 (2.414) 0.191 ++ 0.62 3.009 (1.485) 0.043 ++ 0.93 -0.028 (0.34) 0.936 -+ 0.10 
cg01747591 16 89703612 DPEP1 
 
4.20E-07 -0.408 (0.408) 0.317 -- 0.84 -1.985 (0.842) 0.019 -- 0.40 -1.422 (0.474) 2.71E-03 -- 0.17 -0.101 (0.149) 0.497 -+ 0.02 
cg20278790 20 57583474 CTSZ 
 




Footnote to table S18: 
* Associations were adjusted for base model covariate adjustment (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age 
squared, height and squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. Prediction models were 
additionally adjusted for lung function at time point 1 (FEV1, FEV1/FVC or FVC respectively). 
† Sentinel CpGs: Lung function-specific replication markers were selected for their association with P<5x10
-7 
in discovery meta-analysis from the entire samples of all participants or from the 
subsample of never smokers. 
‡ Associations in children replication sample showing nominal P≤0.05 (shaded light grey) are presented in the table. 
¶ Cross-sectional associations tested: linear regression of cross-sectional association of DNA methylation marker with lung function parameter separately at each time point, (time point 1, 
time point 2) and mixed linear regression with random intercept on the participant of repeated cross-sectional association combining data from both time points in one model. 
** The best P-value for association of the lung function-specific replication CpG with the corresponding lung function parameter observed in adults, either with FEV1, FEV1/FVC or FVC (as 






13. Results: ALEC discovery meta-analysis look-up results of CpGs previously associated with respiratory 
traits  
13.1. Table S19: Results for cross-sectional adjusted associations (Mbase) with FEV1, FEV1/FVC and FVC at time 
point 2 
Table S19: ALEC discovery meta-analysis look-up results for cross-sectional adjusted* associations at time point 2, 
base covariate adjustment (Mbase). 
See table in EXCEL file: Additional_Tables_Imbodenetal.xlsx 
 
Footnote to table S19: 
* Base model (Mbase) EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, 
sex and interaction terms of age, age squared, height and squared deviation of height with sex, education (low, medium, high), 
body mass index, spirometer type, study center as well as cell composition. 
 
14. Results: Two-sample Mendelian Randomization look-up in publicly available databases 
We found genetic instruments for 13 of the 57 replicated CpGs and finally only for eight CpGs a two sample MR on 
cross-sectional lung function could be completed. Results for FEV1 are presented in table S20. There was evidence 
for causal effect of cg23771366, cg11660018 (PRSS23) and cg21990700 (C1RL) and cg00073460 (ZC3H12D) on FEV1 
percent predicted and of cg00073460 (ZC3H12D) and cg24086068 (SHROOM3) on FVC. Of the four top loci 
associated with FEV1/FVC (AHRR, F2RL3, ALPPL2 and PRSS23, see table 2) we could only identify MR-genetic 
instruments for ALPPL2 and PRSS23 and only the association of PRSS23 with lung function could be obtained from 
the MRbase resource.  
The top CpG of the MR look-up showing causal association with cross-sectional lung function is also one of the three 
dominant smoking-related CpGs which remained significantly associated with lung function (FEV1/FVC) after smoking 
adjustment though the strength of the association was greatly diminished: cg23771366 (PRSS23) had P=4.61x10-8 
((SE)= 0.130(0.024); Msmok see table S7) versus P=5.38x10
-27 ((SE)= 0.233(0.022); Mbase see table 2). Both other 
dominant smoking-related CpGs which also remained significant after smoking adjustment (cg05575921 (AHRR) 
having P=2.69x10-11 (Msmok) versus P=7.22
-50 (Mbase) and cg03636183 (F2RL3) having P=1.02x10
-8 (Msmok) versus 
P=4.5x10-43 (Mbase)) were not available in the mQTL database and thus their causal association with lung function 
remains to be investigated. 
 
14.1. Table S20: Two-sample MR results for FEV1 predicted percentage and for FVC 
Table S20A: Two-sample Mendelian Randomization for association with FEV1 predicted percentage*  
CpG ID/Exposure instrument chr position Locus Beta† SE P-value P-valueFDR‡ 
CpG part of 
Mediation-SI 
CpG associated with  
(EWAS results) 
cg23771366 rs67939314 11 86510998 PRSS23 0.06001 0.01358 9.92E-06 4.76E-04 no 
Cross-sectional FEV1/FVC 
Cross-sectional FEV1 
cg11660018 rs36061072 11 86510915 PRSS23 0.0484 0.01464 9.48E-04 0.015 no 
Cross-sectional FEV1/FVC 
Cross-sectional FEV1 
cg21990700 rs3782925 12 7260776 C1RL -0.04477 0.01431 1.76E-03 0.018 no Cross-sectional FEV1 
cg00073460 rs12660849 6 149806502 ZC3H12D -0.04814 0.01681 4.18E-03 0.029 no Cross-sectional FEV1 
cg24086068 rs17001890 4 77356008 SHROOM3 0.03555 0.0153 0.020 0.054 no 
Cross-sectional FEV1 
Cross-sectional FVC 
cg09935388 rs115427247 1 92947588 GFI1 0.03309 0.01665 0.047 0.094 yes Cross-sectional FEV1/FVC 




Footnote to table S20A: 
* FEV1: Using UKB-a:235 dataset on genome-wide association results on forced expiratory volume in 1-second (FEV1) predicted percentage in 
European Population (n= 11,0423), Data from http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas.  
† beta: effect estimate represents the change in outcome per unit increase in the methylation of the CpG. SE: standard error 
‡FDR: False discovery rate adjusted P-value for multiple testing correction. 
 
Table S20B: Two-sample Mendelian Randomization for association with FVC* 
CpG ID/Exposure instrument chr position Locus Beta† SE P-value P-valueFDR‡ 
CpG part of 
Mediation-SI 
CpG associated with  
(EWAS results) 
cg00073460 rs12660849 6 149806502 ZC3H12D -0.02163 0.007787 5.47E-03 0.030 no Cross-sectional FEV1 
cg24086068 rs17001890 4 77356008 SHROOM3 0.01939 0.007095 6.28E-03 0.030 no 
Cross-sectional FEV1 
Cross-sectional FVC 
cg21990700 rs3782925 12 7260776 C1RL -0.01461 0.006627 0.027 0.064 no Cross-sectional FEV1 
cg05593667 rs7755718 6 35490744 TULP1 0.008383 0.003879 0.031 0.064 no Cross-sectional FEV1 
cg11660018 rs36061072 11 86510915 PRSS23 0.007944 0.006823 0.244 0.366 no 
Cross-sectional FEV1/FVC 
Cross-sectional FEV1 
cg09935388 rs115427247 1 92947588 GFI1 -0.003923 0.007859 0.618 0.760 yes Cross-sectional FEV1/FVC 




Footnote to table S20B: 
* FVC: Using UKB-a:336 dataset on genome-wide association results on forced vital capacity (FVC) in European Population (n= 30,7638), Data 
from http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas. 
† beta: effect estimate represents the change in outcome per unit increase in the methylation of the CpG. SE: standard error 






15. Results: Mediation analysis and Mediation smoking index (Mediation-SI) 
 
15.1. Table S21: List of smoking effect mediating candiate CpGs and CpG list of mediation smoking index (Mediation-SI) 
Table S21: List of CpGs* contributing to the Mediation-SI, sorted by P-value for association with smoking (Smoking PFDR). The previously reported candidate CpG for 
mediation were looked-up in the meta-analyzed repeat cross-sectional covariate Mbase-adjusted EWAS meta-analysis in discovery cohorts (ECRHS, NFBC1966 and SAPALDIA) 
combining data on methylation and spirometry of both time points. 
















cg01940273 2 233'284'934 ALPPL2 9.80E-30 ---------------- 5 3.10E-11 +++ 
cg05951221 2 233'284'402 ALPPL2 6.80E-23 ---------------- 34 1.59E-06 ??+ 
cg05575921 5 373'378 AHRR 6.10E-22 -----------+---- 1 3.59E-16 +++ 
cg21566642 2 233'284'661 ALPPL2 4.50E-21 ---------------- 4 1.39E-11 +++ 
cg06126421 6 30'720'080 IER3 1.70E-20 ---------------- 31 1.25E-06 ??+ 
cg03636183 19 17'000'585 F2RL3 5.70E-17 ---------------- 2 5.25E-13 +++ 
cg09935388 1 92'947'588 GFI1 7.00E-14 -----------+---- 19 3.60E-07 +++ 
cg21161138 5 399'360 AHRR 7.90E-13 ---------------- 7 1.62E-10 +++ 
cg24859433 6 30'720'203 NA 2.20E-09 ---------------- 61 3.58E-06 +++ 
cg22994830 7 623‘846 PRKAR1B 0.0001 +++++++++++-++-- 414635 0.488 -+- 
 
Footnote to table S21:  
* set of ten CpG markers previously identified to be associated with smoking and to mediate the effect of smoking on lung function [46]. Two CpGs (cg05951221 and cg06126421) were 
present only on 450K array and thus missing in NFBC1966 data from time point 2 and in ECRHS data from both time points. Values for Mediation-SI score for missing data for cg05951221 
and cg06126421 were imputed to mean of never-smokers in each cohort. 
† Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported direction of effects for association with smoking.
 
[45] 





15.2. Table S22: Replication of mediation analyses on FEV1 and on FVC in SAPALDIA 
 
table S22: Mediation* analysis results for the effect of smoking status on FEV1 and on FVC .   
 
CpG 
ACME ADE Total effect Proportion 
Estimate 95%CI p Estimate 95%CI p-value Estimate 95%CI p Estimate 95%CI p 
FEV1             
cg01940273 -0.0563 [-0.0826, -0.0306] <0.001 0.0051 [-0.0600, 0.0729] 0.89 -0.0511 [-0.1127, 0.0133] 0.104 1.0043 [-4.6356, 7.6423] 0.104 
cg03636183 -0.0627 [-0.0905, -0.0368] <0.001 0.0118 [-0.0515, 0.0754] 0.712 -0.0508 [-0.1113, 0.0057] 0.074 1.1768 [-4.5880, 13.3634] 0.074 
cg05575921 -0.0768 [-0.1086, -0.0463] <0.001 0.0264 [-0.0426, 0.0934] 0.432 -0.0504 [-0.1121, 0.0082] 0.098 1.3890 [-9.4984, 15.421] 0.098 
cg05951221 -0.0587 [-0.0907, -0.0284] <0.001 0.0087 [-0.0571, 0.0756] 0.794 -0.0499 [-0.1115, 0.0106] 0.108 1.0660 [-6.8504, 9.6637] 0.108 
cg06126421 -0.0512 [-0.0793, -0.0273] <0.001 0.0014 [-0.0603, 0.0642] 0.980 -0.0497 [-0.1090, 0.0098] 0.110 0.9142 [-6.2106, 6.7037] 0.110 
cg09935388 -0.0257 [-0.0428, -0.0097] <0.001 -0.0243 [-0.0835, 0.0378] 0.430 -0.0500 [-0.1069, 0.0135] 0.100 0.4855 [-1.8394, 4.0124] 0.100 
cg21161138 -0.0398 [-0.0625, -0.0202] <0.001 -0.0105 [-0.0748, 0.0505] 0.722 -0.0503 [-0.1110, 0.0079] 0.082 0.7532 [-3.1370, 6.8135] 0.082 
cg21566642 -0.0681 [-0.0989, -0.0400] <0.001 0.0193 [-0.0451, 0.0833] 0.600 -0.0489 [-0.1079, 0.0138] 0.106 1.2615 [-5.6624, 13.9565] 0.106 
cg22994830 -0.0011 [-0.0054, 0.0013] 0.516 -0.0481 [-0.1100, 0.0085] 0.116 -0.0493 [-0.1110, 0.0078] 0.112 0.0131 [-0.1594, 0.2437] 0.568 
cg24859433 -0.0264 [-0.0449, -0.0094] <0.0010 -0.0223 [-0.0838, 0.0405] 0.484 -0.0487 [-0.1053, 0.0176] 0.128 0.4841 [-2.5739, 6.4572] 0.128 
FVC             
cg01940273 -0.0424 [-0.0701, -0.0162] <0.001 0.0228 [-0.0483, 0.0954] 0.508 -0.0197 [-0.0889, 0.0481] 0.562 0.8896 [-15.335, 16.3599] 0.562 
cg03636183 -0.0451 [-0.0723, -0.0178] <0.001 0.0260 [-0.0429, 0.0948] 0.444 -0.0191 [-0.0847, 0.0474] 0.536 1.0267 [-14.3319, 26.8314] 0.536 
cg05575921 -0.0555 [-0.0872, -0.0242] <0.001 0.0374 [-0.0324, 0.1110] 0.308 -0.0181 [-0.0854, 0.0470] 0.556 1.2442 [-15.3577, 28.1417] 0.556 
cg05951221 -0.0467 [-0.0808, -0.0164] 0.002 0.0266 [-0.0441, 0.0993] 0.450 -0.0201 [-0.0825, 0.0441] 0.528 1.0274 [-14.6674, 17.8390] 0.530 
cg06126421 -0.0437 [-0.0706, -0.0194] 0.002 0.0255 [-0.0422, 0.0953] 0.468 -0.0182 [-0.0822, 0.0439] 0.574 0.9103 [-17.7712, 19.6406] 0.572 
cg09935388 -0.0178 [-0.0346, -0.0011] 0.036 0.0000 [-0.0666, 0.0691] 0.996 -0.0178 [-0.0813, 0.0484] 0.582 0.3412 [-7.2647, 7.4008] 0.602 
cg21161138 -0.0245 [-0.0481, -0.0030] 0.024 0.0078 [-0.0622, 0.0776] 0.776 -0.0167 [-0.0835, 0.0506] 0.616 0.4701 [-10.8600, 14.6598] 0.620 
cg21566642 -0.0499 [-0.0805, -0.0188] <0.001 0.0295 [-0.0412, 0.1000] 0.424 -0.0204 [-0.0851, 0.0442] 0.580 0.9974 [-28.0538, 20.7039] 0.580 
cg22994830 -0.0007 [-0.0050, 0.0018] 0.630 -0.0201 [-0.0898, 0.0439] 0.570 -0.0208 [-0.0899, 0.0440] 0.558 0.0036 [-0.6289, 0.4025] 0.864 
cg24859433 -0.0259 [-0.0473, -0.0076] 0.012 0.0070 [-0.0607, 0.0766] 0.816 -0.0189 [-0.0853, 0.0471] 0.576 0.5115 [-8.4278, 7.0896] 0.584 
Footnote to table S22 
* performed using R package mediation [59]. 
† previously reported candidate CpG for mediation of smoking effect on lung function [46].  
For analogous results for FEV1 or FVC see online supplementary table S22. 




15.3. Figure S6: Association of Mediation-SI with FEV1 and comparison with association of packyears SI with FEV1 
Figure S6: Distribution and association* of Mediation-SI with FEV1, with 95% confidence interval. (A) Boxplot of Mediation-SI (median: 0.3 and range: -1.7 to 5.2) in all participants of 
SAPALDIA. (B) Boxplot of packyears (median: 2.0 and range: 0 to 145.9) in all participants of SAPALDIA  
 
 
Footnote to Figure S6: 
*Associations were adjusted for the base model (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. The Mbase-adjusted model explained 71.0% 
of the variance in the outcome. The Mbase-adjusted model additionally adjusted for the Mediation-SI explained 71.9% of the FEV1 variance (total adjusted R
2
 = 0.719) of which 3.2% of the 
variance was specifically explained by the SI variable. This was comparable to the variance explained by the Mbase-adjusted model additionally adjusted for packyears and smoking status 
corresponding to the Msmok model (R
2
 = 0.721, and with 3.3% of the variance specifically explained by the packyears variable). Model including both smoking adjustments (Msmok and 
additionally Mediation-SI) explained 72.4% of the FEV1 variance.  
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15.4. Figure S7: Association of Mediation-SI with FVC and comparison with association of packyears with FVC 
Figure S7: Distribution and association* of Mediation-SI with FVC, with 95% confidence interval. (A) Boxplot of Mediation-SI (median: 0.3 and range: -1.7 to 5.2) in all participants of 
SAPALDIA. (B) Boxplot of packyears (median: 2.0 and range: 0 to 145.9) in all participants of SAPALDIA 
 
Footnote to Figure S7: 
*Associations were adjusted for the base model (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. The Mbase-adjusted model explained 78.8% 
of the variance in the outcome. The Mbase-adjusted model additionally adjusted for the Mediation-SI explained 79.1% of the FVC variance (total adjusted R
2
 = 0.791) of which 1.2% of the 
variance was specifically explained by the SI variable. This was comparable to the variance explained by the Mbase-adjusted model additionally adjusted for packyears and smoking status 
corresponding to the Msmok model (adjusted R2 = 0.792, and with 0.5% of the variance specifically explained by the packyears variable). Model including both smoking adjustments (Msmok 
and additionally Mediation-SI) explained 79.3% of the FVC variance (total adjusted R
2
 = 0.793).  
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15.5. Table S23: Mediation-SI association with FEV1 and with FVC by smoking strata 
 
Table S23: Meta-analyses* of Mediation-SI on the cross-sectional association with lung function, FEV1 (L) and FVC (L), time point 2, separately, and longitudinally predicting 
the change in lung function during follow-up, FEV1 (ml/year) and FVC (ml/year), base model adjustment (Mbase†), in all study participant, ever and never smokers. 
 























FEV1          
All -0.0650 (0.0089) 2.32E-13 --- 0.31  -0.0038 (0.0005) 9.74E-14 --- 0.24 
Ever smokers -0.0861 (0.0116) 1.02E-13 --- 0.34  -0.0037 (0.0007) 9.74E-08 --- 0.22 
Never smokers -0.0241 (0.0283) 0.394 --+ 0.055  -0.0047(0.0012) 1.15E-04 --+ 0.12 
FVC          
All -0.0252 (0.0101) 0.0125 -+- 0.0066  -0.0034 (0.0007) 4.10E-07 --- 0.021 
Ever smokers -0.0426 (0.0132) 0.0013 -+- 0.031  -0.0041 (0.0009) 5.68E-06 --- 0.12 
Never smokers -0.0207 (0.0323) 0.522 -++ 0.031  -0.0021 (0.0015) 0.151 --- 0.14 
 
Footnotes to table S23: 
*Cohort-specific association results for Mediation-SI were meta-analysed. The 10 CpGs contributing Mediation-SI are shown in online supplement table S21). Note: DNAme predictors used 
were technical bias-adjusted, normalized residuals, thus effect size of the association (beta) are not directly comparable to elsewhere reported effect sizes using normalized %-methylation 
as predictor. 
† Base model covariate adjustment (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared 
deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. Prediction models were additionally adjusted for 
FEV1/FVC at time point 1. 
‡ P-value of meta-analysis: P<0.008 was considered statistically significant, Bonferroni correction for 6 tests per lung function outcome. Order of cohorts for direction of effects: ECRHS, 
NFBC1966, SAPALDIA. 




15.6. Figure S8: Mediation-SI association with FEV1 in ever - and never smokers  
Figure S8: Forest plots of cohort-specific results and meta-analyses of the association of the Mediation-SI with FEV1 and change in FEV1 in ever - and never smokers in the 
discovery cohorts. Associations run applying base model adjustment (Mbase*). 
 
Footnote to Figure S8: 
*Base model (Mbase): EWAS were covariate adjusted for age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and 
squared deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. Prediction models were additionally 




16. Results: Scatter plots of percent methylation with lung function outcomes of 57 replicated CpGs 













17. Results: Candidate Gene based DNAme smoking index (lung-function-gene-SI) 
 
17.1. Table S24: List of CpGs contributing to lung-function-gene-SI 
Table S24: List of CpGs contributing to the gene-based smoking index (lung-function-gene-SI) representing a subset 
of CpG markers previously identified to be associated with smoking* that were located in GWAS identified genes 
associated with lung function. Information on ranks of association of the selected CpGs in the discovery EWAS (Mbase) 
with FEV1 are presented, similar low ranks were observed for association with FEV1/FVC or FVC. 
  Locus CpG ID chr position 
smoking FDR  
P-value* smoking direction of effects* 
rank in EWAS 
on FEV1  
in repeat cross-sectional 
meta-analysis  
(discovery) 
1 ADAM19 cg08295410 5 156'990'663 4.70E-05 ++++++++++++++-+ 113170 
2 ARMC2 cg25127315 6 109'169'227 0.0023 +++-++-++-+++-++ 425861 
3 C10orf11 cg23024158 10 78'011'952 3.00E-04 --+------+---+-- 135262 
4 CDC123 cg19576422 10 12'256'343 7.00E-04 ---+-??------+-- 378523 
5 CFDP1 cg10121429 16 75'466'707 0.0036 -----+---+------ 315711 
6 GPR126 cg11176095 6 142'622'515 7.00E-04 ++-+++++++++++++ 146657 
7 HDAC4 cg11550064 2 240'148'191 5.50E-07 ++-+++++++++++++ 82203 
8 HTR4 cg07102705 5 148'033'896 3.00E-04 +++-+-+++++++-++ 206521 
9 LRP1 cg14621254 12 57'569'787 0.0165 ---+-+-------+-- 151255 
10 MECOM cg02556393 3 168'866'705 2.60E-20 --------------+- 12608 
11 MFAP2 cg04236263 1 17'305'798 0.0099 ---+-----+-+---+ 142956 
12 PPT2 cg06814287 6 32'120'584 1.60E-10 ---+---+------+- 227036 
13 RARB cg27574595 3 25'583'274 0.0062 ++-++++-++++++-- 33899 
14 RHOBTB3 cg02549492 5 95'066'568 0.003 +++++++++++-+-++ 393163 
15 TGFB2 cg07810039 1 218'524'558 0.0024 ++--+-+-++++++++ 260626 
16 TLE3 cg10381071 15 70'391'035 3.60E-06 --+------------- 44658 
17 TNS1 cg06320380 2 218'770'208 0.0011 ++-++++-+++++-++ 131281 
18 ZNF323;ZKSCAN3 cg12212060 6 28'323'405 4.10E-06 ---+-----+---+-- 367753 
 
Footnote to table S24 
*Smoking CpGs defined on the reported FDR corrected P-value <0.05 for association reported with smoking status and reported 
direction of effects for association with smoking.[45] 
 
 
Result Associations of lung-function-gene-SI with FEV1, FEV1/FVC and FVC: 
 
A smoking index (SI) based on 18 candidate CpGs located in previously identified genes to determine lung function 
(lung-function-gene-SI) was constructed. The construction and associations of the SI were performed as for the ALEC 
custom SIs. Meta-analysis results of the lung-function-genes-SI in all participants and by smoking status strata are 
presented below (Table S25). The effect of the lung-function-genes-SI, combining the effects of gene candidate 
CpGs, was not as pronounced as that of the effect of the ALEC custom SI, combining the effects of the smoking-
related CpGs. The strongest associations were observed in ever smokers for cross-sectional associations with FEV1 




17.2. Table S25: Associations of lung-function-gene-SI with FEV1, FEV1/FVC and FVC 
Table S25: Meta-analyses of lung function gene-based candidate smoking index (SI) based on a subset of CpG markers (18 CpG markers, Table S24) previously identified to 
be associated with smoking [45] were located in GWAS identified genes associated with lung function. Associations* on the cross-sectional association with FEV1 (L), 
FEV1/FVC (%) and FVC (L)  at, time point 2 and on the prediction of the change in lung function during follow-up, FEV1 (ml/year), FEV1/FVC (%/year) and FVC (ml/year), base 
model adjustment (Mbase†), in all study participant, ever and never smokers. 
 
Cross-sectional meta-analysis at time point 2 Prediction of SI on change in lung function meta-analysis 
 








         All -0.11 (0.038) 0.0038 --- 0.841 
 
-7.1 (2.7) 0.0078 --- 0.605 
Ever smokers -0.196 (0.053) 0.0002 --- 0.173 
 
10.1 (3.7) 0.0058 --- 0.095 
Never smokers 0.048 (0.059) 0.4178 +-- 0.045 
 
0.3 (4.3) 0.9436 ++- 0.848 
          FEV1/FVC 
         All -1.04 (0.54) 0.0560 --- 0.656 
 
-0.04 (0.05) 0.3568 -+- 0.874 
Ever smokers -0.97 (0.75) 0.1949 -+- 0.363 
 
-0.01 (0.06) 0.8188 ++- 0.837 
Never smokers 0.13 (1.09) 0.9047 +-- 0.925 
 
-0.02 (0.08) 0.8316 --+ 0.830 
          FVC 
         All -0.098 (0.043) 0.0233 --- 0.795 
 
-11.1 (3.6) 0.0021 --- 0.511 
Ever smokers -0.203 (0.059) 0.0006 --- 0.215 
 
-18.1 (5.1) 0.0004 --- 0.019 
Never smokers 0.002 (0.013) 0.8835 +-- 0.020 
 
0.6 (5.7) 0.9223 ++- 0.433 
 
Footnotes to table 25: 
*Cohort-specific association results for lung-function-gene -SI were meta-analysed.  
† Base model covariate adjustment (Mbase): age, age squared, height, squared deviation from the mean of height, sex and interaction terms of age, age squared, height and squared 
deviation of height with sex, education (low, medium, high), body mass index, spirometer type, study center as well as cell composition. Prediction models were additionally adjusted for 
FEV1/FVC at time point 1. 
‡ P-value of meta-analysis: P<0.008 was considered statistically significant, Bonferroni correction for 6 tests per lung function outcome. Order of cohorts for direction of effects: ECRHS, 
NFBC1966, SAPALDIA. 
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cg05575921 5 373378 AHRR yes 0.081 (0.013) 5.12E-10
cg03636183 19 17000585 F2RL3 yes 0.116 (0.022) 7.09E-08
cg21566642 2 233284661 ALPPL2 yes 0.081 (0.016) 2.77E-07
cg01940273 2 233284934 ALPPL2 yes 0.112 (0.022) 5.63E-07
cg03329539 2 233283329 ALPPL2 yes 0.154 (0.033) 4.17E-06
cg21161138 5 399360 AHRR yes 0.157 (0.031) 2.73E-07
cg23771366 11 86510998 PRSS23 yes 0.173 (0.035) 5.31E-07
cg11660018 11 86510915 PRSS23 yes 0.191 (0.034) 1.29E-08
cg21611682 11 68138269 LRP5 yes 0.15 (0.043) 0.0005
cg15342087 6 30720209 FLOT1 yes 0.256 (0.053) 1.56E-06
cg26703534 5 377358 AHRR yes 0.141 (0.036) 9.26E-05
cg25648203 5 395444 AHRR yes 0.139 (0.036) 9.55E-05
cg19572487 17 38476024 RARA yes 0.147 (0.031) 1.84E-06
cg00310412 15 74724918 SEMA7A yes 0.147 (0.044) 0.0008
cg24859433 6 30720203 FLOT1 yes 0.245 (0.048) 3.80E-07
cg09935388 1 92947588 GFI1 yes 0.06 (0.017) 0.0005
cg14753356 6 30720108 FLOT1 yes 0.182 (0.034) 8.01E-08
cg04885881 1 11123118 SRM/EXOSC10 yes 0.16 (0.031) 3.51E-07
cg25949550 7 145814306 CNTNAP2 yes 0.168 (0.059) 0.0046
cg19859270 3 98251294 GPR15 yes 0.262 (0.084) 0.0017
cg03450842 10 80834947 ZMIZ1 yes 0.125 (0.045) 0.0051
cg03707168 19 49379127 PPP1R15A yes 0.146 (0.038) 0.0001
cg17087741 2 233283010 ALPPL2 yes 0.083 (0.031) 0.0083
cg21140898 1 51442318 CDKN2C yes 0.065 (0.023) 0.0040
cg01899089 5 369969 AHRR yes 0.131 (0.041) 0.0014
cg08763102 4 3079751 HTT yes 0.257 (0.052) 6.51E-07
cg21282907 6 74289980 SLC17A5 yes 0.117 (0.044) 0.0078
cg20853880 2 10184444 KLF11 yes 0.049 (0.02) 0.0141
cg16391678 16 30485597 ITGAL yes 0.147 (0.054) 0.0061
Footnote to Table S3: see Supplementary Material Text.
Table S3: Detailed results in all participants: cross-sectional associations with FEV1/                 














+++ 0.418 0.192 (0.041) 3.96E-21 +++ 0.332
+++ 0.235 0.208 (0.032) 1.47E-15 +++ 0.063
+++ 0.035 0.229 (0.036) 3.47E-17 +++ 0.578
+++ 0.186 0.14 (0.017) 8.11E-18 +++ 0.200
+++ 0.506 0.229 (0.036) 1.77E-10 +++ 0.480
+++ 0.700 0.254 (0.039) 6.36E-14 +++ 0.027
+++ 0.974 0.196 (0.034) 2.69E-09 +++ 0.117
+++ 0.564 0.252 (0.045) 5.14E-09 +++ 0.444
+++ 0.415 0.24 (0.046) 1.63E-08 +++ 0.068
+++ 0.249 0.212 (0.049) 4.18E-09 +++ 0.094
+++ 0.710 0.126 (0.013) 1.33E-08 +++ 0.110
+++ 0.592 0.234 (0.041) 5.02E-11 +++ 0.115
+++ 0.053 0.321 (0.061) 4.89E-11 +++ 0.189
-++ 0.063 0.14 (0.046) 3.10E-08 +++ 0.133
+++ 0.215 0.19 (0.037) 1.55E-05 +++ 0.315
+++ 0.756 0.084 (0.017) 9.20E-07 +++ 0.706
+++ 0.499 0.122 (0.051) 2.04E-07 +++ 0.163
+++ 0.466 0.177 (0.031) 6.42E-09 +++ 0.414
+++ 0.394 0.008 (0.173) 1.95E-07 +++ 0.002
-++ 1.76E-05 0.199 (0.023) 8.07E-08 +++ 0.009
+++ 0.673 0.146 (0.04) 1.80E-07 +++ 0.001
+++ 0.147 0.181 (0.023) 4.38E-07 +++ 0.635
+++ 0.559 0.252 (0.036) 5.13E-12 +++ 0.214
+++ 0.042 0.132 (0.024) 3.04E-08 +++ 0.109
+++ 0.842 0.173 (0.06) 3.05E-06 +++ 0.003
+++ 0.474 0.23 (0.045) 0.0037 +++ 0.660
+++ 0.113 0.325 (0.055) 1.65E-09 +++ 0.525
--+ 0.018 0.108 (0.02) 1.23E-07 +++ 0.074
+++ 0.019 0.245 (0.044) 1.27E-07 +++ 0.086
          /FVC at time point 1 and at time point 2, separately: discovery, r     













0.123 (0.011) 3.65E-31 yes ++++- 0.010 0.222 (0.061)
0.209 (0.019) 3.08E-29 yes ++++- 0.040 0.383 (0.088)
0.156 (0.014) 9.35E-28 yes ++++- 0.006 0.18 (0.06)
0.204 (0.02) 7.08E-25 yes ++++- 0.023 0.279 (0.098)
0.261 (0.028) 2.01E-20 yes ++++- 0.228 0.28 (0.114)
0.22 (0.026) 4.09E-17 yes +++++ 0.316 0.149 (0.122)
0.259 (0.028) 4.52E-21 yes +++++ 0.909 0.263 (0.096)
0.275 (0.029) 2.29E-21 yes ++++- 0.586 0.185 (0.11)
0.308 (0.037) 1.38E-16 yes +++++ 0.015 0.326 (0.146)
0.37 (0.044) 6.35E-17 yes ++++- 0.058 0.165 (0.139)
0.253 (0.033) 1.83E-14 yes ++++- 0.002 0.312 (0.159)
0.234 (0.034) 5.71E-12 yes ++++- 0.004 0.198 (0.151)
0.192 (0.027) 7.84E-13 yes +++++ 0.016 0.135 (0.087)
0.262 (0.036) 1.85E-13 yes +++++ 0.397 0.232 (0.134)
0.37 (0.044) 4.14E-17 yes ++++- 0.052 0.146 (0.149)
0.13 (0.016) 4.96E-16 yes +++++ 0.022 0.171 (0.07)
0.174 (0.025) 7.46E-12 yes ++++- 0.066 0.131 (0.109)
0.15 (0.024) 7.21E-10 yes ++++- 0.320 0.154 (0.094)
0.378 (0.053) 1.18E-12 yes +++++ 0.629 0.282 (0.169)
0.406 (0.068) 2.90E-09 yes ++++- 0.008 0.305 (0.171)
0.282 (0.041) 4.66E-12 yes ++++- 0.194 0.107 (0.133)
0.166 (0.029) 1.73E-08 yes ++++- 0.026 0.228 (0.111)
0.136 (0.023) 3.94E-09 yes ++++- 0.001 -0.062 (0.094)
0.09 (0.022) 3.47E-05 yes +-++- 0.024 0 (0.066)
0.132 (0.032) 4.89E-05 yes +-+++ 0.037 0.01 (0.103)
0.209 (0.047) 9.94E-06 yes +-++- 1.55E-05 -0.133 (0.141)
0.083 (0.041) 0.0421 no +-++- 0.094 -0.202 (0.104)
0.046 (0.019) 0.0168 no ++++- 0.395 0.046 (0.061)
0.111 (0.033) 0.0009 yes ++++- 0.272 -0.078 (0.108)
Replication time point 1   (KORA/ LBC1936/ Lifelines/ 


















0.0003 0.124 (0.008) 7.22E-50 +++++++ 0.023 6.10E-22 -----------+----
1.52E-05 0.201 (0.015) 4.50E-43 +++++++ 0.008 5.70E-17 ----------------
0.0027 0.151 (0.011) 5.02E-43 +++++++ 0.043 4.50E-21 ----------------
0.0046 0.206 (0.015) 4.09E-41 +++++++ 0.031 9.80E-30 ----------------
0.0145 0.257 (0.023) 5.58E-30 +++++++ 0.628 9.70E-16 -----------+----
0.2242 0.243 (0.021) 9.72E-30 +++++++ 0.152 7.90E-13 ----------------
0.0067 0.233 (0.022) 5.38E-27 +++++++ 0.286 1.90E-14 ----------------
0.0935 0.238 (0.023) 3.40E-26 +++++++ 0.318 4.40E-21 ----------------
0.0255 0.309 (0.03) 1.26E-25 +++++++ 0.049 4.20E-15 ----------------
0.2345 0.359 (0.036) 5.44E-24 +++++++ 0.169 3.90E-14 -----------+----
0.0502 0.266 (0.026) 7.34E-24 +++++++ 0.101 7.20E-18 -----------+----
0.1895 0.25 (0.026) 9.84E-22 +++++++ 0.194 2.70E-11 ----------------
0.1207 0.196 (0.021) 8.87E-21 +++++++ 0.018 1.60E-16 ----------------
0.0841 0.261 (0.028) 4.01E-20 +++++++ 0.275 1.20E-13 -----------+----
0.3287 0.303 (0.034) 2.05E-19 +++++++ 0.067 2.20E-09 ----------------
0.0142 0.105 (0.012) 7.05E-19 +++++++ 0.034 7.00E-14 -----------+----
0.2282 0.189 (0.021) 9.08E-19 +++++++ 0.405 2.30E-14 ----------------
0.1023 0.168 (0.02) 5.66E-18 +++++++ 0.670 2.70E-11 -----------+----
0.0946 0.335 (0.039) 6.04E-18 +++++++ 0.013 9.30E-21 ----------------
0.0761 0.467 (0.055) 2.80E-17 +++++++ 0.029 6.30E-17 ----------------
0.4212 0.265 (0.031) 2.92E-17 +++++++ 0.003 2.40E-11 ----?------?----
0.0413 0.206 (0.025) 1.27E-16 +++++++ 0.668 3.50E-07 ----?------?----
0.5061 0.161 (0.02) 4.48E-16 ++++++- 1.05E-05 6.10E-07 ----?------?----
0.9974 0.12 (0.017) 4.46E-13 +++++++ 0.103 3.70E-08 ---------?-+----
0.9251 0.172 (0.027) 1.47E-10 +++++++ 0.005 1.80E-12 ----------------
0.3452 0.225 (0.039) 1.20E-08 ++++++- 0.001 3.80E-15 -----------+----
0.0520 0.176 (0.031) 1.28E-08 ++++++- 0.003 1.28E-02 ---+-+---+------
0.4559 0.077 (0.014) 6.05E-08 +++++++ 0.052 3.70E-07 -----------?----
0.4696 0.164 (0.031) 1.15E-07 ++++++- 0.003 3.00E-11 ----------------
Combined meta-analysis ( ECRHS, NFBC66, 
SAPALDIA, KORA, LBC1936, LifeLines, NSPHS)¶
 e point 2 (only LBC1936)

Table S4: Detailed results in all participants: cross-sectional associations with FEV1 at time point 1            

















cg05575921 5 373378 AHRR yes 0.353 (0.094) 0.0002 +-+ 0.035
cg03636183 19 17000585 F2RL3 yes 0.647 (0.153) 2.25E-05 +-+ 0.168
cg21566642 2 233284661 ALPPL2 yes 0.41 (0.114) 0.0003 +++ 0.150
cg01940273 2 233284934 ALPPL2 yes 0.477 (0.16) 0.0029 +-+ 0.055
cg05951221 2 233284402 ALPPL2 yes 0.444 (0.157) 0.0047 ?-+ 0.099
cg21161138 5 399360 AHRR yes 0.686 (0.219) 0.0018 +-+ 0.142
cg03329539 2 233283329 ALPPL2 yes 0.867 (0.24) 0.0003 +++ 0.496
cg11660018 11 86510915 PRSS23 yes 1.147 (0.241) 1.84E-06 +++ 0.998
cg19572487 17 38476024 RARA yes 0.845 (0.219) 1.15E-04 +++ 0.747
cg15342087 6 30720209 FLOT1 yes 1.589 (0.378) 2.62E-05 +++ 0.538
cg27241845 2 233250370 ALPPL2 yes 0.553 (0.22) 0.0119 +-+ 0.237
cg23771366 11 86510998 PRSS23 yes 1.077 (0.246) 1.16E-05 +++ 0.962
cg00310412 15 74724918 SEMA7A yes 1.006 (0.316) 0.0015 +++ 0.347
cg26703534 5 377358 AHRR yes 0.556 (0.259) 0.0318 +++ 0.661
cg07626482 19 47289503 SLC1A5 yes 1.343 (0.441) 0.0023 +++ 0.231
cg25648203 5 395444 AHRR yes 0.709 (0.255) 0.0053 +-+ 0.044
cg02583484 12 54677008 HNRNPA1 yes 0.985 (0.311) 0.0016 +++ 0.661
cg12075928 8 141801307 PTK2 yes 0.584 (0.182) 0.0013 +++ 0.430
cg07986378 12 11898284 ETV6 yes 0.752 (0.199) 0.0002 +++ 0.406
cg18826637 2 145116633 yes 0.421 (0.125) 0.0008 ?++ 0.855
cg03149958 6 36326677 ETV7 yes 1.174 (0.261) 6.68E-06 +++ 0.813
cg19859270 3 98251294 GPR15 yes 1.858 (0.619) 0.0027 +++ 0.000
cg19589396 8 103937374 yes 0.937 (0.284) 0.0010 ?++ 0.462
cg18181703 17 76354621 SOCS3 yes 1.026 (0.255) 5.78E-05 +++ 0.788
cg05673882 5 74862702 POLK yes 1.006 (0.21) 1.68E-06 +-+ 0.034
cg25292882 15 39431467 yes 1.259 (0.399) 0.0016 +++ 0.250
cg27537125 1 25349681 yes 0.841 (0.512) 0.1007 +-+ 0.355
cg01127300 22 38614796 yes 0.813 (0.205) 7.53E-05 +++ 0.122
cg23110422 21 40182073 ETS2 yes 0.834 (0.307) 0.0067 +++ 0.294
cg21393163 1 12217629 yes 1.163 (0.377) 0.0020 +-+ 0.002
cg19266329 1 145456128 yes 0.875 (0.299) 0.0034 +++ 0.449
cg13976502 14 74227875 C14orf43 yes 0.785 (0.355) 0.0270 +++ 0.369
cg24086068 4 77356008 SHROOM3 yes 0.602 (0.187) 0.0013 +++ 0.521
cg04813697 10 22920025 PIP4K2A yes 0.911 (0.237) 1.18E-04 +++ 0.252
cg21990700 12 7260776 C1RL yes 1.161 (0.251) 3.86E-06 +++ 0.483
cg08549335 7 30387954 ZNRF2 yes 0.619 (0.174) 0.0004 ?++ 0.211
cg12303084 20 45985741 ZMYND8 yes 1.234 (0.409) 0.0026 +++ 0.545
cg00666749 13 21637118 LATS2 yes 0.682 (0.314) 0.0301 +-+ 0.001
cg06762457 6 149806635 ZC3H12D yes 0.657 (0.221) 0.0029 +-+ 0.021
cg23205886 5 138611766 SNHG4 yes 1.142 (0.312) 0.0002 +++ 0.215
cg02716826 9 33447032 SUGT1P1 yes 0.668 (0.319) 0.0365 +++ 0.505
cg03547355 1 227003060 yes 1.163 (0.355) 0.0010 +++ 0.335
Discovery time point 1
cg06826457 12 12867669 yes 1.182 (0.293) 5.38E-05 +++ 0.344
cg00741986 4 2748332 TNIP2 yes 0.722 (0.341) 0.0341 -++ 0.160
cg25953130 10 63753550 ARID5B yes 0.676 (0.148) 4.64E-06 +-+ 0.101
cg00073460 6 149806502 ZC3H12D yes 0.513 (0.192) 0.0077 +-+ 0.070
cg05593667 6 35490744 yes 0.533 (0.233) 0.0224 -++ 0.091
cg01882991 6 6677756 yes 1.423 (0.32) 8.92E-06 +++ 0.643
cg16708465 13 95933097 ABCC4 yes 0.546 (0.278) 0.0495 +-+ 0.323
cg01243823 16 50732212 NOD2 yes 0.501 (0.218) 0.0215 +++ 0.426
cg03957124 6 37016869 yes 1.289 (0.395) 0.0011 +++ 0.567
cg05135521 2 161188335 RBMS1 yes 0.485 (0.179) 0.0066 +++ 0.634
cg16288101 14 88621538 yes 0.715 (0.178) 5.97E-05 +++ 0.577
cg05557932 16 3929351 CREBBP yes 1.121 (0.326) 0.0006 +++ 0.263
cg01598596 3 187464648 BCL6 yes 0.563 (0.155) 0.0003 +++ 0.176
cg10691866 7 65817282 TPST1 yes 0.675 (0.182) 0.0002 +++ 0.942
cg21282907 6 74289980 yes 0.708 (0.315) 0.0248 +++ 0.609
cg20059012 12 53613154 RARG yes 0.476 (0.216) 0.0272 +?+ 0.564
cg12761472 6 119031922 yes 1.251 (0.292) 1.79E-05 +++ 0.618
cg11231349 1 162050656 NOS1AP yes 1.17 (0.234) 5.84E-07 ?++ 0.032
cg06505619 16 698072 WDR90 yes 0.787 (0.286) 0.0059 +-+ 0.353
Footnote to Table S4: see Supplementary Material Text.




















0.693 (0.093) 9.33E-14 +++ 0.513 0.835 (0.072) 1.58E-31 yes ++++-
1.112 (0.154) 5.38E-13 +++ 0.632 1.342 (0.123) 1.30E-27 yes +++++
0.775 (0.115) 1.77E-11 +++ 0.466 1.085 (0.097) 5.22E-29 yes +++++
1.047 (0.16) 5.77E-11 +++ 0.523 1.351 (0.131) 7.36E-25 yes ++++-
0.775 (0.18) 1.72E-05 ??+ 1.000 1.242 (0.118) 4.82E-26 yes ++++-
1.306 (0.233) 2.01E-08 +++ 0.889 1.549 (0.171) 1.40E-19 yes +++++
1.276 (0.247) 2.36E-07 +++ 0.606 1.641 (0.189) 3.75E-18 yes ++++-
1.269 (0.23) 3.21E-08 +++ 0.335 1.566 (0.192) 3.53E-16 yes ++++-
1.403 (0.214) 6.04E-11 +++ 0.419 1.399 (0.176) 2.20E-15 yes +++++
2.455 (0.376) 6.23E-11 +++ 0.863 1.943 (0.285) 9.73E-12 yes ++++-
1.198 (0.208) 7.77E-09 +++ 0.299 1.1 (0.175) 3.05E-10 yes +++++
1.079 (0.224) 1.44E-06 +++ 0.280 1.369 (0.18) 3.29E-14 yes ++++-
1.823 (0.304) 2.08E-09 +++ 0.301 1.722 (0.233) 1.31E-13 yes +++++
0.904 (0.284) 0.0014 +++ 0.180 1.716 (0.216) 1.88E-15 yes +++++
2.334 (0.4) 5.39E-09 +++ 0.869 1.911 (0.331) 7.59E-09 yes ++++-
1.465 (0.266) 3.64E-08 +++ 0.826 1.397 (0.224) 4.15E-10 yes ++++-
1.539 (0.285) 6.76E-08 +++ 0.533 1.421 (0.24) 3.28E-09 yes +++++
0.968 (0.186) 1.82E-07 +++ 0.321 0.789 (0.151) 1.66E-07 yes +-++-
0.924 (0.213) 1.42E-05 +++ 0.158 0.822 (0.156) 1.30E-07 yes ++++-
0.642 (0.105) 8.92E-10 +++ 0.573 0.545 (0.119) 4.90E-06 yes +?++-
1.568 (0.228) 5.44E-12 +++ 0.303 0.776 (0.241) 0.0013 +-++-
3.208 (0.583) 3.68E-08 +++ 0.005 2.662 (0.435) 9.41E-10 yes ++++-
1.203 (0.238) 4.51E-07 +++ 0.660 1.139 (0.218) 1.69E-07 yes +++++
1.314 (0.247) 1.04E-07 +++ 0.985 0.985 (0.202) 1.06E-06 yes ++++-
1.311 (0.209) 3.31E-10 +++ 0.178 0.764 (0.16) 1.69E-06 yes +++-+
1.969 (0.361) 5.07E-08 +++ 0.227 0.851 (0.254) 0.0008 +-+++
2.114 (0.491) 1.69E-05 +++ 0.972 2.154 (0.372) 7.31E-09 yes ++++-
1.159 (0.182) 1.85E-10 +++ 0.167 0.692 (0.159) 1.32E-05 yes ++++-
1.506 (0.288) 1.74E-07 +++ 0.534 1.269 (0.271) 2.92E-06 yes ++++-
1.752 (0.378) 3.52E-06 +++ 0.066 1.791 (0.281) 1.87E-10 yes +++++
1.963 (0.299) 5.44E-11 +++ 0.418 0.824 (0.243) 0.0007 +-++-
1.928 (0.358) 7.06E-08 +++ 0.094 1.111 (0.294) 0.0002 yes +-++-
1.055 (0.183) 7.80E-09 +-+ 0.009 0.718 (0.193) 0.0002 yes +?++-
1.209 (0.231) 1.70E-07 +++ 0.940 0.781 (0.168) 3.23E-06 yes ++++-
1.53 (0.251) 1.18E-09 +++ 0.314 0.836 (0.225) 0.0002 yes +++++
1.064 (0.18) 3.16E-09 +++ 0.348 0.41 (0.116) 0.0004 yes +++++
1.896 (0.369) 2.72E-07 +++ 0.886 1.361 (0.323) 2.46E-05 yes +++++
1.535 (0.292) 1.50E-07 +++ 0.007 0.654 (0.219) 0.0028 +-+++
1.092 (0.196) 2.59E-08 +++ 0.426 0.75 (0.158) 1.94E-06 yes ++++-
1.79 (0.299) 2.07E-09 +++ 0.815 0.58 (0.243) 0.0170 +-+++
1.518 (0.295) 2.53E-07 +++ 0.517 1.134 (0.26) 1.33E-05 yes +++++
1.818 (0.344) 1.22E-07 +++ 0.606 0.704 (0.273) 0.0101 +-+++
Discovery time point 2 (ECRHS/ NFBC/ SAPALDIA)
Replication time point 1 (KORA/ LBC1936/ Lifelines/  
FTC)
1.466 (0.284) 2.46E-07 +++ 0.170 0.811 (0.228) 0.0004 yes ++++-
1.7 (0.336) 4.06E-07 +++ 0.900 0.959 (0.251) 0.0001 yes ++++-
0.882 (0.148) 2.74E-09 +++ 0.304 0.526 (0.13) 5.45E-05 yes +++++
0.978 (0.178) 3.60E-08 +++ 0.538 0.698 (0.148) 2.50E-06 yes ++++-
1.33 (0.257) 2.26E-07 +?+ 0.440 0.721 (0.199) 0.0003 yes ++++-
1.739 (0.305) 1.22E-08 +++ 0.517 0.478 (0.243) 0.0494 +-++-
1.492 (0.28) 9.83E-08 +++ 0.587 0.779 (0.257) 0.0024 ++++-
1.157 (0.223) 2.05E-07 +++ 0.146 0.657 (0.183) 0.0003 yes ++++-
2.231 (0.412) 6.01E-08 +++ 0.906 0.543 (0.257) 0.0348 +-++-
0.907 (0.169) 8.53E-08 +++ 0.753 0.347 (0.147) 0.0185 +++++
0.836 (0.144) 5.80E-09 +++ 0.695 0.474 (0.148) 0.0013 +++-+
1.808 (0.336) 7.10E-08 +++ 0.051 0.671 (0.244) 0.0058 ++++-
0.828 (0.163) 3.48E-07 +++ 0.052 0.198 (0.132) 0.1337 +-+++
0.906 (0.179) 3.89E-07 +++ 0.196 0.237 (0.144) 0.0992 --+++
1.744 (0.298) 4.60E-09 +++ 0.440 0.572 (0.262) 0.0290 no +-++-
0.964 (0.185) 1.77E-07 +++ 0.274 0.338 (0.162) 0.0370 no ++?+-
1.676 (0.308) 5.28E-08 +++ 0.887 0.705 (0.268) 0.0086 no ++++-
1.262 (0.242) 1.92E-07 ??+ 1.000 0.444 (0.183) 0.0150 no +-++-






















0.431 0.97 (0.242) 7.51E-05 0.785 (0.0567) 1.48E-43 +++++++ 0.429 6.10E-22
0.841 1.496 (0.352) 2.67E-05 1.275 (0.0975) 4.08E-39 +++++++ 0.663 5.70E-17
0.720 0.667 (0.24) 0.0057 0.939 (0.0741) 7.43E-37 +++++++ 0.192 4.50E-21
0.211 0.896 (0.395) 0.0237 1.254 (0.1029) 3.30E-34 +++++++ 0.345 9.80E-30
0.829 1.11 (0.337) 0.0011 1.115 (0.0986) 1.14E-29 ??+++++ 0.258 6.80E-23
0.106 1.247 (0.487) 0.0108 1.563 (0.143) 8.88E-28 +++++++ 0.740 7.90E-13
0.011 1.224 (0.457) 0.0077 1.614 (0.1513) 1.46E-26 +++++++ 0.293 9.70E-16
0.008 0.913 (0.442) 0.0397 1.51 (0.1496) 6.09E-24 +++++++ 0.126 4.40E-21
0.006 0.41 (0.349) 0.2401 1.323 (0.1368) 4.29E-22 +++++++ 0.001 1.60E-16
0.041 0.827 (0.557) 0.1383 2.172 (0.2277) 1.41E-21 +++++++ 0.189 3.90E-14
0.001 0.78 (0.366) 0.0336 1.316 (0.1381) 1.63E-21 +++++++ 0.259 2.70E-10
0.016 1.017 (0.387) 0.0090 1.32 (0.1424) 1.93E-20 +++++++ 0.102 1.90E-14
0.009 0.539 (0.538) 0.3170 1.723 (0.1872) 3.40E-20 +++++++ 0.010 1.20E-13
0.087 2.023 (0.633) 0.0015 1.583 (0.1754) 1.75E-19 +++++++ 0.044 7.20E-18
0.123 1.878 (0.707) 0.0082 2.29 (0.2551) 2.76E-19 +++++++ 0.989 7.40E-13
0.319 1.276 (0.603) 0.0349 1.474 (0.1744) 2.87E-17 +++++++ 0.968 2.70E-11
0.446 1.398 (0.512) 0.0066 1.563 (0.1863) 5.04E-17 +++++++ 0.821 1.70E-20
0.000 0.275 (0.276) 0.3198 0.993 (0.1199) 1.21E-16 +++++++ 0.005 1.90E-10
0.000 0.407 (0.332) 0.2214 1.038 (0.1323) 4.28E-15 +++++++ 0.113 3.30E-07
0.086 0.613 (0.0789) 8.24E-15 ++++++? 0.705 3.70E-05
0.062 0.411 (0.384) 0.2844 1.268 (0.1635) 8.55E-15 +++++++ 0.126 1.60E-08
0.011 0.38 (0.691) 0.5820 2.741 (0.3559) 1.34E-14 +++++++ 0.000 6.30E-17
0.005 0.426 (0.376) 0.2585 1.216 (0.1596) 2.50E-14 +++++++ 0.070 1.70E-09
0.422 1.131 (0.44) 0.0104 1.196 (0.158) 3.74E-14 +++++++ 0.994 4.20E-06
0.076 0.363 (0.337) 0.2829 0.969 (0.1306) 1.17E-13 +++++-+ 0.009 7.20E-09
0.000 0.28 (0.46) 0.5431 1.689 (0.2306) 2.36E-13 +++++++ 0.007 2.80E-07
0.155 0.248 (0.893) 0.7813 2.156 (0.2987) 5.28E-13 +++++++ 0.378 5.50E-16
0.392 0.349 (0.354) 0.3253 0.853 (0.12) 1.19E-12 +++++++ 0.060 7.60E-09
0.050 0.088 (0.537) 0.8703 1.415 (0.2002) 1.60E-12 +++++++ 0.144 3.50E-11
0.252 0.648 (0.797) 0.4166 1.628 (0.231) 1.81E-12 +++++++ 0.069 3.80E-12
0.014 -0.07 (0.448) 0.8749 1.34 (0.1908) 2.16E-12 ++++++- 0.005 4.00E-04
0.025 0.359 (0.547) 0.5125 1.576 (0.2303) 7.86E-12 +++++++ 0.088 5.00E-08
0.408 0.911 (0.1332) 7.92E-12 +-++++? 0.029 1.00E-04
0.491 0.382 (0.32) 0.2333 0.953 (0.1394) 7.93E-12 +++++++ 0.584 5.80E-07
0.497 0.267 (0.628) 0.6711 1.166 (0.1716) 1.06E-11 +++++++ 0.137 3.90E-17
0.553 0.522 (0.24) 0.0303 0.713 (0.1053) 1.26E-11 +++++++ 0.146 0.0162
0.617 0.618 (0.669) 0.3561 1.608 (0.2415) 2.76E-11 +++++++ 0.770 4.20E-15
0.005 0.305 (0.419) 0.4676 1.249 (0.189) 3.81E-11 +++++++ 0.006 0.0054
0.505 0.016 (0.298) 0.9583 0.816 (0.1235) 3.90E-11 +++++++ 0.081 1.10E-06
0.060 0.526 (0.475) 0.2687 1.258 (0.1919) 5.63E-11 +++++++ 0.194 2.10E-09
0.999 0.855 (0.613) 0.1638 1.281 (0.198) 9.68E-11 +++++++ 0.840 3.00E-04
0.001 0.318 (0.547) 0.5619 1.409 (0.2201) 1.54E-10 +++++++ 0.332 1.20E-08
Combined meta-analysis ( ECRHS, NFBC66, 
SAPALDIA, KORA, LBC1936, LifeLines, NSPHS)¶
      / NSPHS/ Replication time point 2 
(only LBC1936)
0.048 0.338 (0.551) 0.5400 1.124 (0.181) 5.35E-10 +++++++ 0.044 2.90E-05
0.355 0.461 (0.484) 0.3422 1.246 (0.2017) 6.52E-10 +++++++ 0.325 5.40E-08
0.197 -0.332 (0.276) 0.2300 0.618 (0.1004) 7.24E-10 ++++++- 0.006 2.90E-09
0.775 -0.218 (0.272) 0.4224 0.701 (0.114) 8.03E-10 ++++++- 0.015 2.10E-09
0.303 0.209 (0.426) 0.6234 0.964 (0.1609) 2.08E-09 +?+++++ 0.195 2.30E-16
0.020 0.127 (0.474) 0.7885 1.162 (0.1947) 2.39E-09 +++++++ 0.066 5.40E-07
0.106 0.032 (0.452) 0.9430 1.081 (0.1895) 1.15E-08 +++++++ 0.038 6.60E-05
0.501 0.175 (0.525) 0.7392 0.816 (0.1435) 1.31E-08 +++++++ 0.079 2.00E-04
0.034 0.384 (0.47) 0.4143 1.238 (0.2188) 1.53E-08 +++++++ 0.077 2.00E-05
0.579 0.198 (0.267) 0.4583 0.628 (0.1122) 2.25E-08 +++++++ 0.340 2.20E-07
0.182 -0.134 (0.223) 0.5464 0.554 (0.0999) 2.98E-08 +++++-- 0.003 1.30E-05
0.304 0.014 (0.567) 0.9801 1.137 (0.2051) 2.99E-08 +++++++ 0.022 0.0012
0.289 0.62 (0.262) 0.0183 0.583 (0.1056) 3.49E-08 +++++++ 0.054 5.00E-04
0.015 0.328 (0.327) 0.3152 0.613 (0.1154) 1.07E-07 ++++-++ 0.014 1.40E-14
0.068 -0.521 (0.418) 0.2136 1.042 (0.1964) 1.12E-07 ++++++- 0.001 0.0128
0.409 0.404 (0.336) 0.2294 0.656 (0.1266) 2.22E-07 +++?+++ 0.119 4.40E-21
0.298 -0.158 (0.407) 0.6974 1.033 (0.2005) 2.58E-07 ++++++- 0.019 4.90E-05
0.174 -0.017 (0.29) 0.9540 0.74 (0.1443) 2.90E-07 ??++++- 0.017 1.50E-06
















































































cg03149958 6 36326677 ETV7 yes 0.573 (0.297) 0.0537 -++ 0.679
cg08549335 7 30387954 ZNRF2 yes 0.507 (0.198) 0.0104 ?++ 0.476
cg19266329 1 145456128 yes 0.721 (0.339) 0.0332 -++ 0.411
cg05575921 5 373378 AHRR yes -0.029 (0.107) 0.7881 --+ 0.196
cg03636183 19 17000585 F2RL3 yes 0.076 (0.174) 0.6627 +-+ 0.663
cg23205886 5 138611766 SNHG4 yes 0.799 (0.354) 0.0238 -++ 0.080
cg24086068 4 77356008 SHROOM3 yes 0.324 (0.211) 0.1257 +++ 0.878
cg25953130 10 63753550 ARID5B yes 0.579 (0.168) 0.0006 +++ 0.248
Footnote to Table S5: see Supplementary Material Text.
Table S5: Detailed results in all participants: cross-sectional associations with FVC at time p              






















1.383 (0.254) 5.19E-08 +++ 0.298 0.897 (0.275) 0.0011 yes +-++-
1.004 (0.199) 4.74E-07 +++ 0.375 0.474 (0.132) 0.0003 yes +++++
1.911 (0.334) 1.03E-08 +-+ 0.037 0.594 (0.276) 0.0313 no +-++-
0.27 (0.106) 0.0109 +-+ 0.008 0.428 (0.081) 1.18E-07 yes ++++-
0.537 (0.173) 0.0019 +-+ 0.158 0.668 (0.140) 1.82E-06 no +++++
1.725 (0.335) 2.55E-07 +++ 0.381 0.512 (0.275) 0.0630 no +-++-
1.069 (0.204) 1.59E-07 +++ 0.107 0.448 (0.211) 0.0334 no +?++-
0.845 (0.165) 2.79E-07 +++ 0.104 0.333 (0.147) 0.0239 no +-+++
             point 1 and at time point        
Discovery time point 2 
(ECRHS/ NFBC/ 
SAPALDIA)


















0.080 0.486 (0.487) 0.3179 1.2459 (0.186) 1.88E-11 +++++++ 0.355
0.948 0.764 (0.304) 0.0123 0.7439 (0.119) 3.80E-10 +++++++ 0.522
0.161 0.103 (0.567) 0.8554 1.2535 (0.216) 6.36E-09 +-+++++ 0.015
0.487 0.614 (0.312) 0.0494 0.3704 (0.064) 8.79E-09 +-+++++ 0.027
0.598 0.778 (0.454) 0.0875 0.6182 (0.11) 2.04E-08 +-+++++ 0.360
0.217 0.937 (0.601) 0.1197 1.2061 (0.217) 2.74E-08 +++++++ 0.324
0.751 na na 0.7835 (0.147) 9.89E-08 ++++?++ 0.123
0.063 -0.271 (0.351) 0.4395 0.5908 (0.113) 1.55E-07 ++++-++ 0.028
Combined meta-analysis (ECRHS, NFBC66, 
SAPALDIA, KORA, LBC1936, LifeLines, NSPHS)¶
















Table S9: Detailed results in never smokers: cross-sectional associations with lung function at ti               















cg2575839 1 3623859 TP73 no 3.095 (0.808) 0.0001 ?-+ 0.003
cg1866450 3 169487465 ARPM1 no -2.513 (0.885) 0.0045 +-- 0.008
cg0446037 9 130661175 ST6GALNAC yes 2.768 (0.544) 3.54E-07 +++ 0.349
cg0091155 12 8234647 NECAP1 no -5.031 (0.974) 2.43E-07 --- 0.779
cg2027879 20 57583474 CTSZ no 1.913 (0.656) 0.0036 --+ 1.02E-04
FEV1/FVC
cg2575839 1 3623859 TP73 no 0.496 (0.109) 5.17E-06 ?-+ 0.001988
cg0578529 1 204654622 LRRN2 no 0.118 (0.28) 0.6748 -++ 0.8757
cg1598199 3 169487311 ARPM1 no -0.623 (0.169) 0.0002 ?-- 0.005147
cg1866450 3 169487465 ARPM1 no -0.311 (0.121) 0.0104 ++- 0.003122
cg2723503 6 29976917 HLA-J no 0.383 (0.075) 3.54E-07 -++ 0.08295
cg1264793 6 70576740 COL19A1 no -1.018 (0.185) 3.67E-08 --- 0.5412
cg1356224 8 33368277 C8orf41 no 0.394 (0.1) 7.58E-05 +++ 0.1845
cg1926838 15 23086595 NIPA1 no -0.381 (0.289) 0.1864 ?-- 0.01075
cg0988407 15 23086698 NIPA1 no -0.352 (0.147) 0.0167 +-- 0.006672
cg2027879 20 57583474 CTSZ no 0.453 (0.088) 2.81E-07 +++ 0.1306
FVC
cg25758391 3623859 TP73 no 1.594 (0.937) 0.0888 ?-+ 0.227
cg12752421 43751363 C1orf210 no -0.004 (1.08) 0.9971 -++ 0.585
cg25633958 1616622 DLGAP2 no 0.251 (1.344) 0.8518 -++ 0.975
cg256680512 115183175 no -3.322 (0.64) 2.10E-07 --- 0.803
cg049751414 106438118 ADAM6 no -3.485 (0.668) 1.78E-07 --- 0.080
cg056226816 58501611 NDRG4 no -0.725 (1.162) 0.5329 +-+ 0.139
cg267688119 30302793 CCNE1 no -18.361 (3.654) 5.02E-07 --- 0.385
Footnote to Table S9: see Supplementary Material Text.
Discovery meta-analysis at time 
point 1 (ECRHS/ NFBC/ SAPALDIA)
























5.287 (0.878) 1.727E-09 ??+ 1 -0.027 (0.584) 0.9630 -+-+- 0.341
-5.687 (1.012) 1.917E-08 --- 0.220 -1.327 (0.604) 0.0280 ----- 0.685
1.252 (0.547) 0.0220 -++ 0.360 0.094 (0.373) 0.8012 --++- 0.209
1.95 (1.891) 0.3025 +-+ 0.407 -1.333 (0.735) 0.0697 -++-- 0.363
3.255 (0.631) 2.507E-07 -++ 0.028 -0.284 (0.499) 0.5691 --+-- 0.211
0.708 (0.127) 2.687E-08 ??+ 1.000 -0.153 (0.096) 0.1130 ---+- 0.2228
-1.003 (0.188) 9.099E-08 -+- 0.015 -0.136 (0.13) 0.2952 --++- 0.9149
-1.223 (0.224) 5.042E-08 ??- 1.000 -0.099 (0.077) 0.1959 -+--- 0.4040
-0.802 (0.145) 2.929E-08 +-- 0.008 -0.155 (0.083) 0.0611 ----- 0.7823
0.203 (0.084) 0.0153 +++ 0.598 0.073 (0.073) 0.3171 ++-+- 0.7204
0.04 (0.202) 0.8432 -+- 0.429 -0.074 (0.15) 0.6227 -+--+ 0.2800
0.537 (0.103) 1.928E-07 +++ 0.884 0.169 (0.093) 0.0698 +++-- 0.3062
-5.263 (0.964) 4.774E-08 ??- 1.000 -0.163 (0.141) 0.2472 ----- 0.5399
-0.845 (0.149) 1.384E-08 --- 0.164 -0.064 (0.1) 0.5172 --+-+ 0.7946
0.473 (0.09) 1.618E-07 -++ 0.003 0.046 (0.088) 0.5985 --+-+ 0.0200
5.311 (1.01) 1.44E-07 ??+ 1.000 0.85 (0.704) 0.2272 -++-- 0.290
5.288 (1.044) 4.03E-07 +++ 0.546 0.884 (0.729) 0.2251 -++++ 0.646
-7.498 (1.477) 3.87E-07 --- 0.004 0.444 (0.808) 0.5824 -++-- 0.849
-1.366 (0.604) 0.0238 --- 0.778 0.205 (0.461) 0.6568 --++- 0.463
-0.518 (0.705) 0.4628 +-- 0.578 -0.852 (0.666) 0.2010 --?-- 0.449
6.201 (1.21) 2.98E-07 +++ 0.482 -0.217 (0.758) 0.7750 +---- 0.844
5.29 (3.87) 0.1717 -+- 0.080 1.427 (2.549) 0.5756 +-++- 0.601
Discovery meta-analysis at time point 2 
(ECRHS/ NFBC/ SAPALDIA)
Replication meta-analysis (KORA/ 
LBC1936/ Lifelines/ NSPHS/ FTC)
                           nalyses.











-0.027 (0.584) 0.9630 1.926 (0.541) 0.0004 ??+--++ 4.02E-05
-1.327 (0.604) 0.0280 -1.807 (0.517) 0.0005 ------+ 3.80E-05
0.094 (0.373) 0.8012 0.912 (0.325) 0.0049 -+++-++ 0.630
-1.333 (0.735) 0.0697 -0.623 (0.719) 0.3861 +-++--+ 0.090
-0.284 (0.499) 0.5691 1.908 (0.448) 2.02E-05 -+++--+ 0.003
-0.117 (0.345) 0.7351 0.213 (0.083) 0.0107 ??+--+- 1.78E-06
-0.122 (0.814) 0.8806 -0.423 (0.111) 0.00014 -+-+-+- 0.001
0.003 (0.618) 0.9961 -0.231 (0.073) 0.00163 ??----+ 9.38E-05
-0.235 (0.466) 0.6140 -0.308 (0.072) 2E-05 +------ 1.88E-04
-0.045 (0.212) 0.8318 0.121 (0.057) 0.03368 +++-++- 0.621
0.601 (0.91) 0.5092 -0.092 (0.124) 0.4595 -+----+ 0.791
0.082 (0.236) 0.7275 0.349 (0.074) 2.7E-06 +++++-+ 0.206
-2.179 (1.434) 0.1302 -0.263 (0.14) 0.06145 ??----- 5.37E-06
-0.406 (0.713) 0.5697 -0.308 (0.084) 0.00026 ---+--- 0.001
-0.12 (0.253) 0.6366 0.319 (0.07) 5E-06 -+++--- 4.13E-05
1.792 (1.74) 0.3041 2.541 (0.63) 5.46E-05 ??++--+ 0.002
1.262 (1.164) 0.2797 2.327 (0.577) 5.44E-05 ++++-++ 0.028
-1.113 (1.935) 0.5657 -1.99 (0.768) 0.0096 ---+--- 1.95E-05
0.49 (0.773) 0.5265 -0.206 (0.372) 0.5798 ---+-++ 0.187
-0.343 (1.231) 0.7807 -0.596 (0.52) 0.2518 +--?--- 0.756
-0.817 (1.287) 0.5266 1.598 (0.67) 0.0171 +++-+-- 0.001
7.903 (6.389) 0.2175 3.941 (2.093) 0.0597 -+-++++ 0.329
Combined meta-analysis (ECRHS/ NFBC/ 
SAPALDIA/KORA/ LBC36/ Lifelines/ NSPHS)
Replication time point 2 
(only LBC36)
Table S19: ALEC discovery meta-analysis look-up results for cross-section                             




cg05575921 5 373378 AHRR yes
cg01940273 2 233284934 ALPPL2 yes
cg21566642 2 233284661 ALPPL2 yes
cg03636183 19 17000585 F2RL3 yes
cg21161138 5 399360 AHRR yes
cg09935388 1 92947588 GFI1 yes
cg24859433 6 30720203 IER3 yes
cg17386185 3 52321266 GLYCTK no
cg05951221 2 233284402 ALPPL2 yes
cg25623459 11 1861344 TNNI2 no
cg25028542 7 36429120 ANLN no
cg06126421 6 30720080 IER3 yes
cg13471990 10 97515222 ENTPD1 no
cg09076123 1 183559527 NCF2 no
cg18142353 12 12420574 LRP6 no
cg25957124 16 21171084 TMEM159 no
cg02240622 15 40601467 PLCB2 no
cg12582959 19 56159199 CCDC106 no
cg21126943 19 42259395 CEACAM6 no
cg23140706 12 54689278 NFE2 yes
cg24412501 11 13690194 FAR1 no
cg00563932 9 139871049 PTGDS yes
cg03143849 11 2904951 CDKN1C no
cg20981615 4 48136280 TXK no
cg20125091 1 92952641 GFI1 no
cg07525077 14 21359943 RNASE3 no
cg12949760 11 2542862 KCNQ1 no
cg09358725 11 33914088 LMO2 no
cg01120308 11 85780971 PICALM no
cg08529852 9 139557920 EGFL7 yes
cg07658590 21 46963587 SLC19A1 yes
cg27067618 19 15751949 CYP4F3 no
cg01899253 13 29070056 FLT1 no
cg23547429 11 57195025 SLC43A3 no
cg22242539 17 1665220 SERPINF1 no
cg11378484 3 63848695 THOC7 no
cg24621042 14 94857275 SERPINA1 no
cg06394229 19 39303775 LGALS4 no
cg01143454 20 2795601 C20orf141 no
cg17173423 11 59823993 MS4A3 no
cg19258882 12 56472805 ERBB3 no
cg11719283 19 42574717 no
cg19168338 16 4465731 CORO7 no
cg22224704 11 67352041 GSTP1 no
cg23713742 20 34202721 SPAG4 no
cg04988978 17 56359578 MPO no
cg06196379 6 41254885 TREM1 no
cg07409200 13 43354674 C13orf30 no
cg25732252 9 130679915 ST6GALNAC4 no
cg13745346 16 89044523 CBFA2T3 yes
cg05228408 1 11865352 CLCN6 yes
cg02600394 4 48136234 TXK no
cg10453758 3 132380190 UBA5 yes
cg24898863 1 153363580 S100A8 no
cg17753124 19 13259872 IER2 yes
cg26259865 16 2880359 ZG16B no
cg22467534 17 73841658 UNC13D no
cg00833777 16 31271642 ITGAM yes
cg11098259 15 58430391 AQP9 no
cg22994830 7 623846 PRKAR1B yes
cg00622552 15 76016335 ODF3L1 no
cg18884741 7 66204797 RABGEF1 no
cg03165378 1 153329882 S100A9 no
cg18089000 9 136039706 GBGT1 no
cg06812844 21 45773782 TRPM2 no
cg14870461 3 69062103 C3orf64 no
cg00554250 11 47281370 NR1H3 no
cg27461196 19 35630106 FXYD1 no
cg08519905 12 6308774 CD9 no
cg24841244 11 118213330 CD3D no
cg23320649 3 50604613 C3orf18 yes
cg18463686 7 141646690 CLEC5A no
cg23181133 19 42300812 CEACAM3 no
cg16361890 5 179220545 LTC4S yes
cg13053608 17 40345673 GHDC no
cg26944434 10 112064524 SMNDC1 no
cg05995267 16 29822529 PRRT2 no
cg10057295 13 99230004 STK24 no
cg15337006 16 31271009 ITGAM yes
cg21120249 9 139921971 C9orf139 yes
cg21019522 11 2920789 SLC22A18 no
cg16967583 2 241807859 AGXT no
cg18934187 18 51882189 STARD6 no
cg24092253 20 61848099 YTHDF1 no
cg00645579 11 617140 IRF7 no
cg24949488 10 98064362 DNTT no
cg23839680 7 56118238 CCT6A no
cg21182407 6 3119541 BPHL yes
cg05512099 19 30155866 PLEKHF1 no
cg11009736 2 119699682 MARCO no
cg11584690 19 42574196 yes
cg22381196 16 72041376 DHODH no
cg13745870 3 57094763 SPATA12 yes
cg03801286 21 35884508 KCNE1 no
cg14070162 17 40575582 PTRF no
cg23732182 21 44898090 C21orf84 no
cg12810837 12 9822287 CLEC2D no
cg08510456 3 49591008 BSN no
cg21480743 10 89621419 KILLIN yes
cg26616347 7 128577752 IRF5 no
cg21283680 3 15384005 SH3BP5 no
cg02830467 6 153018721 MYCT1 no
cg17329164 6 32121259 PPT2 no
cg09418321 12 4699618 DYRK4 no
cg25050026 3 158519410 MFSD1 no
cg10506318 5 60239580 ERCC8 no
cg02863947 3 119499190 NR1I2 no
cg03891319 3 52016838 ACY1 yes
cg07156669 17 28705245 CPD no
cg27210390 17 52978583 TOM1L1 no
cg09037813 2 238599761 LRRFIP1 no
cg11939496 1 160833560 CD244 no
cg12971694 9 35618412 CD72 no
cg08399444 12 13248548 GSG1 no
cg00666746 19 15217781 SYDE1 yes
cg05989054 19 1402626 GAMT yes
cg03574571 19 35820181 CD22 no
cg09848074 7 139172610 no
cg05347985 1 77751443 AK5 no
cg23902550 8 144681106 EEF1D yes
cg15484375 11 18287647 SAA1 no
cg14700707 6 32191840 NOTCH4 no
cg12564453 16 56995840 CETP no
cg02225847 16 67563418 FAM65A no
cg13277939 14 39735211 CTAGE5 no
cg16989646 13 41364245 SLC25A15 no
cg11916609 2 102927488 IL1RL1 no
cg19154438 19 45825730 CKM no
cg26206598 20 47445432 PREX1 no
cg06521852 22 38141419 TRIOBP yes
cg10266490 1 55013709 ACOT11 no
cg10257049 5 154230308 C5orf4 yes
cg15125472 19 36248077 HSPB6 no
cg08840010 1 8000314 TNFRSF9 no
cg06810647 16 1665094 CRAMP1L no
cg24091474 19 36399185 TYROBP yes
cg15528736 19 50015780 FCGRT no
cg01240931 5 112074043 APC yes
cg02266731 12 69357333 CPM no
cg24612198 11 118175631 CD3E no
cg07376232 11 118084920 AMICA1 yes
cg21256649 17 66507610 PRKAR1A no
cg10521852 19 19739820 LPAR2 yes
cg01441777 22 38714416 CSNK1E no
cg17952262 4 683240 MFSD7 no
cg08130265 15 77519170 C15orf5 no
cg17296078 10 99259721 MMS19 yes
cg02679745 9 139927646 C9orf139 no
cg05037688 9 139556554 EGFL7 no
cg05961212 3 119298195 ADPRH no
cg13765621 1 158149228 CD1D no
cg09039163 2 239009036 ESPNL no
cg22534509 12 123215119 GPR81 no
cg03330678 17 75316233 Sep-09 no
cg14178895 6 11778902 C6orf105 no
cg07351267 19 33684846 LRP3 no
cg09453312 5 156608118 ITK no
cg21716693 6 36806882 CPNE5 no
cg00278366 12 110940287 RAD9B no
cg06270401 12 4699085 DYRK4 no
cg20276088 3 133502917 no
cg22285621 11 67071322 SSH3 no
cg11921829 1 157777140 FCRL2 no
cg00443307 12 9141740 KLRG1 no
cg09106999 12 56360065 CDK2 no
cg20070090 1 153363489 S100A8 no
cg00615377 22 36236649 RBM9 no
cg03340878 6 27925166 OR2B6 yes
cg17536532 9 138370739 KIAA0649 yes
cg21491308 19 43892826 TEX101 no
cg02564061 12 49998963 FAM186B yes
cg04541607 22 27013978 CRYBB1 no
cg25226014 3 45984942 CXCR6 no
cg09457245 12 54778750 ZNF385A no
cg14324675 6 31554848 LST1 no
cg02357714 5 176936563 DOK3 yes
cg05979020 2 176981336 HOXD10 yes
cg24489015 17 56316162 LPO no
cg25341726 16 28518331 IL27 no
cg15376097 11 118135270 MPZL2 no
cg01526089 17 3819390 P2RX1 yes
cg22322184 19 7734203 RETN no
cg15977278 12 104234975 NT5DC3 no
cg03763616 19 50921997 SPIB no
cg00187686 11 59634218 TCN1 no
cg15195412 16 57406955 CX3CL1 no
cg27060381 22 30723363 TBC1D10A yes
cg25600606 11 33308345 HIPK3 no
cg18413900 12 58160989 CYP27B1 no
cg07285167 1 36948981 CSF3R no
cg01578324 6 31704774 CLIC1 no
cg09427311 9 129885730 ANGPTL2 no
cg21653913 19 41307778 EGLN2 no
cg20564273 8 114446439 CSMD3 no
cg27606341 5 39219632 FYB no
cg04908668 6 32823941 PSMB9 no
cg07073964 19 698371 no
cg21578541 3 52260090 TLR9 no
cg15958424 3 132036067 ACPP no
cg15552238 19 14785749 EMR3 no
cg19904425 14 94984530 SERPINA12 no
cg01861509 10 73849626 SPOCK2 no
cg22892904 17 77751089 CBX2 no
cg09313705 17 46622491 HOXB2 no
cg14292823 8 144681097 EEF1D yes
cg16097772 12 69742232 LYZ no
cg06759890 5 77806538 LHFPL2 no
cg12585943 6 32121368 PPT2 yes
cg21033855 15 43662581 TUBGCP4 no
cg24821554 13 51639953 GUCY1B2 no
cg02181506 14 94856984 SERPINA1 yes
cg24211388 6 31582837 AIF1 no
cg24958765 19 41283667 RAB4B no
cg12556134 20 35201610 TGIF2 no
cg20340242 2 102608349 IL1R2 yes
cg05253159 7 101928560 SH2B2 no
cg11738543 12 93967225 SOCS2 no
cg01980222 6 41130917 TREM2 no
cg08458487 10 81709191 SFTPD no
cg09175620 1 54484536 LDLRAD1 no
cg12491659 5 57786356 GAPT no
cg20178764 5 137609835 GFRA3 no
cg12380764 1 206971195 IL19 no
cg03600318 10 81708991 SFTPD no
cg24453664 11 33758413 CD59 yes
cg10236239 2 108994514 SULT1C4 yes
cg15746187 1 11713123 FBXO2 no
cg20764656 14 65410479 GPX2 yes
cg15836722 2 113593785 IL1B no
cg27019278 4 101438804 EMCN no
cg18333690 1 17634716 PADI4 no
cg08368934 16 57701455 GPR97 no
cg12845808 5 141338604 PCDH12 no
cg07300408 14 21058360 RNASE12 no
cg07195577 17 27052828 TLCD1 yes
cg06280210 7 26331247 SNX10 no
cg00333528 6 89927485 GABRR1 yes
cg04353769 11 59951557 MS4A6A no
cg09440215 19 58480646 C19orf18 no
cg17709873 6 31540456 LTA no
cg19531130 11 101786659 KIAA1377 no
cg02415431 22 23923255 IGLL1 no
cg15743985 19 35819809 CD22 yes
cg01623438 20 57582894 CTSZ no
cg05714729 18 33234096 GALNT1 no
cg11846968 20 31823545 PLUNC no
cg01718139 19 54566838 VSTM1 no
cg22438810 9 130911792 LCN2 no
cg07408456 19 15590532 PGLYRP2 yes
cg19906550 NA NA NA no
cg15374234 17 72709026 CD300LF no
cg16872071 9 135997155 RALGDS no
cg11905488 12 10123604 CLEC12A no
cg14961391 2 148758708 ORC4L no
cg27485921 2 46747379 ATP6V1E2 no
cg05973262 6 32191895 NOTCH4 no
cg05697976 12 29376483 FAR2 no
cg10287137 11 72929054 P2RY2 no
cg11340260 17 4835476 GP1BA no
cg06041363 22 46663418 TTC38 no
cg01274660 7 100465625 TRIP6 no
cg06874144 2 231576873 CAB39 no
cg09868035 20 62492074 C20orf135 no
cg15784615 12 6493767 LTBR no
cg15248035 9 36169949 CCIN no
cg22972055 7 872293 UNC84A no
cg09134726 19 841082 PRTN3 no
cg07099407 6 43027930 KLC4 no
cg10094443 4 39529866 UGDH no
cg02595219 11 74178761 KCNE3 yes
cg10107958 1 228783383 DUSP5P no
cg04881903 2 85637116 CAPG no
cg00739120 19 36035875 GAPDHS yes
cg26112639 1 247580106 NLRP3 yes
cg02901679 NA NA NA no
cg21991396 1 247581417 NLRP3 no
cg06645778 2 64680425 HSPC159 no
cg23265096 20 57582594 CTSZ no
cg19601328 17 43368729 MAP3K14 no
cg09303642 12 54690818 NFE2 no
cg18399183 12 51318138 METTL7A no
cg17777592 13 49975418 CAB39L no
cg10126923 19 51875451 NKG7 no
cg10787197 6 11779941 C6orf105 no
cg05767404 1 247712591 C1orf150 yes
cg02635407 4 8200549 SH3TC1 no
cg05252264 19 55385587 FCAR no
cg20713492 1 154293482 AQP10 no
cg09624565 22 37256900 NCF4 no
cg10275770 17 62084205 ICAM2 no
cg27187881 22 42466345 NAGA no
cg12836863 13 32889023 BRCA2 yes
cg21432842 17 38171697 CSF3 no
cg04451770 10 97515372 ENTPD1 no
cg04113075 6 146865487 RAB32 no
cg03760759 1 156549533 TTC24 no
cg25923056 19 41306455 EGLN2 yes
cg02828993 3 42775696 CCDC13 no
cg19008649 2 217560292 IGFBP5 no
cg17749456 NA NA NA no
cg06317209 12 58210878 AVIL no
cg11024597 NA NA NA no
cg06022671 11 59439293 no
cg15512851 6 36973518 FGD2 no
cg23090046 14 104094619 KLC1 no
cg04790874 19 42381950 CD79A no
cg05949660 6 109777642 MICAL1 no
cg26861460 22 44575455 PARVG no
cg23710823 14 20020657 P704P no
cg10384245 18 909086 ADCYAP1 no
cg11919271 3 151102879 MED12L no
cg11298343 19 41306150 EGLN2 yes
cg09001777 19 5851504 FUT3 no
cg02656594 16 27412496 IL21R no
cg24777950 14 25046121 CTSG no
cg19399532 1 178512495 C1orf220 no
cg06625767 5 176836695 F12 no
cg15361231 1 193075191 GLRX2 no
cg12554857 4 95264019 HPGDS no
cg17823175 19 828170 AZU1 no
cg09305224 9 139927245 C9orf139 yes
cg21275690 16 3072970 HCFC1R1 no
cg05769349 12 114847043 TBX5 no
cg26215727 12 6485537 SCNN1A no
cg10585486 19 41304133 EGLN2 no
cg02676865 10 99259738 MMS19 no
cg26105232 10 6105656 IL2RA no
cg07239938 19 852813 ELANE no
cg04182865 5 141346431 RNF14 no
cg13791183 19 41316697 CYP2A6-
AK097370 no
cg04121771 3 149191624 TM4SF4 no
cg27347104 12 6233657 VWF no
cg16745604 2 202047459 CASP10 no
cg12089698 8 145086882 SPATC1 no
cg22670733 15 78914284 CHRNA3 no
cg01813965 16 57729104 CCDC135 no
cg16463460 11 32454718 WT1 yes
cg11822932 11 33913716 LMO2 no
cg26928972 3 122043799 CSTA no
cg06172871 16 72088244 HP no
cg17142183 2 102608192 IL1R2 no
cg18084554 19 929046 ARID3A no
cg13703437 5 39219698 FYB no
cg24474182 3 151047307 MED12L no
cg07730301 11 67777952 ALDH3B1 no
cg17078393 1 32717002 LCK no
cg26060255 20 3025968 MRPS26 yes
cg15096140 2 192109731 MYO1B no
cg20938359 12 322250 SLC6A12 no
cg10465696 11 124767948 ROBO4 no
cg21842274 5 76248637 CRHBP no
cg25587233 9 131872005 CRAT no
cg02593766 17 48608677 MYCBPAP no
cg08044694 19 15391927 BRD4 no
cg24354652 1 28502908 PTAFR no
cg14210862 9 91193195 no
cg14511156 19 54604124 OSCAR no
cg22854223 11 44586505 CD82 no
cg14289461 6 112575929 LAMA4 no
cg00134539 21 43824071 UBASH3A no
cg20720686 7 75582881 POR no
cg22566906 12 52399713 GRASP no
cg24921089 11 10472840 AMPD3 no
cg17356733 21 34774627 IFNGR2 no
cg00974864 1 161601053 FCGR3B no
cg08700306 19 33686390 LRP3 yes
cg06147863 11 47400113 SPI1 no
cg08525145 1 155911361 RXFP4 no
cg25832796 14 24038103 JPH4 no
cg15880738 11 118215112 CD3G no
cg25634666 11 71846788 FOLR3 no
cg23889010 20 43882990 SLPI no
cg14654385 11 63973006 FERMT3 no
cg16158874 19 46095562 GPR4 no
cg05681757 12 32655034 FGD4 no
cg03559389 10 679322 DIP2C no
        nal associations with FEV1, FEV1/FVC and FVC, at time point 2, base covariate adjustment (Mb               
associated trait reported PMID Preported for FEV1
Preported for 
FEV1/FVC beta (SE)
FEV1, FVC, FEF25-75 30343628;30390659 NA NA 0.69 (-0.09)
lung function 30390659 NA NA 1.05 (-0.16)
lung function 30390659 NA NA 0.77 (-0.12)
FEF25-75 30343628;30390659 NA NA 1.11 (-0.15)
lung function 30390659 NA NA 1.31 (-0.23)
lung function 30390659 NA NA 0.48 (-0.12)
FEV1 30343628;30390659 9.57E-09 NA 1.44 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 9.06X10-26 0.88 (-0.84)
FEF25-75 30343628;30390659 NA NA 0.78 (-0.18)
COPD, FEV1, FEV1pFVC 22161163 NA 3.01X10-24 1.7 (-0.68)
COPD, FEV1, FEV1pFVC 22161163 NA 9.32X10-28 0.39 (-0.47)
FEV1, FVC, FEF25-75 30343628;30390659 1.43E-12 NA 0.78 (-0.17)
COPD, FEV1, FEV1pFVC 22161163 NA 1.25X10-24 0.51 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 3.05X10-24 0.59 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 5.68X10-13 -0.53 (-0.28)
COPD, FEV1, FEV1pFVC 22161163 NA 3.78X10-15 -0.88 (-0.63)
COPD, FEV1, FEV1pFVC 22161163 NA 1.42X10-30 0.72 (-0.5)
COPD, FEV1, FEV1pFVC 22161163 NA 1.40X10-12 -0.42 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 9.95X10-28 0.32 (-0.57)
COPD, FEV1, FEV1pFVC 22161163 NA 3.55X10-29 1.22 (-0.48)
FEV1pFVC 28621160 9.80E-06 NA 1.13 (-0.88)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-16 -0.67 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 1.22X10-27 0.58 (-0.26)
COPD, FEV1, FEV1pFVC 22161163 NA 2.44X10-30 -1.02 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 2.32X10-17 0.97 (-0.54)
COPD, FEV1, FEV1pFVC 22161163 NA 1.79X10-26 0.43 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 4.50X10-19 -0.14 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 1.40X10-29 0.83 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 4.59X10-28 0.82 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 5.62X10-27 0.54 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 6.57X10-24 1.28 (-0.33)
COPD, FEV1, FEV1pFVC 22161163 NA 1.12X10-17 0.37 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 2.36X10-22 0.42 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 2.70X10-29 0.66 (-0.56)
COPD, FEV1, FEV1pFVC 22161163 NA 4.77X10-30 0.23 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 3.16X10-15 2.74 (-0.74)
COPD, FEV1, FEV1pFVC 22161163 NA 4.32X10-14 0.63 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 2.67X10-22 0.25 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 8.82X10-15 1.26 (-0.5)
COPD, FEV1, FEV1pFVC 22161163 NA 5.24X10-30 0.14 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 2.47X10-21 1.08 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 2.22X10-21 1.16 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 6.74X10-26 -0.41 (-0.72)
FEV1 at time point 2   
COPD, FEV1, FEV1pFVC 22161163 NA 1.30X10-29 0.98 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 7.85X10-24 -0.37 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.42X10-21 0.87 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.84X10-27 -0.03 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 9.71X10-30 0.1 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 9.12X10-21 0.82 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 2.30X10-30 1.49 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 9.31X10-27 0.65 (-0.33)
COPD, FEV1, FEV1pFVC 22161163 NA 8.04X10-31 -0.06 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 1.02X10-12 0.43 (-0.29)
COPD, FEV1, FEV1pFVC 22161163 NA 2.41X10-31 0.98 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 3.54X10-30 1.14 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.16X10-12 1.27 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 8.59X10-23 -0.14 (-0.7)
COPD, FEV1, FEV1pFVC 22161163 NA 5.57X10-17 -0.77 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 3.17X10-25 0.22 (-0.39)
lung function 30390659 NA NA -0.32 (-0.2)
COPD, FEV1, FEV1pFVC 22161163 NA 5.63X10-24 0.44 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.65X10-29 0.52 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-13 0.55 (-0.33)
COPD, FEV1, FEV1pFVC 22161163 NA 4.28X10-15 0.71 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 9.07X10-34 0.08 (-0.5)
COPD, FEV1, FEV1pFVC 22161163 NA 1.97X10-23 0.11 (-0.58)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-16 -0.92 (-0.5)
COPD, FEV1, FEV1pFVC 22161163 NA 2.49X10-35 0.01 (-0.63)
COPD, FEV1, FEV1pFVC 22161163 NA 2.04X10-24 0.85 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 7.67X10-24 -0.39 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 4.02X10-29 1 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 6.58X10-25 1.35 (-0.61)
COPD, FEV1, FEV1pFVC 22161163 NA 1.68X10-23 0.29 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 5.56X10-27 0.03 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 2.08X10-30 0.43 (-0.56)
FEV1pFVC 28621160 5.10E-06 NA 0 (-1.09)
COPD, FEV1, FEV1pFVC 22161163 NA 5.11X10-18 0.39 (-0.72)
COPD, FEV1, FEV1pFVC 22161163 NA 2.21X10-25 0.87 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 2.65X10-22 -0.4 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.67X10-25 0.87 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 1.12X10-24 0.06 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 1.06X10-28 0.42 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 8.28X10-21 -0.29 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 1.98X10-28 0.39 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 3.19X10-22 -0.3 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 7.33X10-24 1.08 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 3.66X10-23 0.44 (-0.21)
COPD, FEV1, FEV1pFVC 22161163 NA 6.27X10-30 1.1 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 4.58X10-23 0.54 (-0.29)
COPD, FEV1, FEV1pFVC 22161163 NA 8.54X10-27 0.56 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 8.41X10-13 0.23 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 7.12X10-26 -0.24 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 2.30X10-24 1.05 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 4.09X10-30 0.77 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 3.21X10-32 0.63 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 9.24X10-15 0.49 (-0.29)
COPD, FEV1, FEV1pFVC 22161163 NA 2.95X10-23 0.46 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 2.90X10-25 0.09 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 5.11X10-16 -0.7 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 1.19X10-11 -0.22 (-0.65)
COPD, FEV1, FEV1pFVC 22161163 NA 7.82X10-17 -1.03 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 1.84X10-13 0.28 (-0.21)
COPD, FEV1, FEV1pFVC 22161163 NA 1.05X10-19 0.2 (-0.2)
COPD, FEV1, FEV1pFVC 22161163 NA 2.45X10-20 0.22 (-0.5)
COPD, FEV1, FEV1pFVC 22161163 NA 6.05X10-26 0.34 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 1.39X10-20 -0.12 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 6.03X10-29 -0.15 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 7.38X10-18 1.07 (-1.21)
COPD, FEV1, FEV1pFVC 22161163 NA 6.80X10-10 0.07 (-0.25)
COPD, FEV1, FEV1pFVC 22161163 NA 3.64X10-21 0.85 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 6.66X10-17 0.16 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 7.20X10-26 0.5 (-0.3)
COPD, FEV1, FEV1pFVC 22161163 NA 4.46X10-24 -1.15 (-0.79)
COPD, FEV1, FEV1pFVC 22161163 NA 1.07X10-22 -0.32 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 2.13X10-18 -0.35 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-16 -0.56 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 4.57X10-24 0.23 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 2.41X10-18 -0.13 (-0.41)
FVC 28621160 8.90E-06 NA -0.09 (-0.6)
COPD, FEV1, FEV1pFVC 22161163 NA 4.75X10-16 0.88 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 2.16X10-16 0.57 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 6.81X10-26 0.01 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 1.99X10-23 0.18 (-0.21)
COPD, FEV1, FEV1pFVC 22161163 NA 2.99X10-15 0.34 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.37X10-31 -0.7 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 1.50X10-11 0.22 (-0.3)
COPD, FEV1, FEV1pFVC 22161163 NA 1.07X10-19 0.09 (-0.25)
COPD, FEV1, FEV1pFVC 22161163 NA 2.31X10-21 0.28 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 5.60X10-30 0.56 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.11X10-11 0.34 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 2.05X10-24 -0.1 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 2.34X10-22 -0.98 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 3.11X10-15 -0.1 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 2.67X10-25 -0.02 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 1.83X10-12 -0.22 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 7.41X10-24 -0.55 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.02X10-23 -0.59 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 2.14X10-10 0.63 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.44X10-29 0.59 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 6.59X10-27 0.5 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 7.72X10-27 -0.16 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 4.20X10-13 0.1 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 4.25X10-15 -0.03 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.24X10-33 0.46 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.18X10-24 0.45 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 1.44X10-33 -0.36 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 6.03X10-20 -0.49 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 2.01X10-34 0.72 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 7.63X10-23 0.5 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 6.57X10-19 0.41 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 2.14X10-26 0.52 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 2.32X10-22 -0.11 (-0.26)
COPD, FEV1, FEV1pFVC 22161163 NA 3.11X10-20 0.12 (-0.3)
COPD, FEV1, FEV1pFVC 22161163 NA 1.25X10-26 0.06 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 1.76X10-19 -0.1 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 1.94X10-17 1.03 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 6.09X10-22 0.19 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 4.75X10-09 -0.13 (-0.57)
COPD, FEV1, FEV1pFVC 22161163 NA 2.59X10-21 0.88 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 2.37X10-25 -0.06 (-0.47)
FEV1 28621160 8.70E-06 NA 1.11 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 6.36X10-20 0.46 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 3.72X10-25 0.21 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.02X10-23 0.4 (-0.21)
COPD, FEV1, FEV1pFVC 22161163 NA 4.95X10-22 0.59 (-0.61)
COPD, FEV1, FEV1pFVC 22161163 NA 1.35X10-28 0.53 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 3.64X10-23 -0.21 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 2.20X10-17 0.3 (-0.16)
COPD, FEV1, FEV1pFVC 22161163 NA 4.98X10-12 1.06 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.68X10-14 0.26 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 4.12X10-14 -1.04 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 6.50X10-23 -0.82 (-0.68)
COPD, FEV1, FEV1pFVC 22161163 NA 8.51X10-32 0.11 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 1.08X10-24 0.16 (-0.24)
COPD, FEV1, FEV1pFVC 22161163 NA 2.57X10-27 -0.07 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.99X10-14 0.05 (-0.46)
COPD 26425700 0.00384 -0.43 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 5.62X10-24 0.01 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 5.55X10-25 0.09 (-0.3)
COPD, FEV1, FEV1pFVC 22161163 NA 2.80X10-27 0.14 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 1.58X10-23 -0.33 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 6.01X10-15 -0.03 (-0.48)
FEV1 28621160 9.60E-06 NA -1.91 (-1.33)
COPD, FEV1, FEV1pFVC 22161163 NA 1.03X10-14 0.14 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-13 -0.57 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 2.84X10-19 0.45 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 4.97X10-20 0.79 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 5.58X10-23 -0.72 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.30X10-21 -0.12 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 6.10X10-30 -0.11 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 4.86X10-28 -0.55 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 2.10X10-22 -0.28 (-0.38)
NA 29092026 NA NA -0.09 (-0.08)
FEV1pFVC 28621160 7.30E-06 NA 0.25 (-1.04)
COPD, FEV1, FEV1pFVC 22161163 NA 7.10X10-31 -0.34 (-0.47)
NO2 exposure 29410382 NA NA 0.6 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 4.03X10-14 0.12 (-0.28)
COPD, FEV1, FEV1pFVC 22161163 NA 4.48X10-18 -0.31 (-0.71)
COPD, FEV1, FEV1pFVC 22161163 NA 4.20X10-25 -0.18 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 1.85X10-18 -0.85 (-0.47)
FVC 28621160 7.10E-06 NA 0.2 (-0.2)
COPD, FEV1, FEV1pFVC 22161163 NA 8.99X10-21 0.09 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 2.13X10-23 0.67 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 5.70X10-22 -0.05 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 2.33X10-20 0.66 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 2.78X10-29 -0.14 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 2.66X10-23 -0.03 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 2.29X10-15 0.15 (-0.26)
COPD, FEV1, FEV1pFVC 22161163 NA 3.76X10-13 0.81 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 7.71X10-29 -0.33 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.51X10-37 0.97 (-0.54)
COPD, FEV1, FEV1pFVC 22161163 NA 2.42X10-32 -0.27 (-0.47)
NA 29092026 NA NA -1 (-1.34)
COPD, FEV1, FEV1pFVC 22161163 NA 6.94X10-22 -0.45 (-0.64)
COPD, FEV1, FEV1pFVC 22161163 NA 5.69X10-21 -0.05 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 9.83X10-19 -0.37 (-0.67)
COPD, FEV1, FEV1pFVC 22161163 NA 1.91X10-22 0.35 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 9.95X10-28 -0.07 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 1.07X10-29 -0.39 (-0.49)
FEV1pFVC 28621160 3.40E-06 NA -0.17 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 2.36X10-23 -0.36 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 9.50X10-07 0.29 (-0.23)
COPD, FEV1, FEV1pFVC 22161163 NA 5.29X10-32 -0.23 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 1.97X10-22 0.28 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 6.45X10-25 -0.04 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 4.88X10-20 -1.31 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 5.84X10-15 0.59 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 4.00X10-18 -0.04 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 1.38X10-22 -0.76 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 6.24X10-20 0.02 (-0.32)
COPD, FEV1, FEV1pFVC 22161163 NA 2.46X10-19 0.37 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 1.51X10-29 0.02 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 1.08X10-13 -0.43 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 8.23X10-15 0.14 (-0.18)
COPD, FEV1, FEV1pFVC 22161163 NA 1.03X10-06 0.64 (-0.32)
FEV1pFVC 28621160 7.70E-06 NA -0.23 (-0.84)
COPD, FEV1, FEV1pFVC 22161163 NA 3.70X10-25 0.13 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 3.23X10-24 -0.26 (-0.52)
FEV1 28621160 7.70E-06 NA -0.42 (-0.71)
COPD, FEV1, FEV1pFVC 22161163 NA 4.67X10-26 0.01 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 4.87X10-19 -0.14 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 8.09X10-16 -0.43 (-0.58)
COPD, FEV1, FEV1pFVC 22161163 NA 6.51X10-25 0.48 (-0.45)
COPD, FEV1, FEV1pFVC 22161163 NA 6.44X10-27 -0.55 (-0.51)
COPD, FEV1, FEV1pFVC 22161163 NA 4.91X10-22 0.26 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 1.39X10-11 0.17 (-0.19)
COPD, FEV1, FEV1pFVC 22161163 NA 7.38X10-18 -0.13 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 3.95X10-17 -0.73 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 7.13X10-23 -0.27 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 3.32X10-27 0.15 (-0.69)
COPD, FEV1, FEV1pFVC 22161163 NA 3.52X10-19 0.45 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 7.69X10-23 -0.01 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 1.26X10-23 -0.44 (-0.33)
FEV1 25633388 4.20E-06 NA 0.21 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 2.89X10-34 0.19 (-0.51)
COPD, FEV1, FEV1pFVC 22161163 NA 7.70X10-25 -0.23 (-0.3)
COPD, FEV1, FEV1pFVC 22161163 NA 5.30X10-27 -0.61 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 1.12X10-26 0.86 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 5.52X10-11 0.35 (-0.23)
COPD, FEV1, FEV1pFVC 22161163 NA 4.34X10-28 0.58 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 1.57X10-19 0 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 6.43X10-16 -0.25 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.83X10-26 -0.02 (-0.63)
COPD, FEV1, FEV1pFVC 22161163 NA 4.84X10-30 -0.05 (-0.62)
COPD, FEV1, FEV1pFVC 22161163 NA 1.83X10-25 -0.04 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 1.44X10-13 0.12 (-0.23)
COPD, FEV1, FEV1pFVC 22161163 NA 1.91X10-27 -0.04 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 2.90X10-15 0.37 (-0.66)
COPD, FEV1, FEV1pFVC 22161163 NA 2.14X10-06 0.54 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 7.67X10-19 0.05 (-0.48)
FEV1 28621160 8.40E-06 NA 0.88 (-0.6)
COPD, FEV1, FEV1pFVC 22161163 NA 2.37X10-08 0.01 (-0.54)
COPD, FEV1, FEV1pFVC 22161163 NA 4.26X10-17 0.22 (-0.28)
COPD, FEV1, FEV1pFVC 22161163 NA 1.57X10-19 -0.87 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 4.23X10-23 0.67 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 7.66X10-31 0.13 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.22X10-18 -0.43 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 7.21X10-15 0.74 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 4.61X10-24 0.05 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 2.76X10-29 -0.48 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 7.87X10-09 0.52 (-0.63)
COPD, FEV1, FEV1pFVC 22161163 NA 1.08X10-20 0.17 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 1.49X10-23 -0.4 (-0.51)
COPD, FEV1, FEV1pFVC 22161163 NA 2.72X10-15 -0.63 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 5.41X10-14 -0.05 (-0.12)
COPD, FEV1, FEV1pFVC 22161163 NA 1.06X10-27 0.52 (-0.65)
COPD, FEV1, FEV1pFVC 22161163 NA 1.95X10-20 0.3 (-0.33)
COPD, FEV1, FEV1pFVC 22161163 NA 6.99X10-25 -0.37 (-0.57)
COPD, FEV1, FEV1pFVC 22161163 NA 9.51X10-25 0.16 (-0.67)
COPD, FEV1, FEV1pFVC 22161163 NA 1.63X10-28 -0.01 (-0.54)
COPD, FEV1, FEV1pFVC 22161163 NA 7.31X10-31 1.34 (-0.67)
COPD, FEV1, FEV1pFVC 22161163 NA 7.86X10-28 -0.22 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.37X10-17 0.43 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 7.21X10-27 -0.02 (-0.65)
COPD, FEV1, FEV1pFVC 22161163 NA 3.31X10-15 0.17 (-0.52)
FEV1pFVC 28621160 8.20E-06 NA -0.28 (-0.54)
NA 29092026 NA NA 0.1 (-0.37)
FEV1pFVC 28621160 8.20E-06 NA 0.63 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 9.34X10-18 0.45 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 5.77X10-25 0.1 (-0.7)
COPD, FEV1, FEV1pFVC 22161163 NA 1.82X10-26 -0.28 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 4.65X10-23 -0.13 (-0.64)
FEV1pFVC 28621160 3.70E-06 NA -0.33 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 3.94X10-26 -0.63 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 5.37X10-26 0.38 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 2.93X10-23 0.68 (-0.67)
COPD, FEV1, FEV1pFVC 22161163 NA 1.98X10-08 0.24 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 3.99X10-27 -0.42 (-0.41)
FEV1 25633388 6.20E-06 NA 0.17 (-1.09)
COPD 26425700 0.0493 0.41 (-0.43)
COPD, FEV1, FEV1pFVC 22161163 NA 1.53X10-15 -0.05 (-0.22)
NA 29092026 NA NA 0.03 (-0.33)
COPD, FEV1, FEV1pFVC 22161163 NA 1.32X10-28 0.66 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 2.78X10-27 -0.11 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.49X10-30 -0.05 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 7.03X10-23 -0.19 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 9.23X10-27 -0.24 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.07X10-24 0.15 (-0.28)
COPD, FEV1, FEV1pFVC 22161163 NA 5.40X10-18 -0.21 (-0.51)
COPD, FEV1, FEV1pFVC 22161163 NA 3.60X10-24 -0.18 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 1.44X10-26 0.12 (-0.7)
COPD, FEV1, FEV1pFVC 22161163 NA 1.52X10-19 -0.67 (-0.61)
COPD 26425700 0.0377 -0.26 (-0.62)
COPD, FEV1, FEV1pFVC 22161163 NA 1.27X10-29 0.11 (-0.41)
NA 29092026 NA NA 0.27 (-0.47)
COPD, FEV1, FEV1pFVC 22161163 NA 1.76X10-10 -0.13 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 3.23X10-19 0.16 (-0.31)
COPD, FEV1, FEV1pFVC 22161163 NA 2.93X10-23 0.28 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 5.04X10-18 -0.34 (-0.27)
NA 29092026 NA NA 0.06 (0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 1.11X10-19 0.27 (0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 3.64X10-24 0.27 (-0.27)
COPD, FEV1, FEV1pFVC 22161163 NA 2.87X10-17 0.15 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 3.63X10-28 0.06 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 4.51X10-20 -0.75 (-0.59)
COPD, FEV1, FEV1pFVC 22161163 NA 5.12X10-25 0.4 (-0.43)
FEV1,FVC 22532803 5.00E-07 -0.7 (-0.49)
COPD, FEV1, FEV1pFVC 22161163 NA 2.28X10-26 -0.32 (-0.26)
COPD, FEV1, FEV1pFVC 22161163 NA 5.20X10-28 0.27 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 4.61X10-29 -0.12 (-0.25)
COPD, FEV1, FEV1pFVC 22161163 NA 1.10X10-18 -0.05 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 6.91X10-30 -0.31 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 1.45X10-26 -0.22 (-0.6)
COPD, FEV1, FEV1pFVC 22161163 NA 7.74X10-31 -0.41 (-0.4)
COPD, FEV1, FEV1pFVC 22161163 NA 1.22X10-28 0.21 (-0.23)
COPD, FEV1, FEV1pFVC 22161163 NA 1.93X10-28 -0.14 (-0.56)
COPD, FEV1, FEV1pFVC 22161163 NA 4.21X10-14 -0.14 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 4.60X10-13 -0.15 (-0.38)
COPD, FEV1, FEV1pFVC 22161163 NA 5.76X10-15 0.85 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 1.17X10-19 -0.19 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 1.06X10-25 -0.11 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 6.80X10-23 -0.1 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 3.76X10-15 -0.12 (-0.55)
COPD, FEV1, FEV1pFVC 22161163 NA 2.83X10-28 -0.93 (-0.36)
COPD, FEV1, FEV1pFVC 22161163 NA 1.95X10-18 -0.13 (-0.5)
FEV1pFVC 28621160 7.80E-06 NA -0.1 (-0.42)
COPD, FEV1, FEV1pFVC 22161163 NA 2.83X10-24 -0.19 (-1.08)
COPD, FEV1, FEV1pFVC 22161163 NA 2.59X10-25 0.29 (-0.44)
COPD, FEV1, FEV1pFVC 22161163 NA 5.42X10-20 0.36 (-0.57)
COPD, FEV1, FEV1pFVC 22161163 NA 6.92X10-09 -0.2 (-0.23)
COPD, FEV1, FEV1pFVC 22161163 NA 5.49X10-21 0.06 (-0.2)
COPD, FEV1, FEV1pFVC 22161163 NA 1.90X10-25 0.03 (-0.39)
COPD, FEV1, FEV1pFVC 22161163 NA 4.76X10-11 0.21 (-0.51)
COPD, FEV1, FEV1pFVC 22161163 NA 6.21X10-29 0.8 (-0.53)
COPD, FEV1, FEV1pFVC 22161163 NA 1.71X10-27 -0.07 (-0.34)
COPD, FEV1, FEV1pFVC 22161163 NA 1.12X10-32 -0.47 (-0.41)
COPD, FEV1, FEV1pFVC 22161163 NA 1.42X10-13 0.62 (-0.48)
COPD, FEV1, FEV1pFVC 22161163 NA 1.05X10-18 0.25 (-0.56)
COPD, FEV1, FEV1pFVC 22161163 NA 1.15X10-31 -0.3 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 2.00X10-24 0.11 (-0.58)
COPD, FEV1, FEV1pFVC 22161163 NA 5.42X10-31 -0.47 (-0.37)
COPD, FEV1, FEV1pFVC 22161163 NA 6.40X10-24 -0.33 (-0.52)
COPD, FEV1, FEV1pFVC 22161163 NA 4.59X10-30 -0.27 (-0.35)
COPD, FEV1, FEV1pFVC 22161163 NA 3.97X10-06 -0.11 (-0.46)
COPD, FEV1, FEV1pFVC 22161163 NA 8.82X10-17 -0.35 (-0.47)
FEV1pFVC 28621160 8.10E-08 NA -0.04 (-0.34)





















9.3E-14 +++ 0.513 0.13 (-0.01) 4.0E-21 +++ 0.332
5.8E-11 +++ 0.523 0.2 (-0.02) 8.1E-18 +++ 0.200
1.8E-11 +++ 0.466 0.14 (-0.02) 3.5E-17 +++ 0.578
5.4E-13 +++ 0.632 0.18 (-0.02) 1.5E-15 +++ 0.063
2.0E-08 +++ 0.889 0.25 (-0.03) 6.4E-14 +++ 0.027
4.8E-05 +++ 0.705 0.08 (-0.02) 9.2E-07 +++ 0.706
1.7E-05 +++ 0.869 0.21 (-0.05) 1.5E-05 +++ 0.315
0.2941 ++- 0.084 0.52 (-0.12) 1.53E-05 +++ 0.494
1.7E-05 ??+ 1.000 0.11 (-0.03) 6.8E-05 ??+ 1.000
0.0131 +++ 0.933 0.39 (-0.1) 8.65E-05 +++ 0.493
0.4138 +-+ 0.710 0.25 (-0.07) 2.33E-04 +++ 0.210
4.9E-06 ??+ 1.000 0.09 (-0.03) 3.6E-04 ??+ 1.000
0.2310 +-+ 0.084 0.21 (-0.06) 7.29E-04 +++ 0.279
0.1650 +++ 0.759 0.21 (-0.06) 8.41E-04 +++ 0.906
0.0607 --- 0.261 -0.14 (-0.04) 0.0010 --- 0.628
0.1599 ??- 1.000 -0.3 (-0.1) 0.0016 ??- 1.000
0.1493 +-+ 0.181 0.22 (-0.07) 0.0029 +++ 0.889
0.2419 +-- 0.358 -0.15 (-0.05) 0.0046 -+- 0.068
0.5756 --+ 0.337 0.22 (-0.08) 0.0061 +++ 0.771
0.0112 +++ 0.262 0.19 (-0.07) 0.0062 +++ 0.135
0.1964 +++ 0.720 0.33 (-0.12) 0.0062 +++ 0.225
0.0394 +-- 0.300 -0.13 (-0.05) 0.0063 --- 0.778
0.0253 +-+ 0.383 0.1 (-0.04) 0.0086 +++ 0.461
0.0090 --- 0.488 -0.14 (-0.06) 0.0116 --- 0.302
0.0746 +-+ 0.203 0.2 (-0.08) 0.0116 +++ 0.970
0.2511 +-+ 0.147 0.13 (-0.05) 0.0148 +++ 0.236
0.7309 +-+ 0.137 0.15 (-0.06) 0.0152 +++ 0.330
0.0660 +++ 0.624 0.16 (-0.07) 0.0159 +++ 0.514
0.1174 +-+ 0.042 0.18 (-0.08) 0.0180 +++ 0.105
0.2016 +++ 0.701 0.15 (-0.06) 0.0184 +++ 0.880
1.10E-04 +++ 0.134 0.11 (-0.05) 0.0188 +++ 0.813
0.3206 --+ 0.298 0.12 (-0.05) 0.0208 +++ 0.623
0.1774 +++ 0.825 0.1 (-0.05) 0.0222 +++ 0.810
0.2321 +++ 0.655 0.18 (-0.08) 0.0225 +++ 0.466
0.6919 +-+ 0.606 0.2 (-0.09) 0.0225 +++ 0.503
2.30E-04 +++ 0.247 0.24 (-0.11) 0.0232 +++ 0.674
0.1264 --+ 0.200 0.14 (-0.06) 0.0237 +++ 0.948
0.5857 +-- 0.202 0.15 (-0.07) 0.0261 +++ 0.206
0.0122 +++ 0.435 0.16 (-0.07) 0.0311 +++ 0.085
0.7272 +-+ 0.396 0.13 (-0.06) 0.0313 +++ 0.525
0.0020 +++ 0.609 0.11 (-0.05) 0.0319 +++ 0.210
0.0036 +++ 0.063 0.12 (-0.06) 0.0329 +++ 0.432
0.5686 +-+ 0.031 0.22 (-0.1) 0.0339 +-+ 0.085
     (ECRHS/ NFBC/ SAPALDIA) FEV1/FVC at time point 2 (ECRHS/ NFBC/ SAPALDIA)
0.0967 +-+ 0.063 0.18 (-0.09) 0.0349 +++ 0.422
0.3502 --+ 0.362 0.12 (-0.06) 0.0364 +-+ 0.354
0.0625 +++ 0.425 0.14 (-0.07) 0.0365 +-+ 0.101
0.9450 --+ 0.171 0.13 (-0.06) 0.0381 +++ 0.290
0.7602 --+ 0.383 0.1 (-0.05) 0.0399 -++ 0.244
0.0542 +++ 0.580 0.13 (-0.06) 0.0400 +++ 0.596
0.0016 +++ 0.051 0.14 (-0.07) 0.0408 ++- 0.017
0.0472 +++ 0.485 0.1 (-0.05) 0.0422 +++ 0.664
0.8964 ++- 0.180 -0.14 (-0.07) 0.0433 -+- 0.237
0.1357 +++ 0.911 0.09 (-0.04) 0.0442 +++ 0.628
0.0744 +++ 0.227 0.16 (-0.08) 0.0444 +++ 0.616
0.0041 +++ 0.660 0.12 (-0.06) 0.0478 -++ 0.033
4.86E-04 +++ 0.158 0.1 (-0.05) 0.0527 +-+ 0.021
0.8445 +-- 0.833 0.2 (-0.1) 0.0529 ++- 0.279
0.1430 +-- 0.352 -0.15 (-0.08) 0.0532 +-- 0.299
0.5764 +++ 0.972 0.11 (-0.06) 0.0534 +++ 0.827
0.1205 --- 0.97 -0.06 (-0.03) 5.5E-02 --- 0.994
0.2173 +++ 0.876 0.1 (-0.05) 0.0550 ++- 0.039
0.2233 +-+ 0.317 0.12 (-0.06) 0.0550 +++ 0.851
0.0948 --+ 0.097 0.09 (-0.05) 0.0555 +++ 0.464
0.0224 +-+ 0.060 0.09 (-0.05) 0.0576 ++- 0.019
0.8706 --+ 0.274 0.14 (-0.07) 0.0576 +++ 0.665
0.8493 --+ 0.750 0.16 (-0.08) 0.0592 +++ 0.380
0.0640 +-- 0.076 -0.14 (-0.07) 0.0612 --- 0.700
0.9913 ++- 0.680 0.17 (-0.09) 0.0632 ++- 0.090
0.0351 +++ 0.855 0.11 (-0.06) 0.0668 +++ 0.743
0.3594 -+- 0.637 -0.11 (-0.06) 0.0677 --- 0.734
0.0133 +++ 0.695 0.11 (-0.06) 0.0743 +++ 0.667
0.0268 ??+ 1.000 0.17 (-0.09) 0.0769 ??+ 1.000
0.3649 --+ 0.021 0.08 (-0.05) 0.0801 +-+ 0.590
0.9167 +?- 0.885 -0.08 (-0.04) 0.0808 -?- 0.445
0.4460 +-+ 0.094 0.14 (-0.08) 0.0809 ++- 0.152
0.9966 -+- 0.798 -0.26 (-0.15) 0.0815 --+ 0.564
0.5866 +-+ 0.632 0.18 (-0.1) 0.0827 +++ 0.863
0.0523 -++ 0.015 0.11 (-0.06) 0.0875 +++ 0.696
0.4019 --- 0.899 -0.12 (-0.07) 0.0888 --- 0.795
0.0042 +-+ 0.026 0.08 (-0.04) 0.0907 +++ 0.645
0.8967 -+- 0.333 0.12 (-0.07) 0.0928 +++ 0.270
0.4440 +-+ 0.655 0.13 (-0.08) 0.0989 +++ 0.698
0.4072 --+ 0.224 -0.09 (-0.05) 0.0998 --- 0.735
0.3938 +-+ 0.311 0.11 (-0.07) 0.1044 ++- 0.205
0.4205 +-- 0.203 -0.09 (-0.05) 0.1046 -+- 0.072
0.0678 ??+ 1.000 0.15 (-0.09) 0.1063 ??+ 1.000
0.0372 +++ 0.858 0.05 (-0.03) 0.1064 +++ 0.908
0.0613 +++ 0.542 0.13 (-0.08) 0.1131 -++ 0.134
0.0608 +-+ 0.125 0.07 (-0.04) 0.1200 +++ 0.557
0.1384 +-+ 0.386 0.08 (-0.05) 0.1205 +-+ 0.298
0.6099 ++- 0.299 -0.1 (-0.07) 0.1392 -+- 0.071
0.5914 --- 0.867 0.1 (-0.07) 0.1437 +++ 0.723
0.0037 ??+ 1.000 0.08 (-0.06) 0.1446 ??+ 1.000
0.1146 +++ 0.865 0.1 (-0.07) 0.1454 +++ 0.908
0.2382 +++ 0.528 0.11 (-0.08) 0.1466 +++ 0.890
0.0954 +++ 0.813 0.06 (-0.04) 0.1467 +-+ 0.699
0.2337 +++ 0.314 -0.08 (-0.06) 0.1473 --- 0.745
0.8190 +-+ 0.361 0.08 (-0.05) 0.1489 +++ 0.762
0.1020 +-- 0.360 -0.09 (-0.06) 0.1499 ++- 0.037
0.7316 -++ 0.437 -0.13 (-0.09) 0.1513 -+- 0.115
0.0026 --- 0.552 -0.07 (-0.05) 0.1529 --- 0.617
0.1804 ?-+ 0.212 0.04 (-0.03) 0.1532 ?-+ 0.152
0.3249 +++ 0.478 0.04 (-0.03) 0.1536 +++ 0.186
0.6644 +-+ 0.115 0.1 (-0.07) 0.1543 +++ 0.961
0.4858 ++- 0.645 0.1 (-0.07) 0.1550 ++- 0.383
0.6451 +-- 0.641 0.06 (-0.04) 0.1563 +++ 0.984
0.7583 +-+ 0.412 0.1 (-0.07) 0.1580 +++ 0.801
0.3769 --+ 0.320 0.24 (-0.17) 0.1582 -++ 0.055
0.7887 ++- 0.694 0.05 (-0.04) 0.1589 +++ 0.397
0.0020 +++ 0.346 0.06 (-0.04) 0.1602 +++ 0.298
0.7353 ++- 0.134 -0.1 (-0.07) 0.1635 +-- 0.261
0.1004 +++ 0.792 0.06 (-0.04) 0.1674 +++ 0.887
0.1456 ??- 1.000 -0.17 (-0.12) 0.1719 ??- 1.000
0.3682 --+ 0.649 -0.07 (-0.05) 0.1745 --- 0.636
0.5014 +-- 0.087 -0.1 (-0.08) 0.1761 +-- 0.134
0.2797 -+- 0.381 -0.1 (-0.08) 0.1788 -+- 0.256
0.6314 +-+ 0.492 0.09 (-0.07) 0.1792 +++ 0.686
0.7548 +-- 0.426 -0.08 (-0.06) 0.1798 --- 0.872
0.8866 -++ 0.196 0.11 (-0.08) 0.1809 +++ 0.738
0.0141 +++ 0.517 0.07 (-0.05) 0.1823 ++- 0.115
0.0940 +++ 0.753 0.07 (-0.05) 0.1825 +-+ 0.646
0.9876 -+- 0.790 0.09 (-0.07) 0.1829 +++ 0.436
0.3744 -++ 0.638 0.04 (-0.03) 0.1847 +++ 0.692
0.3704 ++- 0.401 -0.07 (-0.05) 0.1855 -+- 0.223
0.0418 --- 0.885 -0.07 (-0.05) 0.1863 +-- 0.492
0.4651 ++- 0.286 -0.06 (-0.04) 0.1919 -+- 0.091
0.7306 ?-+ 0.220 0.05 (-0.04) 0.1934 ?-+ 0.331
0.5170 -++ 0.296 -0.08 (-0.06) 0.1995 --+ 0.225
0.1635 +-+ 0.258 0.07 (-0.06) 0.2074 ++- 0.012
0.3959 --+ 0.192 0.07 (-0.06) 0.2080 +++ 0.837
0.7915 -+- 0.961 -0.07 (-0.06) 0.2102 --- 0.662
0.0204 +-- 0.112 -0.08 (-0.06) 0.2120 +-- 0.092
0.8181 ++- 0.180 -0.08 (-0.07) 0.2123 -+- 0.361
0.9513 --+ 0.049 0.05 (-0.04) 0.2162 +-+ 0.516
0.5306 +-- 0.098 -0.06 (-0.05) 0.2164 +-- 0.403
0.2405 ++- 0.135 -0.08 (-0.07) 0.2168 -+- 0.017
0.1347 +-- 0.459 -0.07 (-0.06) 0.2211 --- 0.476
0.0979 ??+ 1.000 0.07 (-0.06) 0.2220 ??+ 1.000
0.2268 ??+ 1.000 0.09 (-0.08) 0.2230 ??+ 1.000
0.2281 +++ 0.937 -0.07 (-0.06) 0.2232 --- 0.731
0.6816 +-- 0.043 0.07 (-0.06) 0.2257 +-- 0.009
0.8027 ++- 0.227 -0.07 (-0.06) 0.2262 ++- 0.062
0.9313 +-- 0.381 -0.06 (-0.05) 0.2296 -+- 0.270
0.2536 +-+ 0.443 0.07 (-0.06) 0.2309 ++- 0.243
0.3332 +++ 0.686 0.08 (-0.07) 0.2320 ++- 0.393
0.3258 --+ 0.351 0.06 (-0.05) 0.2323 +-+ 0.217
0.4096 ??- 1.000 -0.11 (-0.09) 0.2323 ??- 1.000
0.1310 +++ 0.975 0.08 (-0.07) 0.2350 ++- 0.207
0.2504 +++ 0.951 0.08 (-0.06) 0.2363 +++ 0.904
0.3781 +-+ 0.420 0.08 (-0.07) 0.2418 +++ 0.555
0.2698 +++ 0.921 0.08 (-0.07) 0.2425 +++ 0.375
0.6751 +-- 0.605 -0.04 (-0.04) 0.2481 --- 0.755
0.6876 -+- 0.034 0.05 (-0.04) 0.2552 +++ 0.864
0.9021 --+ 0.214 0.09 (-0.08) 0.2572 +++ 0.577
0.7661 --+ 0.153 0.05 (-0.05) 0.2598 +-+ 0.030
0.0177 +++ 0.082 0.07 (-0.06) 0.2698 +++ 0.993
0.6396 +++ 0.885 -0.06 (-0.06) 0.2717 --- 0.772
0.8202 ??- 1.000 -0.1 (-0.09) 0.2730 ??- 1.000
0.0361 +++ 0.999 0.07 (-0.06) 0.2742 +-+ 0.153
0.9067 +-+ 0.034 0.07 (-0.07) 0.2758 ++- 0.633
0.0079 +++ 0.737 0.07 (-0.06) 0.2767 ++- 0.681
0.2084 +++ 0.710 0.06 (-0.05) 0.2774 ++- 0.231
0.6494 ++? 0.918 0.07 (-0.06) 0.2819 ++? 0.465
0.0550 --+ 0.044 0.03 (-0.03) 0.2839 --+ 0.397
0.3313 +-+ 0.118 0.09 (-0.09) 0.2893 +++ 0.360
0.2012 +-+ 0.018 0.06 (-0.06) 0.2921 +-+ 0.165
0.5377 ++- 0.230 -0.05 (-0.05) 0.2948 +-- 0.575
0.0590 +++ 0.786 0.02 (-0.02) 0.2956 -++ 0.149
0.0229 +++ 0.695 -0.07 (-0.07) 0.2968 -+- 0.632
0.4196 -+- 0.242 0.05 (-0.05) 0.3000 -+- 0.124
0.0049 --- 0.711 -0.06 (-0.05) 0.3013 -+- 0.330
0.2300 +-- 0.087 0.1 (-0.1) 0.3057 ++- 0.284
0.7996 -+- 0.803 -0.07 (-0.06) 0.3087 --+ 0.591
0.5094 +-+ 0.212 0.04 (-0.04) 0.3102 +++ 0.725
0.8650 ++- 0.140 0.05 (-0.06) 0.3214 ++- 0.312
0.9127 +-- 0.209 -0.07 (-0.07) 0.3257 ++- 0.217
0.2021 +-- 0.274 -0.05 (-0.05) 0.3263 -+- 0.273
0.9823 -++ 0.412 0.06 (-0.06) 0.3293 -++ 0.545
0.7676 ++- 0.901 0.04 (-0.04) 0.3346 +++ 0.712
0.7190 +-- 0.035 0.05 (-0.06) 0.3355 +++ 0.266
0.5254 ++- 0.072 -0.07 (-0.07) 0.3366 ++- 0.209
0.9440 +-- 0.902 -0.07 (-0.07) 0.3376 --- 0.887
0.1512 --+ 0.127 -0.18 (-0.19) 0.3393 --- 0.908
0.6816 +-+ 0.063 -0.05 (-0.05) 0.3395 --- 0.790
0.1286 --- 0.482 0.05 (-0.05) 0.3420 ++- 0.355
0.1981 --+ 0.089 0.05 (-0.05) 0.3434 -++ 0.636
0.0504 +++ 0.715 0.06 (-0.06) 0.3448 +++ 0.847
0.0620 --- 0.190 -0.05 (-0.06) 0.3489 --+ 0.563
0.7678 --+ 0.557 -0.06 (-0.06) 0.3511 +-- 0.263
0.8089 --+ 0.371 0.06 (-0.06) 0.3596 +-+ 0.250
0.2391 --- 0.890 -0.06 (-0.07) 0.3612 -+- 0.479
0.4634 --- 0.678 0.05 (-0.06) 0.3650 ++- 0.241
0.2577 --- 0.538 -0.01 (-0.01) 0.3657 --- 0.994
0.8091 -+- 0.835 0.13 (-0.15) 0.3664 -++ 0.614
0.4699 +-+ 0.122 0.06 (-0.07) 0.3698 +-+ 0.550
0.2633 -++ 0.191 -0.07 (-0.07) 0.3723 --- 0.962
0.6704 +++ 0.919 0.04 (-0.04) 0.3728 -++ 0.812
0.6677 ++- 0.097 -0.09 (-0.1) 0.3767 -+- 0.623
0.6773 --+ 0.193 0.05 (-0.06) 0.3839 +++ 0.915
0.0695 --- 0.770 -0.06 (-0.07) 0.3867 --- 0.879
0.3146 +++ 0.998 0.03 (-0.03) 0.3869 -++ 0.165
0.8105 ++- 0.796 -0.05 (-0.06) 0.3871 -+- 0.669
0.0299 +++ 0.116 0.04 (-0.05) 0.3900 ++- 0.219
0.8917 ++- 0.417 0.04 (-0.05) 0.3955 +++ 0.707
0.1005 +++ 0.498 0.05 (-0.06) 0.3963 ++- 0.384
0.7594 +-+ 0.392 0.05 (-0.07) 0.4043 ++- 0.311
0.9279 +-- 0.119 0.04 (-0.04) 0.4064 ++- 0.032
0.5763 ++- 0.427 0.03 (-0.04) 0.4085 +-- 0.223
0.1154 +++ 0.408 0.06 (-0.08) 0.4113 -+- 0.091
0.3841 +-- 0.638 0.05 (-0.06) 0.4156 ++- 0.225
0.0702 +++ 0.604 0.06 (-0.08) 0.4204 +-+ 0.760
0.5706 +-- 0.686 0.05 (-0.07) 0.4233 +-+ 0.580
0.4548 --- 0.834 -0.15 (-0.19) 0.4244 +-+ 0.316
0.4841 ++- 0.397 -0.07 (-0.09) 0.4303 -+- 0.075
0.9104 +-+ 0.187 -0.05 (-0.06) 0.4320 +-- 0.290
0.5873 +-- 0.052 -0.08 (-0.1) 0.4390 +-- 0.257
0.4257 +-+ 0.299 0.05 (-0.06) 0.4542 +-+ 0.713
0.8662 -++ 0.121 0.05 (-0.06) 0.4556 -++ 0.869
0.4312 +-+ 0.507 0.05 (-0.07) 0.4565 +-+ 0.813
0.7375 --+ 0.830 0.05 (-0.07) 0.4603 +-+ 0.684
0.3442 --- 0.810 -0.04 (-0.06) 0.4618 +-- 0.247
0.2169 +++ 0.620 -0.02 (-0.03) 0.4655 +-- 0.874
0.6292 +-+ 0.268 0.05 (-0.07) 0.4689 +++ 0.893
0.5169 --+ 0.057 -0.05 (-0.06) 0.4696 --+ 0.131
0.9346 +-+ 0.721 -0.04 (-0.06) 0.4699 -+- 0.654
0.0025 --- 0.350 -0.04 (-0.06) 0.4774 -+- 0.639
0.1562 +++ 0.818 0.04 (-0.06) 0.4816 ++- 0.499
0.9313 +-- 0.334 0.04 (-0.06) 0.4849 ++- 0.561
0.0463 --- 0.836 -0.04 (-0.06) 0.4875 +-- 0.154
0.9497 --+ 0.068 0.03 (-0.05) 0.4916 +-+ 0.298
0.3869 -++ 0.754 -0.04 (-0.06) 0.4943 -+- 0.265
0.9638 +-+ 0.749 0.05 (-0.08) 0.4960 ++- 0.563
0.3171 --- 0.596 -0.04 (-0.06) 0.5043 --+ 0.245
0.4521 -++ 0.672 0.02 (-0.03) 0.5077 -+- 0.082
0.0460 +++ 0.086 0.03 (-0.05) 0.5085 +-- 0.076
0.7871 +-- 0.215 0.08 (-0.12) 0.5089 ++- 0.106
0.7952 +-+ 0.446 0.05 (-0.07) 0.5110 ++- 0.256
0.6259 +-+ 0.090 -0.05 (-0.08) 0.5148 +-+ 0.315
0.5526 --+ 0.357 -0.07 (-0.1) 0.5149 --- 0.903
0.9733 +-- 0.760 0.03 (-0.04) 0.5181 +-+ 0.597
0.7597 +-- 0.505 -0.04 (-0.07) 0.5186 -+- 0.482
0.4559 +-- 0.569 0.05 (-0.08) 0.5199 +++ 0.967
0.2833 +-+ 0.049 0.04 (-0.07) 0.5309 +-+ 0.509
0.2788 --- 0.611 0.05 (-0.07) 0.5313 +++ 0.660
0.4803 +-+ 0.809 0.03 (-0.05) 0.5376 +++ 0.949
0.3682 -++ 0.189 0.02 (-0.03) 0.5398 ++- 0.466
0.6315 --+ 0.042 0.02 (-0.04) 0.5407 -++ 0.064
0.0715 --+ 0.003 -0.04 (-0.06) 0.5440 --+ 0.332
0.5218 +-- 0.263 -0.04 (-0.06) 0.5440 +-- 0.386
0.8280 -+? 0.418 0.06 (-0.09) 0.5546 -+? 0.510
0.4138 ++- 0.060 0.05 (-0.08) 0.5554 ++- 0.564
0.9867 ++- 0.224 0.04 (-0.07) 0.5554 ++- 0.036
0.1869 --- 0.790 0.03 (-0.05) 0.5584 -++ 0.359
0.7026 +-+ 0.011 0.04 (-0.08) 0.5606 --+ 0.004
0.7133 +-+ 0.926 0.04 (-0.07) 0.5652 +-+ 0.709
0.4433 --- 0.730 0.02 (-0.04) 0.5724 ++- 0.265
0.0775 --- 0.850 0.03 (-0.05) 0.5792 +-+ 0.550
0.0688 +++ 0.317 -0.04 (-0.07) 0.5807 -+- 0.019
0.1397 +-+ 0.326 0.02 (-0.03) 0.5842 +++ 0.982
0.1251 +++ 0.982 0.03 (-0.06) 0.5851 ++- 0.485
0.9973 +-+ 0.954 -0.03 (-0.06) 0.5899 --+ 0.749
0.4753 --+ 0.530 0.03 (-0.05) 0.5947 -++ 0.863
0.9767 ++- 0.437 0.05 (-0.09) 0.5979 -+- 0.349
0.9381 +-- 0.907 -0.05 (-0.09) 0.5987 -+- 0.557
0.9089 --+ 0.091 -0.03 (-0.06) 0.6008 --+ 0.653
0.5966 +-+ 0.780 0.02 (-0.03) 0.6021 -++ 0.835
0.9224 +-+ 0.208 0.03 (-0.06) 0.6074 +++ 0.909
0.5700 ++- 0.628 0.05 (-0.1) 0.6087 -+- 0.078
0.3206 +++ 0.967 -0.04 (-0.08) 0.6092 --+ 0.747
0.9129 +-+ 0.602 -0.04 (-0.07) 0.6093 -+- 0.870
0.1470 ++- 0.407 0.04 (-0.08) 0.6098 -++ 0.813
0.9871 ??+ 1.000 0.04 (-0.08) 0.6139 ??+ 1.000
0.4284 +-+ 0.301 -0.02 (-0.04) 0.6156 ++- 0.326
0.0960 --- 0.343 -0.04 (-0.08) 0.6186 ++- 0.429
0.1734 ++? 0.640 -0.03 (-0.07) 0.6211 +-? 0.002
0.7439 --+ 0.811 0.03 (-0.06) 0.6233 ++- 0.651
0.3049 --- 0.461 -0.03 (-0.06) 0.6241 ++- 0.533
0.0513 +++ 0.883 0.03 (-0.05) 0.6257 ++- 0.806
0.8930 -+- 0.744 -0.03 (-0.06) 0.6302 -+- 0.199
0.2795 +-- 0.164 0.03 (-0.06) 0.6322 ++- 0.360
0.4057 +-+ 0.437 0.04 (-0.09) 0.6394 --+ 0.427
0.5144 ++- 0.163 0.02 (-0.04) 0.6411 ++- 0.295
0.4312 --+ 0.061 0.03 (-0.07) 0.6471 -++ 0.283
0.0766 --- 0.223 -0.02 (-0.05) 0.6490 --+ 0.766
0.6359 -+- 0.898 0.01 (-0.02) 0.6564 -++ 0.550
0.4221 ++- 0.231 -0.04 (-0.09) 0.6570 ++- 0.028
0.3670 +++ 0.936 0.02 (-0.05) 0.6591 -++ 0.739
0.5198 ++- 0.062 -0.04 (-0.08) 0.6615 ++- 0.063
0.8067 ++- 0.445 0.04 (-0.1) 0.6684 -++ 0.624
0.9917 ++- 0.358 -0.03 (-0.08) 0.6692 ++- 0.123
0.0440 +++ 0.371 0.04 (-0.09) 0.6723 +-+ 0.032
0.5313 --+ 0.274 0.02 (-0.05) 0.6724 +-+ 0.695
0.2794 +-+ 0.744 0.02 (-0.06) 0.6768 -+- 0.082
0.9801 ??- 1.000 0.04 (-0.1) 0.6772 ??+ 1.000
0.7459 +-- 0.109 0.03 (-0.07) 0.6789 ++- 0.141
0.5958 +-- 0.258 0.03 (-0.08) 0.6856 -++ 0.593
0.7844 -++ 0.197 0.02 (-0.05) 0.6877 -++ 0.879
0.2818 +-+ 0.413 0.03 (-0.09) 0.6880 +-+ 0.269
0.2968 +-+ 0.391 0.03 (-0.06) 0.6926 ++- 0.607
0.8804 ++? 0.917 0.04 (-0.1) 0.6932 ++? 0.639
0.4784 --+ 0.099 -0.02 (-0.06) 0.7010 --+ 0.321
0.8341 +-? 0.466 0.03 (-0.09) 0.7063 -+? 0.681
0.4989 +-+ 0.009 0.03 (-0.07) 0.7106 +-+ 0.412
0.2891 +-- 0.203 -0.03 (-0.09) 0.7145 ++- 0.296
0.4066 +-+ 0.124 0.02 (-0.07) 0.7240 +-- 0.144
0.3063 ??+ 1.000 -0.04 (-0.1) 0.7258 ??- 1.000
0.5059 +-+ 0.036 0.02 (-0.05) 0.7261 +-- 0.069
0.3028 +-- 0.320 0.02 (-0.06) 0.7352 +-+ 0.692
0.8782 ??+ 1.000 0.06 (-0.17) 0.7385 ??+ 1.000
0.3391 -++ 0.763 -0.02 (-0.06) 0.7391 -+- 0.040
0.8086 --+ 0.907 0.01 (-0.03) 0.7411 -++ 0.958
0.9359 ++- 0.240 -0.02 (-0.05) 0.7449 ++- 0.456
0.2616 +++ 0.966 0.03 (-0.09) 0.7472 -++ 0.876
0.7685 +-- 0.072 0.02 (-0.05) 0.7512 +-+ 0.705
0.9168 +-+ 0.586 0.02 (-0.06) 0.7537 +-+ 0.944
0.7272 +-- 0.149 0.02 (-0.08) 0.7566 ++- 0.113
0.5555 +-- 0.599 0.02 (-0.06) 0.7574 +-+ 0.533
0.6014 +-+ 0.408 0.01 (-0.04) 0.7667 -++ 0.740
0.6749 +-- 0.487 0.02 (-0.07) 0.7679 ++- 0.589
0.7296 --+ 0.597 -0.02 (-0.08) 0.7680 ++- 0.762
0.8661 ??+ 1.000 -0.03 (-0.11) 0.7762 ??- 1.000
0.2678 -+- 0.497 0.02 (-0.09) 0.7790 -+- 0.214
0.6746 -+- 0.671 -0.02 (-0.09) 0.7832 -+- 0.673
0.7971 +-+ 0.979 0.02 (-0.06) 0.7883 -++ 0.158
0.5664 ++- 0.368 -0.02 (-0.07) 0.7886 ++- 0.273
0.7829 ++- 0.638 -0.02 (-0.07) 0.7929 -+- 0.357
0.6071 +-+ 0.490 0.01 (-0.05) 0.7944 ++- 0.121
0.4940 +-+ 0.129 -0.01 (-0.06) 0.8012 +-+ 0.174
0.2138 +-- 0.720 -0.01 (-0.04) 0.8054 +-- 0.174
0.8804 +-+ 0.488 0.01 (0.06) 0.8062 --+ 0.393
0.3290 +-+ 0.659 0.01 (0.04) 0.8133 +-+ 0.776
0.3290 +-+ 0.659 0.01 (-0.04) 0.8133 +-+ 0.776
0.7210 -+- 0.533 -0.01 (-0.06) 0.8174 ++- 0.222
0.8923 +-- 0.039 -0.01 (-0.06) 0.8182 +-- 0.432
0.1994 -+- 0.623 -0.02 (-0.08) 0.8184 ++- 0.404
0.3520 ++- 0.059 -0.01 (-0.06) 0.8253 --+ 0.924
0.1570 ?-- 0.588 -0.01 (-0.07) 0.8377 ?-+ 0.430
0.2211 --- 0.781 -0.01 (-0.04) 0.8415 --+ 0.869
0.6105 ??+ 1.000 0.02 (-0.08) 0.8439 ??+ 1.000
0.6315 ?-- 0.383 -0.01 (-0.04) 0.8463 ?+- 0.354
0.8988 --+ 0.971 0.01 (-0.06) 0.8468 +-- 0.212
0.3760 +-+ 0.163 -0.01 (-0.05) 0.8500 +-+ 0.243
0.7136 --+ 0.869 -0.02 (-0.09) 0.8506 -+- 0.509
0.3069 +-- 0.135 0.01 (-0.06) 0.8550 +-- 0.271
0.3675 -++ 0.628 0.01 (-0.03) 0.8608 -+- 0.802
0.7970 ++- 0.771 -0.01 (-0.08) 0.8621 -+- 0.170
0.7906 -+- 0.700 -0.01 (-0.08) 0.8629 --+ 0.616
0.6890 ++- 0.578 0.01 (-0.05) 0.8633 -+- 0.484
0.0115 +++ 0.828 -0.01 (-0.05) 0.8648 ++- 0.611
0.6265 +-- 0.410 -0.01 (-0.06) 0.8649 +-- 0.772
0.7514 --+ 0.510 0.01 (-0.05) 0.8667 ++- 0.344
0.8009 --+ 0.876 -0.01 (-0.06) 0.8728 ++- 0.597
0.8312 +-- 0.798 -0.01 (-0.08) 0.8729 +-- 0.398
0.0102 --- 0.637 0.01 (-0.05) 0.8928 +-- 0.672
0.7968 ++- 0.602 -0.01 (-0.07) 0.9041 -+- 0.489
0.8134 ++- 0.829 -0.01 (-0.06) 0.9073 -+- 0.112
0.8600 ??- 1.000 0.02 (-0.17) 0.9143 ??+ 1.000
0.5206 ++- 0.475 -0.01 (-0.06) 0.9192 ++- 0.367
0.5351 +-+ 0.145 -0.01 (-0.08) 0.9261 ++- 0.587
0.3966 +-- 0.076 0 (-0.03) 0.9266 +-- 0.008
0.7819 +-+ 0.694 0 (-0.03) 0.9375 -++ 0.650
0.9421 +-+ 0.281 0 (-0.06) 0.9500 +-+ 0.782
0.6759 ++- 0.364 0 (-0.07) 0.9533 +-- 0.250
0.1300 +++ 0.734 0 (-0.08) 0.9557 -+- 0.121
0.8391 --+ 0.511 0 (-0.05) 0.9565 -++ 0.732
0.2515 --- 0.769 0 (-0.06) 0.9620 +-- 0.534
0.1917 +-+ 0.336 0 (-0.07) 0.9626 -+- 0.726
0.6549 ++- 0.859 0 (-0.08) 0.9639 -+- 0.466
0.4109 +-- 0.577 0 (-0.05) 0.9659 +-- 0.109
0.8454 -+- 0.588 0 (-0.08) 0.9705 -+- 0.215
0.1990 --- 0.314 0 (-0.05) 0.9720 --+ 0.190
0.5325 --+ 0.630 0 (-0.08) 0.9746 ++- 0.831
0.4373 +-- 0.373 0 (-0.05) 0.9781 ++- 0.478
0.8090 -+- 0.922 0 (-0.07) 0.9820 -+- 0.701
0.4584 --+ 0.644 0 (-0.07) 0.9885 +-+ 0.918
0.9167 --+ 0.093 0 (-0.05) 0.9904 --+ 0.318
                                   very cohorts.












0.27 (-0.11) 0.0109 +-+ 0.008
0.41 (-0.18) 0.0220 +-+ 0.023
0.33 (-0.13) 0.0123 +-+ 0.054
0.54 (-0.17) 0.0019 +-+ 0.158
0.43 (-0.26) 0.0977 +-+ 0.055
0.21 (-0.13) 0.1129 +-+ 0.294
0.93 (-0.38) 0.0131 +-+ 0.357
-1.37 (-0.95) 0.1482 +-- 0.330
0.56 (-0.2) 0.0043 ??+ 1.000
0.51 (-0.77) 0.5072 +++ 0.978
-0.41 (-0.53) 0.4352 --+ 0.167
0.62 (-0.18) 0.0008 ??+ 1.000
-0.16 (-0.48) 0.7393 --+ 0.180
-0.13 (-0.48) 0.7823 --+ 0.479
0.06 (-0.32) 0.8598 -++ 0.275
-0.11 (-0.68) 0.8689 ??- 1.000
0.01 (-0.56) 0.9860 +-+ 0.170
0.25 (-0.41) 0.5362 +-- 0.253
-0.51 (-0.64) 0.4236 --+ 0.193
0.55 (-0.54) 0.3121 +++ 0.680
-0.3 (-1.02) 0.7690 -++ 0.206
-0.24 (-0.37) 0.5076 +-- 0.116
0.39 (-0.29) 0.1844 --+ 0.174
-0.72 (-0.44) 0.1027 --- 0.673
0.57 (-0.62) 0.3572 +-+ 0.042
0.05 (-0.42) 0.9032 --+ 0.058
-0.87 (-0.47) 0.0618 --- 0.312
0.39 (-0.51) 0.4434 +-+ 0.850
0.46 (-0.6) 0.4422 +-+ 0.125
-0.04 (-0.48) 0.9263 +-- 0.467
1.14 (-0.37) 0.0022 +-+ 0.102
-0.02 (-0.41) 0.9619 --+ 0.339
0.04 (-0.35) 0.9038 +-+ 0.932
0.13 (-0.63) 0.8346 +-+ 0.330
-0.64 (-0.66) 0.3369 --- 0.642
2.56 (-0.85) 0.0025 +++ 0.335
0.15 (-0.46) 0.7462 --+ 0.261
-0.28 (-0.52) 0.5849 +-- 0.332
0.76 (-0.57) 0.1786 +++ 0.836
-0.39 (-0.46) 0.3942 +-- 0.479
1.04 (-0.39) 0.0080 +-+ 0.046
0.89 (-0.44) 0.0436 +-+ 0.040
-1.38 (-0.82) 0.0927 --- 0.358
0.34 (-0.66) 0.6066 +-+ 0.098
-1.01 (-0.45) 0.0240 --- 0.302
0.52 (-0.53) 0.3252 -++ 0.523
-0.65 (-0.5) 0.1940 --+ 0.046
-0.32 (-0.36) 0.3735 --- 0.814
0.56 (-0.48) 0.2406 +++ 0.740
1.18 (-0.53) 0.0272 +++ 0.086
0.39 (-0.37) 0.2879 +++ 0.921
0.44 (-0.55) 0.4252 ++- 0.184
0.11 (-0.32) 0.7265 +-+ 0.922
0.52 (-0.62) 0.4037 +-+ 0.291
0.94 (-0.45) 0.0358 +-+ 0.329
1.09 (-0.41) 0.0073 +++ 0.636
-0.97 (-0.8) 0.2262 --- 0.569
-0.43 (-0.59) 0.4652 ++- 0.483
-0.19 (-0.44) 0.6545 --+ 0.815
-0.13 (-0.23) 0.5604 +-- 0.907
0.05 (-0.4) 0.8948 --+ 0.308
0.21 (-0.48) 0.6634 +-+ 0.149
0.21 (-0.37) 0.5633 --+ 0.139
0.53 (-0.34) 0.1240 +-+ 0.002
-0.5 (-0.57) 0.3841 --+ 0.136
-0.39 (-0.65) 0.5545 --+ 0.481
-0.6 (-0.56) 0.2855 ++- 0.027
-0.72 (-0.71) 0.3083 --- 0.726
0.59 (-0.45) 0.1926 +++ 0.714
-0.16 (-0.48) 0.7363 -+- 0.573
0.85 (-0.45) 0.0590 +++ 0.515
1.2 (-0.66) 0.0675 ??+ 1.000
0.02 (-0.36) 0.9510 --+ 0.027
0.33 (-0.35) 0.3453 +?+ 0.880
0.06 (-0.63) 0.9185 +-+ 0.176
1.17 (-1.26) 0.3531 ++- 0.670
-0.16 (-0.82) 0.8440 +-+ 0.689
0.95 (-0.51) 0.0628 -++ 0.009
0.12 (-0.53) 0.8207 -+- 0.821
0.7 (-0.34) 0.0416 +-+ 0.002
-0.56 (-0.55) 0.3073 -+- 0.492
-0.09 (-0.63) 0.8817 --+ 0.814
-0.05 (-0.4) 0.8970 --+ 0.138
0 (-0.51) 0.9951 +-+ 0.088
0.14 (-0.41) 0.7328 +-+ 0.070
0.81 (-0.64) 0.2046 ??+ 1.000
0.25 (-0.24) 0.2939 +++ 0.924
0.86 (-0.66) 0.1910 +++ 0.248
0.48 (-0.32) 0.1325 +-+ 0.065
0.47 (-0.42) 0.2664 -++ 0.256
0.72 (-0.51) 0.1521 +++ 0.088
-0.55 (-0.5) 0.2694 --- 0.541
1.03 (-0.39) 0.0084 ??+ 1.000
0.8 (-0.55) 0.1495 +++ 0.735
0.29 (-0.59) 0.6204 +-- 0.346
0.44 (-0.33) 0.1753 +++ 0.765
0.83 (-0.43) 0.0553 +++ 0.368
-0.15 (-0.42) 0.7285 +-+ 0.374
-0.4 (-0.48) 0.4087 +-- 0.706
0.59 (-0.74) 0.4224 +++ 0.855
-0.97 (-0.39) 0.0137 --- 0.921
0.16 (-0.24) 0.4894 ?-+ 0.555
0.09 (-0.23) 0.6757 +-+ 0.933
-0.04 (-0.56) 0.9376 +-+ 0.084
0.03 (-0.56) 0.9639 -+- 0.991
-0.42 (-0.3) 0.1568 --- 0.589
-0.68 (-0.54) 0.2053 --- 0.428
0.36 (-1.39) 0.7950 +-+ 0.220
-0.17 (-0.27) 0.5309 --- 0.988
0.82 (-0.3) 0.0072 +++ 0.871
0.64 (-0.54) 0.2349 ++- 0.209
0.4 (-0.34) 0.2436 -++ 0.810
-0.82 (-0.85) 0.3359 ??- 1.000
-0.07 (-0.4) 0.8710 -++ 0.828
0.02 (-0.59) 0.9686 +-- 0.153
-0.16 (-0.59) 0.7888 ++- 0.626
-0.07 (-0.54) 0.8959 --+ 0.495
0.26 (-0.46) 0.5742 +-+ 0.737
-0.76 (-0.7) 0.2805 -++ 0.097
0.73 (-0.4) 0.0689 +++ 0.999
0.4 (-0.38) 0.2943 -++ 0.443
-0.28 (-0.54) 0.6047 --- 0.819
0.05 (-0.23) 0.8234 --+ 0.436
0.84 (-0.43) 0.0508 +++ 0.281
-0.46 (-0.38) 0.2267 --- 0.752
0.49 (-0.34) 0.1482 +++ 0.361
-0.14 (-0.27) 0.6177 ?-- 0.690
0.7 (-0.48) 0.1401 -++ 0.542
0.54 (-0.45) 0.2285 +-+ 0.134
0.25 (-0.46) 0.5798 --+ 0.146
0.25 (-0.45) 0.5863 +++ 0.952
-0.81 (-0.48) 0.0932 --- 0.484
0.29 (-0.51) 0.5704 ++- 0.188
-0.14 (-0.3) 0.6526 --+ 0.023
0.14 (-0.4) 0.7144 ++- 0.146
-0.32 (-0.53) 0.5440 +-- 0.730
-0.42 (-0.44) 0.3391 +-- 0.362
0.59 (-0.41) 0.1546 ??+ 1.000
0.49 (-0.53) 0.3505 ??+ 1.000
0.97 (-0.46) 0.0366 +++ 0.748
-0.53 (-0.45) 0.2407 +-- 0.444
0.6 (-0.45) 0.1823 +++ 0.585
0.37 (-0.4) 0.3582 +-+ 0.216
0.39 (-0.45) 0.3812 --+ 0.166
0.13 (-0.52) 0.8066 ++- 0.900
-0.65 (-0.41) 0.1135 --- 0.151
0.1 (-0.64) 0.8791 ??+ 1.000
0.6 (-0.54) 0.2612 +-+ 0.407
0.21 (-0.49) 0.6685 -++ 0.947
0.3 (-0.52) 0.5595 +-+ 0.133
0.41 (-0.53) 0.4415 -++ 0.433
0.24 (-0.29) 0.3952 +++ 0.735
-0.17 (-0.34) 0.6230 -+- 0.056
-0.2 (-0.59) 0.7371 --+ 0.343
-0.26 (-0.36) 0.4680 --+ 0.539
1.08 (-0.49) 0.0271 +++ 0.084
0.65 (-0.46) 0.1545 +++ 0.535
0.01 (-0.61) 0.9857 ??+ 1.000
0.79 (-0.47) 0.0943 +++ 0.448
-0.07 (-0.53) 0.9005 +-+ 0.003
1.28 (-0.47) 0.0070 +++ 0.887
0.44 (-0.41) 0.2834 +++ 0.772
-0.08 (-0.55) 0.8916 +-? 0.548
0.43 (-0.23) 0.0632 +-+ 0.101
0.26 (-0.69) 0.7035 ++- 0.390
0.6 (-0.47) 0.1987 +-+ 0.118
0.04 (-0.38) 0.9232 ++- 0.397
0.26 (-0.18) 0.1460 +-+ 0.315
1.91 (-0.52) 2.48E-04 +++ 0.704
0.04 (-0.36) 0.9082 -++ 0.699
-1.21 (-0.41) 0.0033 --- 0.220
-1.63 (-0.77) 0.0333 +-- 0.298
0.54 (-0.5) 0.2818 ++- 0.348
0.04 (-0.27) 0.8692 +-+ 0.037
-0.27 (-0.44) 0.5361 +-- 0.432
0.4 (-0.52) 0.4339 +-- 0.161
-0.35 (-0.38) 0.3606 +-- 0.393
-0.14 (-0.46) 0.7588 --+ 0.629
-0.13 (-0.33) 0.6891 --- 0.997
-0.07 (-0.43) 0.8663 +-- 0.095
-0.07 (-0.59) 0.9128 ++- 0.192
0.35 (-0.54) 0.5119 +++ 0.802
-1.26 (-1.52) 0.4059 --+ 0.052
0.35 (-0.39) 0.3673 +-+ 0.142
-0.9 (-0.42) 0.0325 --- 0.216
0.36 (-0.39) 0.3557 --+ 0.038
0.83 (-0.45) 0.0686 +++ 0.958
-0.53 (-0.44) 0.2262 --- 0.617
0.08 (-0.47) 0.8585 -++ 0.427
-0.33 (-0.49) 0.5040 --+ 0.126
-0.22 (-0.53) 0.6774 +-- 0.874
-0.51 (-0.43) 0.2278 --+ 0.136
-0.05 (-0.09) 0.5246 --+ 0.341
-0.45 (-1.2) 0.7089 --- 0.938
-0.53 (-0.53) 0.3146 --+ 0.242
0.97 (-0.62) 0.1182 -++ 0.139
0.09 (-0.31) 0.7855 ++- 0.764
-0.19 (-0.81) 0.8179 ++- 0.023
-0.34 (-0.47) 0.4783 --+ 0.113
-0.81 (-0.53) 0.1237 +-- 0.414
0.15 (-0.23) 0.5205 +-+ 0.623
0.37 (-0.44) 0.4057 +++ 0.685
0.72 (-0.35) 0.0367 +++ 0.092
-0.23 (-0.39) 0.5458 +-- 0.655
0.51 (-0.45) 0.2564 +++ 0.850
-0.24 (-0.51) 0.6440 --+ 0.352
-0.23 (-0.34) 0.5089 +-- 0.547
0.11 (-0.3) 0.7035 +++ 0.959
0.72 (-0.58) 0.2136 +-+ 0.108
-0.67 (-0.43) 0.1200 +-- 0.359
1.12 (-0.61) 0.0664 +++ 0.586
-0.34 (-0.53) 0.5254 --- 0.992
-0.25 (-1.56) 0.8711 -+- 0.153
-0.07 (-0.73) 0.9289 +-- 0.582
0.37 (-0.48) 0.4363 +-+ 0.497
-0.19 (-0.76) 0.8052 +-- 0.087
0.29 (-0.49) 0.5516 --+ 0.274
-0.31 (-0.49) 0.5271 -++ 0.086
-0.65 (-0.56) 0.2460 --- 0.722
-0.28 (-0.59) 0.6347 --- 0.999
-0.22 (-0.43) 0.5996 -+- 0.640
0.48 (-0.26) 0.0654 +++ 0.455
-0.53 (-0.54) 0.3243 --- 0.351
0.6 (-0.49) 0.2228 +-+ 0.405
0.34 (-0.49) 0.4860 +-+ 0.378
-1.37 (-0.49) 0.0054 --- 0.215
0.73 (-0.46) 0.1174 +++ 0.997
-0.06 (-0.47) 0.9067 +-- 0.338
-0.69 (-0.43) 0.1099 --- 0.669
-0.1 (-0.35) 0.7779 --+ 0.413
0.57 (-0.48) 0.2394 -++ 0.548
0.03 (-0.62) 0.9554 +-+ 0.276
-0.42 (-0.48) 0.3765 -+- 0.699
0.01 (-0.2) 0.9445 +-+ 0.905
0.67 (-0.36) 0.0640 +++ 0.580
-0.43 (-0.97) 0.6561 +-+ 0.740
0.09 (-0.56) 0.8733 +-+ 0.851
0.22 (-0.59) 0.7166 +-+ 0.582
-0.32 (-0.83) 0.7022 --+ 0.425
-0.07 (-0.3) 0.8264 +-- 0.933
0.04 (-0.52) 0.9362 +-- 0.324
-0.91 (-0.65) 0.1645 +-- 0.463
0.65 (-0.51) 0.2003 +-+ 0.113
-0.78 (-0.57) 0.1746 --- 0.461
0.25 (-0.42) 0.5484 --+ 0.786
0.16 (-0.21) 0.4577 -++ 0.507
-0.28 (-0.3) 0.3596 --+ 0.064
-0.66 (-0.46) 0.1480 --+ 0.008
-0.21 (-0.47) 0.6489 +-- 0.382
-0.07 (-0.81) 0.9359 -+? 0.522
0.12 (-0.62) 0.8427 ++- 0.072
-0.17 (-0.55) 0.7620 --- 0.979
-0.75 (-0.37) 0.0422 --- 0.993
0.17 (-0.64) 0.7902 +-+ 0.166
0.04 (-0.58) 0.9457 -++ 0.929
-0.35 (-0.33) 0.2895 --+ 0.250
-0.85 (-0.39) 0.0287 --- 0.956
1.24 (-0.53) 0.0205 +++ 0.383
0.27 (-0.26) 0.3032 +-+ 0.329
0.67 (-0.42) 0.1148 +++ 0.729
0.26 (-0.48) 0.5898 +++ 0.897
-0.54 (-0.4) 0.1746 --- 0.698
-0.26 (-0.71) 0.7106 +-- 0.500
0.35 (-0.71) 0.6174 +-+ 0.536
0.19 (-0.44) 0.6603 +-+ 0.284
0.03 (-0.25) 0.9212 +-- 0.430
0.03 (-0.48) 0.9450 +-+ 0.285
0.07 (-0.74) 0.9200 +-- 0.229
0.9 (-0.62) 0.1495 +++ 0.567
0.35 (-0.54) 0.5145 +-+ 0.427
0.83 (-0.71) 0.2452 ++- 0.244
-0.23 (-0.58) 0.6969 ??- 1.000
0.37 (-0.32) 0.2452 +-+ 0.328
-0.87 (-0.59) 0.1407 --- 0.611
1.2 (-0.58) 0.0384 ++? 0.161
0.15 (-0.45) 0.7328 --+ 0.489
-0.25 (-0.47) 0.5905 --+ 0.219
1 (-0.42) 0.0183 +++ 0.691
0.28 (-0.44) 0.5242 +++ 0.940
-0.66 (-0.5) 0.1858 +-- 0.424
0.48 (-0.71) 0.4971 +-+ 0.824
0.18 (-0.3) 0.5391 +-+ 0.351
-0.6 (-0.57) 0.2947 --- 0.165
-0.65 (-0.4) 0.1026 --- 0.352
-0.16 (-0.13) 0.2287 --- 0.924
0.87 (-0.73) 0.2322 +++ 0.367
0.37 (-0.37) 0.3185 +++ 0.769
-0.4 (-0.64) 0.5366 +-- 0.181
-0.06 (-0.75) 0.9399 ++- 0.295
0.09 (-0.61) 0.8761 +-- 0.614
1.53 (-0.77) 0.0476 +++ 0.350
-0.37 (-0.4) 0.3588 --- 0.570
0.49 (-0.44) 0.2706 +-+ 0.066
0.07 (-0.71) 0.9183 ??+ 1.000
0.17 (-0.59) 0.7671 +-+ 0.287
-0.39 (-0.6) 0.5199 +-- 0.059
0.01 (-0.42) 0.9749 -+- 0.165
0.83 (-0.65) 0.2021 +++ 0.863
0.57 (-0.48) 0.2344 +-+ 0.255
0.16 (-0.82) 0.8472 -+? 0.635
-0.18 (-0.44) 0.6777 --+ 0.138
-0.25 (-0.75) 0.7416 +-? 0.306
-0.62 (-0.58) 0.2789 --+ 0.023
-0.59 (-0.67) 0.3795 +-- 0.360
0.65 (-0.52) 0.2057 +-+ 0.432
1.13 (-0.72) 0.1157 ??+ 1.000
0.21 (-0.4) 0.5971 +-+ 0.073
-0.83 (-0.46) 0.0720 --- 0.654
-0.02 (-1.18) 0.9889 ??- 1.000
0.71 (-0.48) 0.1407 +-+ 0.145
-0.06 (-0.24) 0.7995 --+ 0.861
0.13 (-0.37) 0.7175 -+- 0.365
0.89 (-0.66) 0.1781 +++ 0.721
-0.12 (-0.4) 0.7632 +-- 0.103
0.11 (-0.49) 0.8307 +-+ 0.681
-0.21 (-0.63) 0.7437 +-- 0.127
-0.29 (-0.46) 0.5206 --- 0.981
0.16 (-0.31) 0.6081 +-+ 0.225
-0.21 (-0.58) 0.7089 +-+ 0.342
-0.23 (-0.58) 0.6959 --+ 0.324
0.23 (-0.75) 0.7579 ??+ 1.000
-0.99 (-0.68) 0.1468 --- 0.901
-0.29 (-0.7) 0.6728 --+ 0.602
0.04 (-0.46) 0.9313 +-- 0.393
0.34 (-0.53) 0.5264 +++ 0.793
0.06 (-0.52) 0.9109 +-- 0.411
0.18 (-0.35) 0.6131 +-+ 0.226
0.45 (-0.45) 0.3180 +-+ 0.439
-0.33 (-0.3) 0.2724 --- 0.891
0.25 (0.44) 0.5741 +-+ 0.387
0.42 (0.31) 0.1673 +++ 0.742
0.42 (-0.31) 0.1673 +++ 0.742
-0.01 (-0.46) 0.9849 -+- 0.774
0.18 (-0.46) 0.6918 ++- 0.058
-0.89 (-0.66) 0.1757 --- 0.823
0.32 (-0.48) 0.5011 ++- 0.013
-0.75 (-0.55) 0.1749 ?-- 0.920
-0.37 (-0.29) 0.2048 --- 0.823
0.46 (-0.57) 0.4156 ??+ 1.000
-0.06 (-0.28) 0.8290 ?-+ 0.175
-0.17 (-0.46) 0.7050 --+ 0.480
-0.06 (-0.39) 0.8812 --+ 0.532
-0.09 (-0.68) 0.8942 --+ 0.813
-0.44 (-0.46) 0.3304 +-- 0.379
0.35 (-0.26) 0.1693 --+ 0.275
-0.09 (-0.63) 0.8844 +-- 0.940
-0.5 (-0.59) 0.3969 -+- 0.869
-0.29 (-0.42) 0.4981 +-- 0.629
1.22 (-0.37) 0.0011 +++ 0.947
-0.28 (-0.43) 0.5161 +-- 0.598
-0.07 (-0.39) 0.8489 --+ 0.110
-0.02 (-0.43) 0.9640 --+ 0.710
-0.09 (-0.63) 0.8844 -+- 0.893
-1.16 (-0.41) 0.0045 --- 0.362
0 (-0.56) 0.9971 +-- 0.734
-0.04 (-0.47) 0.9310 +-- 0.720
-0.43 (-1.17) 0.7135 ??- 1.000
0.47 (-0.50) 0.3433 +-+ 0.495
0.6 (-0.65) 0.3570 +-+ 0.161
-0.26 (-0.26) 0.3203 --- 0.603
0.01 (-0.23) 0.9697 +-+ 0.667
0.29 (-0.44) 0.5141 +-+ 0.508
0.34 (-0.57) 0.5502 ++- 0.692
0.99 (-0.59) 0.0940 +++ 0.512
0.05 (-0.39) 0.8878 --+ 0.466
-0.53 (-0.46) 0.2507 --- 0.777
0.87 (-0.54) 0.1070 +-+ 0.146
0.54 (-0.63) 0.3879 +-+ 0.638
-0.34 (-0.41) 0.4084 --- 0.764
0.16 (-0.66) 0.8028 +-+ 0.971
-0.65 (-0.42) 0.1219 -+- 0.291
-0.2 (-0.59) 0.7392 -++ 0.263
-0.27 (-0.39) 0.5006 --+ 0.378
-0.13 (-0.52) 0.8045 --- 0.955
-0.41 (-0.53) 0.4376 --+ 0.534
0 (-0.38) 0.9956 --+ 0.374

